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Summary 
To date, the need for effective treatments to tackle ischaemic diseases such as 
CHD and PAD remains unmet. As such, there has been a great deal of interest in 
developing cell therapies in order to address these important pathologies. The 
main goals of a cell therapy strategy for ischaemic disease remain prompt 
restoration of blood supply to the affected areas in order to salvage tissue 
and/or regeneration of tissues previously lost to ischaemia. 
Derived from the Inner Cell Mass (ICM) of an embryo at the blastocyst stage, 
hESC have been proposed as a potential source of functional, transplantable 
cells for a variety of cell therapy applications. Although successful 
differentiation of multiple cell types from hESC has been demonstrated, the 
molecular processes governing the cell commitment process remain poorly 
understood, and differentiation efficiency often fails to provide the number of 
cells required to see clinical benefit in the patient. As such, a more thorough 
transcriptional characterisation of cardiovascular cell types derived from hESC 
was the goal of this study. 
MicroRNAs (miRNA; miR) are small (~22nt), non-coding RNAs which negatively 
regulate mRNA. MiR-1 and miR-133 were previously shown to play a role in 
regulating cardiac differentiation with miR-1 potentiating cardiac differentiation 
and miR-133 having an inhibitory effect. Optimisation of lentiviral vectors 
showed generation of single pre-miR overexpression lentiviruses for miR-1 and 
miR-133 in a construct using the SFFV promoter to be possible. Furthermore, it 
was realised SA461 hESC were unsuitable for cardiac differentiation, however, 
using a modified version of the LaFlamme protocol in a monolayer system 
resulted in beating cells with a cardiomyocyte phenotype in H1 hESC. Despite 
successful overexpression of miR-1 and miR-133, there was very little effect on 
cardiac differentiation over no virus control. 
Previously published methods for the generation of vascular endothelial cells 
(EC) have reported varying efficiency and target cell population purity (~3 – 
30%). This laboratory recently reported the successful generation of functional 
EC-like cells from hESC in a feeder-free manner. HESC-EC were analysed by LC 
Sciences miRNA microarray at early time points day 0, day 2, day 4 and day 10 
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after initiation of differentiation with time-matched pluripotent controls. An 
induction of miR-99b, -181a and -181b over time was observed, and validated in 
H1 hESC. In addition, miR-99b, -181a and -181b were also found to be expressed 
in other mesodermal cell types including adult human saphenous vein 
endothelial cells (HSVEC). No statistically significant expression of these miRNAs 
could be found in representative cell types of ectoderm and endoderm germ 
layers, therefore it was hypothesised that these miRNAs were largely mesoderm 
specific. Despite initial data showing a significant difference in expression 
between HSVEC from control patients and patients undergoing coronary artery 
bypass grafting (CABG), classical pathophysiological stimuli to cause endothelial 
cell stress did not change the expression of miR-99b, -181a and -181b in vitro. 
 In order to understand more about gene expression in early lineage 
commitment, hESC-EC were analysed by Illumina microarray at early timepoints 
day 0, day 2, day 4 and day 10 after initiation of differentiation with time-
matched pluripotent controls. In parallel, primary human saphenous vein 
endothelial cells (HSVEC) were analysed. Illumina technology permitted whole-
genome profiling in a high throughput chip format. Due to overall expression 
levels being lower intensity than expected, no cut-off of fold-change was 
applied to the dataset. Analysis of the dataset showed a large number of 
significantly differentially expressed probes at each time point: Day 2 of 
endothelial differentiation compared to Day 0 pluripotent control showed 1040 
significant differentially expressed probe changes, Day 4 of endothelial 
differentiation compared to Day 0 pluripotent control showed 2400 significant 
differentially expressed probe changes and Day 10 of endothelial differentiation 
compared to Day 0 pluripotent control showed 2157 significant differentially 
expressed probe changes (all False Discovery Rate <0.05). Although significant 
downregulation of pluripotency markers were observed, few endothelial 
associated genes were present at hESC-EC day 10. Analysis of HSVEC compared 
to hESC-EC Day 10 reveals 6133 significantly differentially expressed probes (FDR 
<0.05). This suggests that although day 10 hESC-ECs have previously been shown 
satisfy criteria for endothelial cells in vitro and in vivo, their transcriptional 
profiling demonstrates that they remain different in comparison to adult ECs.  
A transient induction of several transcription factors was observed at hESC-EC 
day 2, accounting for some 10% of gene changes at this time point. We 
21 
hypothesised that these transcription factors may play key roles in the early 
mesoderm/EC commitment process. Of these, FOXA2, a transcription factor not 
previously associated with mesoderm or EC commitment, was upregulated, and 
this was further validated by both qRT-PCR and ICC in SA461, H1 and RC10 hESC 
lines. In addition to gene expression data, an in silico prediction of gene 
epigenetic status was made using a previously published chromatin 
immunoprecipitation sequencing (ChIP-SEQ) dataset performed in H9 hESC. 
Approximately 3000 genes are bivalently marked, meaning they have both 
H3K4me3 active chromatin and H3K27me3 repressive chromatin at their 
transcriptional start sites (TSS). This conveys a poised state, with the potential 
for the gene to be rapidly activated and/or repressed. Of these bivalent genes it 
was noted that FOXA2 was marked as being potentially bivalent. Upon further 
investigation using ChIP it was revealed that FOXA2 carried both H3K4me3 and 
H3K27me3 chromatin modifications in the TSS region, both in H9 and SA461 
pluripotent hESC. It was hypothesised that epigenetic modification was 
responsible for the dynamic expression of FOXA2, although this hypothesis 
remains to be investigated further. Lastly, several of the miRNA targets for miR-
99b, miR-181a and miR-181b were downregulated by hESC-EC day 10 compared 
to hESC-EC day 0, although whether these targets play a role in refining 
differentiation to EC warrants further investigation. 
In summary, a range of molecular biology techniques were employed to 
investigate the master control of hESC differentiation. These studies have 
contributed to existing knowledge on mesodermal and cardiovascular lineage 
specification. They provide evidence to support the continued in depth 
investigation of these processes in order to develop a clinically relevant cell 
therapy for ischaemic diseases. 
 
 
  
 
 
 
 
Chapter 1:  Introduction 
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1.1 Cardiovascular Disease 
 Worldwide, the leading cause of non-infectious morbidity is cardiovascular 
disease (CVD) (http://www.who.int, 2009). The term cardiovascular disease 
encompasses diseases of the heart and circulatory systems, including coronary 
heart disease (CHD (associated with MI)) and peripheral artery disease (PAD). 
Atherosclerosis, a disease process where cholesterol accumulates in atheroma 
plaques on blood vessel walls is the primary cause of CVD including CHD and 
PAD. 
Coronary heart disease involves the coronary arteries becoming narrowed due to 
the presence of cholesterol rich atheroma plaques on the vessel walls. This leads 
to reduced blood flow to the heart and causes the symptoms of angina. CHD and 
stroke are responsible for the highest percentage of deaths worldwide 
(http://www.who.int, 2009). CHD has the highest mortality rate in the developed 
world compared to any other disease, including cancers 
(http://www.bhf.org.uk, 2008). In Europe 21% of all deaths in men (Figure 1.1A) 
and 22% of all deaths in women (Figure 1.1B) can be attributed to CHD. 
Approximately 2.5 million people are living with CHD in the UK, accounting for 
around 94,000 deaths per year (http://www.bhf.org.uk, 2008).  
When an atherosclerotic plaque within a coronary artery is acutely disrupted it 
can completely occlude the vessel, causing ischaemia and often, myocardial 
infarction (MI). The resulting ischaemic damage to the heart vasculature and 
muscle causes survivors to suffer from negative cardiac remodelling, including 
tissue necrosis and formation of non-contractile scar tissue, resulting in 
debilitating cardiac insufficiency. The current best practice guidelines promote 
prompt revascularisation via administration of fibrinolytic drugs, percutaneous 
coronary intervention (PCI), or in more severe cases coronary artery bypass graft 
(CABG). The effectiveness of these treatments is largely based upon a rapid 
access to medical help. Optimal door to needle time for administration of 
fibrinolytic therapy is within 30 minutes and door-to-balloon time to be within 
90 minutes (Members et al., 2004, Brodie et al., 2001). Achieving treatment 
within these timescales remains challenging. While procedural revascularisation 
reduces the risk of further infarction and ischaemia, it does nothing to heal 
injured tissues, reverse the ventricular dysfunction already established or 
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restore the substantial cardiomyocyte deficit. As many as 1 billion 
cardiomyocytes can be damaged as the result of a major MI (Murry et al., 2006). 
This leads to an inflammatory response in which macrophages remove the 
damaged cells, which are replaced with scar tissue. Pharmacological 
intervention does go some way to lessen symptom severity, however cannot stall 
the inevitable progression to congestive heart failure, for which the median 
survival without intervention is 1.7 years in men and 3.2 years in women (Lloyd-
Jones, 2001). 
In addition, peripheral arterial disease (PAD) is a marker of systemic 
atherosclerosis, in which build up of atheroma in arteries supplying the leg 
muscles can lead to critical limb ischaemia (CLI). PAD affects 4-12 % of people 
aged between 55 and 70 years of age, and 20% of those over 70 years of age 
worldwide (Robless et al., 2007). Patients with PAD suffer from a profound 
reduction in functional mobility and balance capacity, depression and overall 
poor quality of life (Ruo et al., 2007, McDermott et al., 2011). In addition, 
patients with PAD have the same risk as patients with CAD of death from cardiac 
or cerebrovascular causes (Hirsch et al., 2006). Currently, the management of 
PAD includes smoking cessation, strict control of diabetes (if present), control of 
hypertension (if present), control of cholesterol levels, exercise therapy, anti-
platelet therapy and surgical or endovascular revascularisation using balloon 
angioplasty, stent placement or bypass surgery. Success of these treatments can 
be limited by restenosis after angioplasty or bypass surgery or by a lack of 
suitable vessels to perform the bypass. If these strategies fail then major 
amputation is often the only option left, which occurs in approximately 30% of 
all incidences of severe limb ischaemia (Winitsky et al., 2005, Bradbury et al., 
2005). Therefore regenerative medicine therapies could allow new strategies for 
revascularisation of ischaemic limbs, with the goal being to stimulate new vessel 
formation. 
Regenerative medicine can be defined as focus on the “repair, replacement or 
regeneration of cells, tissues or organs” (Mason and Dunnill, 2007) and has seen 
a surge in popularity in recent years. If such technology achieves its full 
potential, an alternative cell-based regenerative treatment for cardiovascular 
diseases would be extremely attractive. 
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Figure 1.1: All cause European deaths in 2009.  
All cause mortality in 2009 in Europe for men (A), women (B). Source: BHF. 
 
1.2 Cardiovascular regenerative medicine 
1.2.1  Intrisic regeneration 
Unlike tissues such as skeletal muscle or liver, the postnatal human heart has 
very little (if any) capacity for regeneration after damage. A key goal of 
cardiovascular regenerative medicine is to repopulate the ischaemically 
damaged area with functional cardiomyocytes and vascular endothelial cells, in 
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order to effectively increase the functionality of the damaged heart as 
demonstrated in animal models (Segers and Lee, 2008).  
The candidate cell population for these regenerative strategies would need to 
have several key properties; it must have myogenic and/or angiomyogenic 
potential to replace the elements of tissues that have been lost, be easily 
produced in large quantities, have high survival rates once transplanted and be 
non immunogenic, preferably useable without the immunosuppressive drug 
regimes in force for donor transplant.  
The regeneration of the heart has remained a controversial yet intensely 
investigated area for over 150 years. Replacement of lost myocytes to improve 
cardiac function is a key aim for cell therapy. Similarly, improvement in blood 
flow in tissue ischaemia, both cardiac and peripheral, is an important endpoint 
for cell therapy strategies.  
It seems possible that the mammalian heart has some endogenous regenerative 
potential, but that it remains sub-optimal for repair of the damage caused by 
cardiovascular complications (Winitsky et al., 2005, Jackson et al., 2001, Oh et 
al., 2004).  
Although amphibious, zebrafish have been extensively used as a model organism 
for heart regeneration due to its amenability to genetic modification and 
capacity for cardiac regeneration (Poss et al., 2002). In landmark studies 
involving surgical amputation of the cardiac apex (which accounts for 
approximately 20% of the ventricular mass) zebrafish were able to completely 
regenerate the area, initially with a fibrin/collagen clot which was then 
replaced steadily with new, functional heart tissue within 30 days (Jopling et 
al., 2010). In transgenic zebrafish where all pre-existing cardiomyocytes were 
labelled GFP+ by tamoxifen treatment, it was shown that the new tissue was 
also GFP+ and was therefore derived from division of existing cardiomyocytes 
and not from a progenitor population as was previously hypothesised (Kikuchi et 
al., 2010, Jopling et al., 2010).  
Limited cardiac regeneration has also been documented in rodent studies 
(Soonpaa and Field, 1998). In order to ascertain whether cardiomyocyte renewal 
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was due to existing cardiomyocyte division similar to zebrafish, or the result of 
migratory cardiac progenitor stem cells, studies using labelled cardiomyocytes in 
transgenic adult mice were performed. GFP was only expressed in 
cardiomyocytes with 83% successfully labelled (Hsieh et al., 2007). After 1 year 
of normal aging the percentage of GFP+ cardiomyocytes remained the same, 
however after MI the percentage dropped to 67.5% GFP+ cells in areas around 
the infarction (Hsieh et al., 2007). This would suggest the regeneration of these 
areas was not the result of existing cardiomyocytes dividing, but that a 
progenitor/stem cell population was responsible. 
Recent studies performed in neonatal mice have highlighted the fundamental 
differences between cardiac regeneration in zebrafish and mammals. There are 
important differences between fish and mammalian cardiac structure with the 4 
chambered double circulation heart of mammals working at high pressure 
compared to the 2 chambered single circulation fish heart, which more closely 
resembles the mammalian heart before septation in the embryo (Porrello et al., 
2011). Researchers hypothesised that due to the similarities between the 
embryonic mammalian heart and the adult zebrafish heart that the mechanisms 
of regeneration might be conserved (Porrello et al., 2011). Resection of ~15% of 
the embryonic mouse heart of 1 day old neonatal mice resulted in a similar 
zebrafish-like process being observed; complete regeneration beginning with a 
clot which is gradually replaced with functional cardiac tissue derived from 
existing cardiomyocytes and full function appearing to be restored by 21 days 
(Porrello et al., 2011). However, performing this procedure in 7 day old 
neonates did not induce cardiac regeneration, but instead resulted in significant 
fibrosis and scar formation. Therefore, the ability of the neonatal mammalian 
heart to regenerate was lost within the first week of life (Porrello et al., 2011). 
Many questions remain, for example whether the loss of regeneration is due to 
adult cardiomyocytes intrinsic withdrawal from cell cycling or a loss of mitogenic 
cell signals in the adult heart. 
Cardiac regeneration in the adult human remains difficult to study and a 
contentious subject area, with a variety of techniques attempted to overcome 
the many technical difficulties. Studies using direct measurement of DNA 
synthesis or expression of markers associated with proliferation, pulse-chase 
experiments and measurement of 14C levels (caused by nuclear bomb tests in the 
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1950’s incorporated into DNA) as an indication of cell turnover appear to suggest 
that human cardiomyocytes do divide, albeit at low levels and that this is 
increased post-MI (Bergmann et al., 2009). However, the rate at which this turn 
over occurs depends on the experimental technique used, ranging between 
complete replacement every 4.5 years to ~50% of cells being replaced over a 
lifetime (Steinhauser and Lee, 2011). Regardless of the most accurate estimates, 
the rate of innate regeneration is not sufficient to repair damage after MI. 
Clearly, novel interventions are therefore required.  
The physiological response to PAD involves vascular remodelling of the collateral 
blood vessels. In a process termed arteriogenesis, the diameter of the pre-
existing vessels in an effort to restore perfusion to the ischaemic area and is 
thought to be stimulated by shear stress (van Royen et al., 2001). Angiogenesis is 
the process of new capillary formation within a tissue and is thought to be 
stimulated by ischaemia (Hershey et al., 2001) This effect is blunted in those 
with diabetes as a co-morbidity, which accounts for a substantial proportion of 
those affected (Spinetti et al., 2008) and often is inadequate to rescue 
ischaemic tissue, hence the requirement for new therapeutic strategies.  
1.2.2 Cardiovascular cell therapy 
Use of cell therapy in cardiovascular regenerative medicine remains an 
attractive prospect and substantial work is ongoing worldwide. The main goals of 
a cell therapy strategy for heart disease and PAD remain prompt restoration of 
blood supply to the affected areas in order to salvage ischaemic tissue and/or 
regeneration of tissues previously lost to ischaemia.  
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Figure 1.2: Schematic representation of cardiovascular cell therapy, and the major barriers to success. 
The hostile environment that any cell therapy population will face upon introduction after MI or CLI, including ischaemia, immune system activation and inflammation 
and extensive scarring. It is not yet known whether the cells themselves will elicit a regenerative response or if paracrine factors produced by the cells will exert any 
benefit seen. Adapted from (Steinhauser and Lee, 2011). 
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1.2.2.1 Skeletal myoblasts 
One of the first regenerative strategies to improve myocardial ischaemia 
involved direct injection of autologous skeletal myoblasts (SKM) (Menasche, 
2007). Although not able to differentiate into cardiomyocytes (Laflamme and 
Murry, 2005), myoblasts are contractile, can be harvested for autologous 
transplantation, are resistant to ischaemia, able to differentiate to myotubes in 
vivo  and can improve ventricular function in animal models (Menasche, 2007). 
However they do not couple electrically to the existing cardiomyocytes and 
therefore beat asynchronously (Menasche, 2007). Clinical trials have focused on 
chronic ischaemic cardiomyopathy rather than post MI due to the need for 
autologous SKM to undergo expansion ex vivo before being used therapeutically. 
However, although good safety data was observed there was an increase in 
arrhythmia events in the phase 1 clinical trial (Menasché et al., 2003). Upon 
further investigation little benefit was observed in the prospective randomised 
placebo-controlled phase 2 trial (MAGIC) in patients with chronic ischaemic 
cardiomyopathy, with the trial discontinued prematurely (Menasché et al., 
2008). In mouse skeletal muscle a population of cells that can give rise to 
spontaneously beating cells resembling cardiomyocytes has been identified 
(Winitsky et al., 2005) however, no such population of cells have been described 
in the human. As such, it is unlikely that skeletal myoblasts are the most 
effective cell population to utilise in cell therapy for human CVD. 
 
1.2.2.2 Bone-marrow-derived cells 
Early studies reporting transdifferentiation of bone-marrow-derived 
haematopoietic stem cells to cardiomyocytes highlighted the regenerative 
potential of bone-marrow derived cells (Orlic et al., 2001). It has since been 
reported that upon transplantation, haematopoietic stem cells do not 
differentiate into cardiomyocytes but become mature blood cells (Balsam et al., 
2004, Murry et al., 2004a) and elicit no regenerative effect on the myocardium 
(Figure 1.3). Despite these findings, a number of clinical trials involving bone 
marrow derived stem cells as therapy for MI are in progress. Results from the 
clinical trials suggest that delivery of bone marrow derived stem cells is safe, 
but the clinical benefits have been subtle with left ventricular ejection fraction 
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increased by no more than ~3%, below the minimum change of ~5% thought to be 
required to improve quality of life and survival for the patient (Abdel-Latif et 
al., 2007). Other measurements of infarct remodelling or exercise capacity 
seemed to be positively affected by bone marrow stem cell therapy, suggesting 
that bone marrow derived-stem cells are acting in a paracrine fashion to salvage 
ischaemic areas of the heart by secretion of angiogenic growth factors (Korf-
Klingebiel et al., 2008). In vitro studies designed to interrogate this paracrine 
effect further showed that media pre-conditioned on hypoxic and genetically 
modified Akt+ mesenchymal stem cells inhibits apoptosis and can stimulate rat 
cardiomyocytes to contract (Gnecchi et al., 2006). When the conditioned media 
was injected into a rat model of MI, infarct size and LV function was measurably 
improved within 72 hours (Gnecchi et al., 2006). This was considered to be due 
to the presence of several protein including vascular endothelial growth factor 
(VEGF), fibroblast growth factor-2 (FGF2), hepatocyte growth factor (HGF), and 
insulin-like growth factor-1 (IGF-1) being upregulated in hypoxic Akt-MSCs, as 
these factors could mediate the beneficial effects shown (Gnecchi et al., 2006).  
In 2002, the first small clinical trial using autologous bone-marrow mononuclear 
cells (BMMNC) in CLI demonstrated an improvement in ankle-brachial index 
(ABI), transcutaneous oxygen pressure (TcPO2), rest pain and pain-free walking 
distance at both 4 and 24 weeks post treatment. In contrast, those injected with 
peripheral blood mononuclear cells showed no improvement (Tateishi-Yuyama et 
al., 2002). This promising result stimulated great interest in the therapeutic 
angiogenic capacity of a readily available autologous cell source. Recent clinical 
trials performed with bone marrow derived cells can be found in Table 1.1. Bone 
marrow progenitor cell therapy remains an interesting prospect, and further 
work to investigate the benefits of these treatments in the long term is 
essential. 
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Table 1.1: Studies performed on Bone marrow mononuclear cells for PAD. 
Clinical trials performed using BMMNC in patients with PAD and/or CLI. Adapted from (Lawall et al., 2010). ABI = Ankle brachial index, TcPO2 = trans cutaneous partial 
pressure of oxygen, NM = not mentioned, + = increase, - = decrease, +/- = no change. 
 
Year Reference Study Type 
Number of 
Subjects ABI TcPO2 Pain 
Amputatio
n 
+/- overall 
result 
2002  (Tateishi-Yuyama et al., 2002) Randomised, non-blinded controlled trial 45 + + - - + 
2002  (Esato et al., 2002) Patient series/uncontrolled trial 8 + NM - - + 
2004  (Saigawa et al., 2004) Patient series/uncontrolled trial 8 + + - - + 
2004  (Higashi et al., 2004) Patient series/uncontrolled trial 8 + + - - + 
2004  (Miyamoto et al., 2004) Patient series/uncontrolled trial 12 + NM - NM + 
2005  (Nizankowski et al., 2005) Patient series/uncontrolled trial 10 + + - - + 
2006  (Durdu et al., 2006) Randomised, non-blinded controlled trial 28 + + - - + 
2006  (Bartsch et al., 2006) Patient series/uncontrolled trial 10 + + NM NM + 
2006  (Miyamoto et al., 2006) Patient series/uncontrolled trial 8 NM NM - NM + 
2007 (Kajiguchi et al., 2007) Patient series/uncontrolled trial 7 +/- + - ? +/- 
2007  (Huang et al., 2007) Controlled trial 74 + + - NM + 
2007  (Hernández et al., 2007) Patient series/uncontrolled trial 12 + + - - + 
2008  (Gu et al., 2008) Patient series/uncontrolled trial 16 + + - - + 
2008  (Chochola et al., 2008) Patient series/uncontrolled trial 28 + + - - + 
2008  (Wester et al., 2008) ? 8 NM NM - - + 
2008  (Van Tongeren et al., 2008) Patient series/uncontrolled trial 27 + + - ? + 
2008  (Vriese et al., 2008) Patient series/uncontrolled trial 16 +/- + - ? +/- 
2009  (Amann et al., 2009) Patient series/uncontrolled trial 51 + + - - + 
2009  (Prochazka et al., 2009) Patient series/uncontrolled trial 37 + + - NM + 
33 
1.2.2.3 Endothelial progenitor cells  
In a landmark study by Asahara et al. in 1997, it was reported that a sub-
population of bone marrow derived cells have the ability to differentiate into 
endothelial cells and as such are termed endothelial progenitor cells (EPCs) 
(Young et al., 2007, Asahara et al., 1997). However, there is a lack of consensus 
as to the definition of an EPC, with more detailed characterisation required. 
CD34+ haematopoietic cells were shown to give rise to cells expressing 
endothelial markers both in vitro and in vivo (Asahara et al., 1997). As CD34 is 
also expressed on endothelial cells, other groups have used CD133 as a marker 
for EPCs (Gehling et al., 2000). However, further investigation called into 
question the suitability of these markers when another group were not able to 
derive endothelial-like cells from progenitors that were CD34+CD133+KDR+ (Case 
et al., 2007). In addition, when this cell population was subjected to chromatin 
immunoprecipitation (ChIP) analysis, it was found that the transcriptional start 
site of endothelial nitric oxide synthase (eNOS), a gene which appears to be 
important in EPC mediated functional vascular improvement, was populated by 
repressive histone modifications suggesting that this population of cells are not 
solely fated to give rise to endothelial progenitors (Ohtani et al., 2011). 
Alternatively, several groups have previously shown several different CD34+ or 
CD133+ populations to possess the ability to express endothelial genes and form 
vessel-like structures both in vitro or in vivo (Kawamoto et al., 2006, Kocher et 
al., 2001, Masuda et al., 2011). Furthermore, in the zebrafish model, human 
CD34+ cells contributed to the embryonic vasculature when injected pre-
gastrulation, and when injected post-gastrulation were recruited into newly-
forming vessels (Pozzoli et al., 2011). Further studies involving a subpopulation 
of CD34+ cells which co-express KDR, reported that these cells gave rise to a 
higher incidence of EPCs (Madeddu et al., 2004). In contrast CD133+CD34-KDR+ 
cells were found to be more potent in vascular repair, but appeared to be an 
immature cell type which could further differentiate into CD133+CD34+KDR+ 
cells (Friedrich et al., 2006). CD45 is expressed at a low level on 90% CD34+ 
progenitor cell types, and it was previously reported that it is those cells types 
which remain CD45- which give rise to EPCs, forming endothelial-like structures 
in vitro (Case et al., 2007). Whilst these cells have not been shown to 
differentiate into cardiomyocytes in vivo, it is suggested they play a role in 
promoting angiogenesis (Rubart and Field, 2006, Young et al., 2007) both by 
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directly contributing to the vasculature and by having a paracrine effect on 
cardiomyocyte survival (Narmoneva et al., 2004). However, EPCs isolated from 
patients with diabetes or hypertension display a reduction in their capacity for 
endothelialisation of denuded arteries and blood flow recovery after ischaemia 
when introduced into immunocompromised mice (Giannotti et al., 2010, 
Landmesser et al., 2004, Sorrentino et al., 2007) meaning that the potential of 
EPCs for cardiac regeneration or revascularisation in PAD may be hampered by 
existing co-morbidities in patients. 
1.2.2.4 Cardiac progenitor cells 
The discovery of cardiac progenitor cells (CPCs) have been reported by several 
different groups (Beltrami et al., 2003, Peng et al., 2011). CPC populations 
appear to express different markers suggesting multiple CPC types or CPCs at 
different stages of maturation being isolated and studied, that would perhaps 
converge given the correct stimuli (Pfister et al., 2008). C-KIT expressing CPCs 
have been studied in greater detail than others (Laflamme and Murry, 2011). C-
KIT is expressed on mature cells such as haematopoietic stem cells and mast 
cells, and immature endothelial and cardiomyocytes (Tallini et al., 2009). CPCs 
expressing c-KIT were discovered in the perivascular compartment of the adult 
heart and following isolation from both rat and human hearts, have given rise to 
cardiomyocytes, smooth muscle cells and endothelial cells (Bearzi et al., 2007). 
Studies have also indicated that upon transplantation in the rat, c-KIT+ CPCs can 
induce regeneration in the infarcted heart with myogenesis and angiogenesis 
reportedly being stimulated in the damaged area (Bearzi et al., 2007). A phase I 
clinical trial to test the safety, feasibility and efficacy of this treatment in 
humans is currently underway (SCIPIO, ClinicalTrials.gov identifier NCT00474461) 
(Bolli et al., 2011). Researchers recruited patients with post-MI left ventricular 
dysfunction (LVEF) classified as ejection fraction of less than 40% before 
coronary artery bypass grafting and 1 million autologous CPCs were administered 
by intracoronary infusion at a mean of 113 days post surgery (Bolli et al., 2011). 
Control patients were given no treatment. Interim analyses performed at 4 
months after 14 patients received CPC treatment showed an increase in LVEF 
from 30.3% to 38.5% (p<0.001) with no change in 7 control patients over the 
same time period (Bolli et al., 2011). Infarct size in 7 treated patients on whom 
cardiac MRI could be performed was reduced by 24% at 4 months and 30% at 1 
35 
year. Importantly, there were no CPC related adverse effects reported (Bolli et 
al., 2011).  
Other CPC populations currently under investigation include cardiosphere-
forming cells, so-called for their ability to migrate out of cardiac tissue in 
culture and form spheroids in suspension culture (Chimenti et al., 2010, 
D'Amario et al., 2011). These cells are a mixed population with some expressing 
c-KIT. This population has been reported to be able to differentiate to 
cardiomyocytes both in vitro and in vivo following transplantation (Chimenti et 
al., 2010). An improvement in cardiac function post MI was also observed 
(Chimenti et al., 2010). A phase I clinical trial using CPC cardiospheres forming 
cells after myocardial infarction enrolled patients 2-4 weeks post-MI, and infused 
autologous CPC’s into the affected artery 1.5-3 months post-MI. They recently 
reported that CPC treatment was safe and resulted in reduction of scar mass, 
increase in viable heart mass and regional contractility however end-diastolic 
volume, end-systolic volume and EF did not differ by 6 months (Makkar et al., 
2012). 
Although the recent findings in the CPC field are encouraging, there is a lack of 
research on the endogenous role of CPCs in development, normal physiology and 
ageing, with most of the studies performed involving transplantation and 
alleviation of disease (Laflamme and Murry, 2011). 
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Table 1.2: Current Cell therapy clinical trials for cardiovascular disease. 
Recent clinical trials using cell therapy for cardiovascular disease, including trial identifier, trial name, patient number, cell type used, primary endpoints of the study, 
route of cell delivery, outcome (if any available) and references. 
 
ID Trial Name 
No. of 
Patients Cell Type Primary End Point Route of Delivery Outcome Ref 
NCT007
11542 REPAIR-ACS 100 
Bone marrow-derived 
progenitor cells 
Coronary flow reserve in the 
infarct vessel Intracoronary Ongoing  
NCT003
55186 SWISS-AMI 150 
Bone marrow mononuclear 
cells LVEF Intracoronary No data published 
(Sürder et al., 
2010) 
NCT009
84178 TECAM2 120 
Bone marrow mononuclear 
cells 
LVEF; Left ventricular end-systolic 
volume Intracoronary No data published  
NCT003
50766 EMRTCC 300 
Bone marrow mononuclear 
cells LVEF Intracoronary No data published 
(Dohmann et 
al., 2008) 
NCT006
84021 The TIME Study 120 
Bone marrow mononuclear 
cells LVEF Intracoronary No data published 
(Traverse et 
al., 2009) 
NCT006
84060 
The Late TIME 
Study 87 
Bone marrow mononuclear 
cells LVEF Intracoronary 
 Safe but no 
improvement at 6 
months 
(Traverse Jh 
and et al., 
2011) 
NCT006
91834 ReNeW 50 
Bone marrow mononuclear 
cells 
LVEF; Occurrence of arrhythmia, 
heart failure and death Intracoronary  No data published  
NCT008
74354 REVI-TALIZE 30 
Bone marrow mononuclear 
cells Safety and feasibility; LVEF Intracoronary  No data published  
NCT002
68307 - 60 
Bone marrow mononuclear 
cells Safety Intracoronary 
 Safe and favourable 
remodelling 
(Traverse et 
al., 2010) 
NCT009
39042 - 40 
Bone marrow mononuclear 
cells LVEF Intracoronary  Ongoing  
NCT007
65453 REGEN-AMI 102 
Bone marrow-derived 
progenitor cells LVEF Intracoronary  Ongoing  
NCT004
37710 CARDIAC 50 
Bone marrow-derived stem 
cells 
Mortality; Mortality and Morbidity; 
Left ventricular function Intracoronary  No data published  
NCT002
75977 - 10 
Bone marrow-derived stem 
cells LVEF Intracoronary  No data published 
(Wollert et 
al., 2004) 
NCT005
29932 SELECT-AMI 60 
CD133+ enriched bone 
marrow cells 
Safety; Myocardial thickening in 
non-viable akinetic/hypokinetic LV 
wall segments Intracoronary  Ongoing  
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NCT007
25738 TRACIA STUDY 80 CD34+ cells LVEF Intracoronary  No data published  
NCT009
36819 ENACT-AMI 100 
Early endothelial progenitor 
cells LVEF Intracoronary  No data published  
NCT005
01917 MAGIC 116 Peripheral blood stem cells LVEF Intracoronary  No data published 
(Kang et al., 
2011) 
NCT005
55828 - 25 
Mesenchymal precursor 
cells Feasibility and safety Transendocardial  Ongoing  
NCT008
77903 Prochymal® 220 
Adult human mesenchymal 
stem cells 
Left ventricular end systolic 
volume Intravenous  Ongoing  
NCT008
93360 CADUCEUS 30 
Cardiosphere-derived stem 
cells Safety Intracoronary 
 Safe and favourable 
remodelling 
(Makkar et al., 
2012) 
NCT003
26989 Cellwave Study 100 
Bone marrow progenitor 
cells LVEF Intracoronary  No data published  
NCT008
24005 FOCUS 87 
Bone marrow mononuclear 
cells 
Maximal oxygen consumption, left 
ventricular end systolic volume, 
reversible defect size Transendocardial  No data published 
(Willerson et 
al., 2010) 
NCT008
10238 C-Cure 240 
Bone marrow-derived 
cardiosphere cells LVEF Transendocardial 
 Significantly 
improved LVEF and 6 
min walk test 
Reported at 
BCS 
conference 
2011. 
NCT006
90209 - 30 
Bone marrow-derived stem 
cells 
Left ventricular columns and 
contractility 
Transepicardial 
during CABG  Ongoing  
NCT004
18418 - 60 
Bone marrow-derived stem 
cells LVEF 
Transepicardial 
during CABG  No data published  
NCT010
49867 - 10 
CD133+ Endothelial 
precursor cells 
Regional and global myocardial 
contractility Intracoronary  Ongoing  
NCT010
33617 IMPACT-CABG 20 
CD133+ bone marrow stem 
cells 
Freedom from major adverse 
cardiac event; Freedom from 
major arrhythmia 
Transepicardial 
during CABG  Ongoing  
NCT009
50274 PERFECT 142 
CD133+ bone marrow stem 
cells LVEF 
Transepicardial 
during CABG  Ongoing  
NCT004
62774 Cardio133 60 CD133+ marrow cells LVEF 
Transepicardial 
during CABG 
 Significantly 
improved LVEF 
(Stamm et al., 
2007) 
NCT003
46177 - 30 CD34+ cells 
Safety, LVEF, heart failure 
symptoms Transendocardial 
 Withdrawn due to 
lack of funding  
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NCT006
20048 - 10 CD34+ cells 
Safety, LVEF, heart failure 
symptoms Transendocardial 
 Withdrawn due to 
lack of funding  
NCT002
21182 - 10 CD34+ cells 
Myocardial perfusion 
abnormality/Safety   
 Withdrawn due to 
lack of participants  
NCT007
21045 - 60 
Mesenchymal precursor 
cells Safety and feasibility Transendocardial No data published  
NCT010
76920 MESAMI 10 Mesenchymal stem cells Safety and feasibility Transendocardial Ongoing  
NCT010
87996 
The POSEIDON-
Pilot Study 30 
Bone-marrow derived 
mesenchymal stem cells TE-SAE Transendocardial  No data published  
NCT007
68066 TAC-HFT 60 
Mesenchymal cells/Bone 
marrow cells TE-SAE Transendocardial  No data published 
(Trachtenberg 
et al., 2011) 
NCT005
87990 PROMETHEUS 45 Mesenchymal stem cells Serious adverse events 
Transepicardial 
during CABG  No data published  
NCT009
08622 PERCUTANEO 50 Skeletal myoblasts LVEF; wall motion score index 
Percutaneous 
Implantation  Ongoing  
NCT005
26253 MARVEL 390 Skeletal myoblasts 
6 minute walk test; Quality of Life 
Questionnaire Transendocardial  Ongoing  
NCT004
74461 SCIPIO 40 Cardiac stem cells Safety/Efficacy Study Intracoronary Ongoing 
(Bolli et al., 
2011) 
NCT009
81006 ALCADIA 6 Cardiac-derived stem cells Safety 
Transepicardial 
during CABG  Ongoing  
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1.2.2.5 Human embryonic stem cells 
Derived from the Inner Cell Mass (ICM) of an embryo at the blastocyst stage 
(Thomson et al., 1998, Reubinoff et al., 2000, Shamblott et al., 1998), human 
embryonic stem cells (hESC) have been proposed as a potential source of 
functional, transplantable cells for a variety of cardiovascular-related 
applications including repair of infarcted myocardium, improvement in cardiac 
function and induction of angiogenesis in ischaemic tissues. This broad potential 
is due to the capacity of hESC for self-renewal, scale-up and ability to become 
any cell type in the human body (Evans and Kaufman, 1981, Reubinoff et al., 
2000, Thomson et al., 1998). The ability of hESC to undergo indefinite self-
renewing division, retain a normal diploid karyotype and remain pluripotent 
makes a powerful tool in regenerative medicine. Early studies demonstrated that 
directing differentiation to bias for the cell type of choice was possible, with 
early studies being published for neural generation (Carpenter et al., 2001, 
Reubinoff et al., 2001, Zhang et al., 2001), cardiomyocyte generation (Xu et al., 
2002, Kehat et al., 2001).  
Recently, hESC have been approved for use in phase I clinical trials, with Geron 
conducting the first ever trial in patients with severe spinal cord injury (2009). 
The trial was halted by the FDA when safety concerns were raised over benign 
tumours found in animal models following treatment, however extensive in vivo 
characterisation demonstrated the therapy was safe enough to continue, and 
patients began to be recruited in October 2010. Disappointingly, in November 
2011, Geron discontinued the trial citing financial reasons (Scott and Huggett, 
2012). The 4 patients already enrolled will be followed up as per the original 
study design, however as yet no data has been published and it is thought the 
numbers remain too low to be able to demonstrate efficacy.  
In addition, phase I clinical trials using hESC therapy for the eye disorders 
Stargardt’s macular dystrophy and dry age-related macular degeneration were 
initiated by ACT (NCT01345006 and NCT01344993) (Schwartz et al., 2012). 
Preliminary findings from the first 2 patients to receive the treatment indicate 
that hESC-derived retinal pigment epithelial cells (RPE) transplanted attached 
and persisted during the study, and no adverse effects such as abnormal cell 
growth or immune rejection were present in the first 4 months (Schwartz et al., 
40 
2012). Furthermore, there was no detrimental effect on the patients existing 
vision, and slight improvement in vision was observed in both patients, although 
more so in the patient with Stargardt’s macular dystrophy who went from being 
able to see hand motions, to being able to count fingers (Schwartz et al., 2012). 
These results appear promising, however clearly many more patients require to 
be tested and with longer follow-up times. 
Alternate sources of “stem cells”, produced via the ability to reprogram 
differentiated somatic cells back into a pluripotent stem cell-like state (induced 
Pluripotent Stem Cells, iPSC) by exogenous expression of transcription factors 
such as Kruppel-like factor 4 (Klf4), v-Myc myelocytomatosis viral oncogene 
homolog (avian) (C-Myc), POU class 5 homeobox 1 (POU5F1, Oct4), SRY (sex 
determining region Y)-box 2 (Sox2), Lin-28 homolog A (Lin28) and homeobox 
transcription factor Nanog (Nanog) has been extensively reported and reviewed 
(Lai et al., 2011, Takahashi and Yamanaka, 2006, Yu et al., 2007). Collectively, 
hESC and iPSC offer substantial potential for regenerative medicine.  
Safety concerns with using hESC have largely limited the number of clinical trials 
and difficulties with licensing a therapy for use in humans. Steps should be taken 
to genetically profile the hESC line used to minimise risk of conferring genetic 
mutations (Hovatta, 2011). In addition, cell culture protocols should be good 
manufacturing process (GMP) compliant and xeno-free, however this often 
results in differentiation efficiency being reduced (Sidhu et al., 2008). 
Furthermore, adequate purification measures to ensure no contaminating 
pluripotent cells are left in the population are crucial to reduce the risk of 
teratoma formation, such as FACS or MACS (Tang et al., 2011). As with most 
transplanted tissues, there is a risk of immune rejection (Zhao et al., 2011). 
Steps can and have been taken to address these safety issues, however, these 
technologies should be developed towards the clinic with thorough attention to 
detail, and due caution.  
1.2.2.5.1 Pluripotency 
 
The self-renewing and pluripotent potential of these cell types represent 
complex biological processes, with stringent regulatory processes in place that 
govern cell phenotype. During development, pluripotency in embryonic cells is 
41 
transient, existing for a brief duration. Shortly after embryogenesis initiates, 
cells become “fated” to form the extra-embryonic tissues or pluripotent 
progenitors that give rise to the 3 germ layers, from which all foetal tissues are 
derived. It is these cells which, if isolated and cultured, remain indefinitely 
pluripotent in long term culture (Thomson et al., 1998). However, the 
phenotype of these cells can vary, with some differentiation bias seen. The shift 
from pluripotency to a cell differentiation program involves the inhibition of 
self-renewal in order for the cell to commit to a specific lineage. The 
mechanisms controlling this shift remain incompletely understood. HESC 
differentiation to specific lineages is controlled by complex transcriptional 
activation of gene networks. Concomitantly, regulation in the genome to 
suppress expression of genes driving towards a differentiated cell type is 
required to maintain pluripotency. This is governed by networks including 
transcriptional activation/suppression, epigenetic regulation at the genome level 
as well as post-transcriptional regulation via non-coding RNA molecules including 
miRNAs (Smale, 2010, Kashyap et al., 2009). To maintain pluripotency, a core 
set of pluripotency factors, Oct4 (encoded by Pou5f1), Sox2 and Nanog are 
essential. Their importance was made apparent from several studies; disruption 
of Oct4 through Pou5f1 knockdown resulted in blastocyst stage embryos, 
however the ICM of the embryos were not pluripotent and could only give rise to 
extraembryonic trophoblast lineages (Nichols et al., 1998), knockdown of Nanog 
results in nonviable embryos unable to reach epiblast stage (Silva et al., 2009) 
and knockdown of Sox2 also resulted in embryonic lethality (Avilion et al., 
2003). Although Nanog is not strictly required in order for ESC to proliferate, it 
promotes a stable pluripotent state and co-occupies most sites with Oct4 and 
Sox2 in the genome of ESC (Marson et al., 2008, Chambers et al., 2007). These 
core transcription factors not only occupy and activate essential pluripotency 
genes, they also collaborate to positively regulate their own promoters (Boyer et 
al., 2005) (Figure 1.3). This phenomenon of autoregulatory positive feedback 
explains why overexpression of TF’s can reprogram cells to iPSC, with the 
exogenously expressed factors initiating the endogenous TF transcription 
(Jaenisch and Young, 2008). 
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Figure 1.3: Regulation by core pluripotency transcription factors. 
Oct4, Sox2 and Nanog transcription factors bind to and cause expression of Oct4, Sox2 and Nanog 
genes, resulting in more transcription factor expression. These in turn bind to several hESC 
maintenance genes. 
 
Genome-wide chromatin immunoprecipitation (ChIP) investigation in hESC has 
shown that Oct4, Sox2 and Nanog can bind or indeed co-bind to transcriptional 
start sites of several genes including miRNAs, genes involved in epigenetic 
regulation and genes encoding signalling proteins (Boyer et al., 2005). This 
suggests that Oct4, Sox2 and Nanog are some of the master regulators of 
pluripotency and additionally activate themselves and each other in a complex 
regulatory circuit (Rodda et al., 2005, Boyer et al., 2005). 
1.2.2.5.2 HESC cardiomyocyte differentiation 
 
Differentiation methods for hESC lineage commitment to cardiomyocytes shortly 
followed the initial discovery of hESC (Kehat et al., 2001, Mummery et al., 2003, 
Xu et al., 2002). Developmental biology studies using mouse and other organisms 
have allowed a better understanding of the molecular processes at work, with 
examples of published cardiac differentiation protocols listed in Table 1.2 and 
an overview of marker acquisition during cardiomyocyte differentiation from 
pluripotent hESC in Figure 1.4. 
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Figure 1.4: Overview of marker acquisition during hESC-CM commitment. 
A schematic timeline of hESC-CM differentiation, showing the stages of differentiaton with the 
markers acquired. Adapted from (Adam Young et al., 2011). 
 
Embryoid body (EB) formation involves allowing hESC in suspension to form cell 
aggregates, thereby recapitulating early embryogenesis and allowing 
differentiation to all 3 germ layers, including mesoderm and hence EC, blood 
and cardiomyocytes (Kehat et al., 2001, Mummery et al., 2003, Xu et al., 2002). 
EBs can then be partially dissociated and plated out, with some adhering areas 
spontaneously beating several days later (Laflamme et al., 2007). This typically 
results in less than 1% of cells becoming cardiomyocytes, and as such further 
improvements (such as removal of serum and forced aggregation) to this 
protocol as seen in table 1.2 can greatly increase differentiation efficiency.  
Through detailed research of embryonic development in the mouse and other 
organisms, it was realised that endoderm can play a role in inducing cardiac 
differentiation (Mummery et al., 2003, Mummery et al., 1991). As such, co-
culture of hESC with END2 cells, derived from mouse P19 embryonal carcinoma 
cells, which are a visceral endoderm-like cell line, has been found to induce 
cardiomyocyte differentiation, even in those lines that had been unable to 
differentiate through an EB protocol (Mummery et al., 2003). Indeed, media 
conditioned upon END2 cells was sufficient to induce differentiation in hESC at 
approximately a 10% efficiency (Graichen et al., 2008).  
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Directed differentiation with cells in a monolayer exposed to growth factors has 
been shown to be successful with just 2 factors; activin A and BMP4 (Laflamme 
et al., 2007, Takahashi et al., 2007, Xu et al., 2010). Activin A and BMP4 are 
both members of the TGFβ superfamily, and have established roles in 
mesodermal development and cardiogenesis in the embryo (Ladd et al., 1998, 
Schultheiss et al., 1997). Other growth factors shown to have an effect on 
mesoderm specification and cardiogenesis, include Wnt/β-catenin member 
Wnt3A and dickkopf homolog 1 (DKK1) (Tran et al., 2009). Wnt3A treatment of 
day 0-2 EBs increased mesoderm and cardiac differentiation (Tran et al., 2009), 
and also when Wnt3A was added along with activin A when plating EBs out the 
resulting differentiations contained as much as 50% cardiomyocytes (Paige et al., 
2010). In contrast, addition of DKK1 (which is a canonical Wnt inhibitor) in the 
early stages of differentiation inhibited cardiogenesis (Tran et al., 2009) 
although addition at day 5-10 improved differentiation efficiency (Paige et al., 
2010).  
It is apparent that cardiac differentiation efficiency can be dramatically 
affected by seemingly small changes in concentration, combination or timing of 
growth factor treatment, and it is likely that protocols will require some 
tailoring to individual cell lines. 
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Table 1.3: Examples of published cardiac differentiation protocols.  
Details of published hESC-CM differentiation protocols, listing differentiation style, conditions, growth factor or small molecules used and how many days for, whether 
serum is included, the approximate percentage of cardiomyocyte-like cells derived and references. 
 
Differentiation Conditions Factor/molecule Duration (days) Serum % Cardiomyocytes References 
Embryoid body Spontaneous     Yes <1% 
Kehat et al. 2001., LaFlamme et al. 
2007. 
  Growth Factors BMP4 (0.5 ng/mL) 0 to 1 No 
~40% with low O2 before 
D12 Yang et al. 2008. 
    Activin A (3 ng/mL) 1 to 4       
    BMP4 (10 ng/mL) 1 to 4       
    VEGF (10 ng/mL) 1 to 4       
    bFGF (5 ng/mL) 1 to 4       
    DKK1 (150 ng/mL) 4 to 8       
  Growth Factors BMP4 (1ng/mL) 0 to 1 No ~60% Kattman et al. 2011. 
    bFGF (5 ng/mL) 1 to 3       
    Activin A (6 ng/mL) 1 to 3       
    BMP4 (10 ng/mL) 1 to 3       
    DKK1 (150 ng/mL) 3 to 5       
    VEGF (10 ng/mL) 3 to 5       
    SB431542 (5.4 µM) 3 to 5       
    Dorsomorphin (0.25 µM) 3 to 5       
    DKK1 (150 ng/mL) 5 to 7       
    VEGF (10 ng/mL) 5 to 7       
    VEGF (10 ng/mL) 7 onwards       
    bFGF (5 ng/mL) 7 onwards       
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  Growth Factors 1-thioglycerol (400 µM) 0 to 2   ~95% Burridge et al. 2011 
    PVA (4 mg/mL) 0 to 2       
    Hr-insulin (10 µg/mL) 0 to 2       
    BMP4 (25 ng/mL) 0 to 2       
    FGF2 (5 ng/mL) 0 to 2       
    
Chemically defined lipids 
(1%) 0 to 2       
    Y-27632 (1 µM) 0 to 2       
    1-thioglycerol (400 µM) 2 to 4       
    
Chemically defined lipids 
(1%) 2 to 4       
    HSA (5 mg/mL) 2 to 4       
    L-ascorbic acid (280 µM) 2 to 4       
    1-thioglycerol (400 µM) 4 onwards       
    Hr-insulin (10 µg/mL) 4 onwards       
    
Chemically defined lipids 
(1%) 4 onwards       
END2 Co-culture     
Yes or 
No Higher yield if no serum 
Mummery et al. 2003., Passier et al. 
2005. 
  
Conditioned 
medium SB203580 (5 µM) 0 to 3 No ~20% Graichen et al. 2008 
  Defined medium PG12 (2 µM) 0 to 12 No ~10% Xu et al. 2008. 
    SB203580 (5 µM) 0 to 12       
Adherant culture Growth Factors Activin A (100 ng/mL) 0 to 1 No ~30% LaFlamme et al. 2007 
    BMP4 (10 ng/mL) 1 to 5       
  Growth Factors Activin A (100 ng/mL) 0  to 1 No ~50% Paige et al. 2010. 
    Wnt3A (100 ng/mL) 0 to 1       
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    BMP4 (10 ng/mL) 1 to 5       
  Growth Factors BMP4 (25 ng/mL) 0 to 1 No ~65% Zhang et al. 2011. 
    bFGF (6 ng/mL) 0 to 1       
    Activin A (100 ng/mL) 1 to 2       
    Noggin (250 ng/mL) 3 to 5       
    DKK1 (200 ng/mL) 5 to 8       
    RA (1 µM) 5 to 8       
    DKK1 (200 ng/mL) 8 onwards       
  Growth factors Activin A (100 ng/mL) 0 to 1 No ~30-70% Uosaki et al. 2011. 
    BMP4 (10 ng/mL) 1 to 5       
    bFGF (10 ng/mL) 1 to 5       
    DKK1 (100 ng/mL) 5 to 7       
  Growth factors BMP4 (20-40 ng/mL) 0 to 3 No ~24% Elliot et al.2011 
    Activin A (20 ng/mL) 0 to 3       
    VEGF (30 ng/mL) 0 to 3       
    SCF (40 ng/mL) 0 to 3       
    Wnt3A (50-80 ng/mL) 0 to 3       
    Hr-insulin (1 µg/mL) 0 to 3       
  Growth Factors BMP4 (20 ng/mL) 0 to 3 No ~60% Hudson et al. 2012 
    Activin A (6 ng/mL) 0 to 3       
    IWP-4 4 to 15       
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1.2.2.5.3 Endothelial differentiation 
 
Differentiation of hESC to endothelial cells (EC) is a complex and poorly defined 
process and remains suboptimal for cell therapy in humans. Models of hindlimb 
ischaemia in the mouse have previously demonstrated that implantation of 
endothelial cells derived from hESC improves perfusion and limb viability (Sone 
et al., 2007, Yamahara et al., 2008, Cho et al., 2007, Kane et al., 2010a). 
Endothelial differentiation can be achieved by EB, co-culture with other cell 
types or by directed differentiation using growth factors, shear stress, or 
isolation of a progenitor cell phenotype. As with commitment to any lineage, the 
cells undergo dramatic changes in gene expression, miRNA signature, growth 
characteristics and morphology. No standard protocol exists for EC derivation 
from hESC.  
EB differentiation, which gives rise to spontaneous differentiation of several cell 
types simultaneously, can generate ECs but at just 1-3% efficiency and requires 
the use of a problematic dissociation step to yield isolated populations 
(Levenberg et al., 2002, Wang et al., 2004, Cho et al., 2007, Lu et al., 2007). 
Co-culture of hESC with a murine fibroblast feeder layer generated functional 
endothelial cells capable of vessel formation in vivo, although differentiation 
efficiency after isolation of CD34+ cells remained low at ~10% (Wang et al., 
2007b). Directed differentiation protocols offer a feeder-free method of 
inducing differentiation negating the potential for contaminating cell 
populations to be carried over during selection of the cell type of choice. With 
the serum-free culture method reported by Lagarkova et al., fast differentiation 
can be achieved with ~50% cells expressing CD31 and VE-cadherin within 4 days 
(Lagarkova et al., 2008). However, there were no in vivo  functionality 
assessments made and a significant population of pluripotent cells remained 
(Lagarkova et al., 2008). Recently, our laboratory described a feeder-free, 
serum-free method of generating functional endothelial-like cells by directed 
differentiation (Kane et al., 2010a). In vitro the hESC-EC produced nitric oxide, 
migrated across a wound, and formed vessel-like structures in matrigel (Kane et 
al., 2010a). In vivo hESC-EC subjected to differentiation conditions for 10 days 
before being transplanted into the ischaemic hindlimb of a mouse induced 
revascularisation of the limb, an increase in the number of vessels and were 
incorporated into the host vasculature (Kane et al., 2010a). 
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Whether the improvements in hindlimb ischaemia models are a result of the 
injection, the integration of cells into the host vasculature, of a paracrine action 
or a combination of some or all of these actions requires further investigation. 
Coaxing cells to an endothelial cell lineage remains a challenging prospect for 
vascular cell therapy, with several methods resulting in viable prospective cell 
populations. The question of which population of cells would be most clinically 
useful and at what stage to transplant, remains to be interrogated. Our 
laboratory previously reported that mature EC were unable to elicit an 
angiogenic response in animal models of ischaemia, therefore suggesting that an 
endothelial progenitor type cell may be more suited for cell therapy applications 
(Kane et al., 2010a). 
1.2.2.5.4 Epigenetic Regulation of human embryonic stem cells 
 
Control of gene expression can also come from epigenetic modification, where 
post-translational alteration of histone proteins leads to changes in chromatin 
structure (Jenuwein and Allis, 2001, Margueron et al., 2005) . Histone H3 lysine 
4 tri-methylation (H3K4me3) and lysine 27 tri-methylation (H3K27me3) are 
particularly pertinent to hESC, as they are associated with heritable lineage-
specific gene expression profiles as regulated by trithorax- and Polycomb-group 
proteins (Ringrose and Paro, 2004). H3K4me3 recruits nucleosome remodelling 
enzymes and histone deactylases (HDACs), resulting in positive regulation of 
transcription (Santos-Rosa et al., 2003, Pray-Grant et al., 2005, Sims et al., 
2005, Wysocka et al., 2005). H3K27me3 negatively regulates transcription by 
promoting compact chromatin (Grau et al., 2011, Francis et al., 2004, Ringrose 
et al., 2004). During mammalian development, chromatin undergoes crucial 
changes (Park et al., 2012, Delaval and Feil, 2004). Large scale chIP studies 
performed in mESC and hESC report the presence of both H3K4me3 and 
H3K27me3 marks over ~3000 transcriptional start sites (TSS) of genes associated 
with development and lineage specification, thus the term “bivalent” in the 
context of epigenetic regulation was introduced (Bernstein et al., 2006, Ku et 
al., 2008, Azuara et al., 2006). It is thought that these bivalent genes are held in 
a poised state so that dynamic gene expression changes can be quickly and 
precisely effected upon differentiation of pluripotent cells to a defined lineage 
(Bernstein et al., 2006). 
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Figure 1.5: Description of how histone modifications can alter transcription.  
When DNA is wrapped around tightly packed nucelosomes, Transcription Factors (TF) cannot gain 
access therefore the gene remains silenced, as in H3K27me3. In H3K4me3 nucleosomes are less 
tightly packed, allowing TF to transcribe gene. 
 
1.2.2.5.5 MicroRNAs 
 
First reported in C. Elegans in 1993, microRNAs (miRNA; miR) are small non-
coding RNAs that control translation of mRNA by induction of mRNA degradation 
or blockade of translation (He and Hannon, 2004, Mendell, 2005, Lee et al., 
1993). Lin-4 was the first of these powerful molecules to be discovered by the 
joint efforts of the Ambros and Ruvkin laboratories, when it was noted that lin-4 
mutant C. Elegans were unable to lay eggs and displayed a failure in temporal 
development (Chalfie et al., 1981, Lee et al., 2004). It was then discovered that 
a null mutation in lin-14 gene had the opposite phenotype from lin-4 mutation 
(Ferguson et al., 1987, Lee et al., 2004). When the lin-4 gene was cloned it was 
found that the gene had no conventional start and stop codons, and any 
mutation in the putative open reading frame (ORF) did not result in a change in 
function of lin-4 (Lee et al., 1993, Lee et al., 2004). This led to the belief that 
lin-4 did not encode a protein, and upon further investigation it was found to 
encode for 2 transcripts of 61 bp and 22bp in length (Lee et al., 1993, Lee et al., 
2004). Independantly, the Ruvkin laboratory noted that lin-14 was post-
transcriptionally downregulated, and when the 2 groups shared unpublished data 
they realised that the lin-4 transcripts were complementary to a repeated 
sequence in the 3’ UTR of the lin-14 gene (Lee et al., 2004). As a result both 
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groups published that lin-4 regulates lin-14 through its 3’ UTR region, and the 
miRNA field was born (Lee et al., 1993, Wightman et al., 1993) Although small, 
each microRNA can target up to several hundred genes, providing a widespread 
method of regulation. MiRNAs are transcribed into long primary transcripts 
termed pri-microRNA (pri-miRNA) which are processed within the nucleus into 
~70 nucleotide pre-miRNAs by Drosha, a RNase III type protein, and the double 
stranded RNA binding domain (dsRBD) protein DGCR8 (Lee et al., 2003). Exportin 
5 then transports the pre-miRNAs to the cytoplasm (Lund et al., 2004) where 
they are processed by Dicer into a mature miRNA duplex ~22nt in length (Knight 
and Bass, 2001). One strand of the duplex is then preferentially loaded into the 
RNA-induced silencing complex (RISC) which, depending on the level of 
complementarity between the microRNA and its target, blocks translation or 
cleaves the mRNA (Figure 1.6) (Huntzinger and Izaurralde, 2011).  
The focus of many recent studies has been to elucidate the role of miRNAs in 
embryonic stem cells, with research performed either on mouse embryonic stem 
cells (mESC) or hESC.  
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Figure 1.6: microRNA biogenesis. 
In the nucleus, the pri-miRNA is transcribed from the miRNA gene, then processed by DGCR8 and 
Drosha to form the pre-miRNA. The pre-miRNA is then transported to the cytoplasm, where it 
undergoes further processing by Dicer to form a mature miRNA duplex. One strand of this duplex is 
preferentially loaded into the RNA induced silencing complex (RISC), where, dependant on the 
level of complementarity of the miRNA for its target sequence, translation is inhibited or the mRNA 
is degraded. 
 
Early evidence for the contribution of miRNA in the regulation of ESC was shown 
by the use of DGCR8 and Dicer knockout ESC, which lack in all mature miRNAs 
53 
(Kanellopoulou et al., 2005, Wang et al., 2007a). Whilst DGCR8 is not required 
for siRNA processing, Dicer is essential for both miRNA and siRNA. (Denli et al., 
2004, Gregory et al., 2004, Wang et al., 2007a). DGCR8 knockout cells are 
defective in differentiation, abnormally display markers of germ line 
differentiation and are unable to effectively downregulate pluripotency markers. 
(Wang et al., 2007a).  
Dicer-knockout ESC exhibit a slower proliferation rate and an altered cell cycle 
phenotype with an increase in the population of cells at the non-dividing G1 and 
G0 stages of the cell cycle. When differentiated as EBs, Oct4 fails to silence 
completely, in conjunction with the lack of classical differentiation markers 
(Kanellopoulou et al., 2005). 
Although miRNAs are expressed widely in a variety of cell types and tissues, 
there are lower numbers in pluripotent hESC (Gangaraju and Lin, 2009). Specific 
pluripotent miRNAs decrease when a cell differentiation program is initiated 
(Lakshmipathy et al., 2007). The role for these key miRNAs in pluripotent cells 
has been the subject of several studies. MiRNAs involved in self renewal appear 
to be distinct; the miR-302 cluster is expressed in both mESC and hESC, but miR-
290 cluster is expressed only in mESC (Figure 1.6) (Kim, 2009). As mentioned 
previously, DGCR8 knockout mESC exhibit an abnormal cell cycle (Wang et al., 
2007a). To interrogate this further,  266 mouse miRNAs were investigated 
against the DGCR8 knockout background in mESC and assayed for rescue of the 
cell cycle phenotype (Wang et al., 2008b). A set of miRNAs were identified; miR-
291a-3p, miR-291b-3p, miR-294, miR-295, and miR-302 which were able to 
restore cell cycle, and denoted as ES cell-specific cell cycle-regulating (ESCC) 
miRNAs (Figure 1.6). They are reported to function by promoting the G1-S phase 
transition by targeting inhibitors of the cyclinE-Cdk2 complex, Cdkn1a (an 
experimentally validated target), and Rb1, Rbl1, Rbl2 and Lats2 (all predicted 
targets by Targetscan) (Wang et al., 2008b).  
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Figure 1.7: MiRNAs and targets involved in maintenance and inhibition of pluripotency.  
In the maintenance of pluripotent ESC, transcription factors Oct4, Sox2 and Nanog upregulate miR-290 family, -302 family and -92b which in turn negatively regulate 
cell cycle repressors Cdkn1a, Cyclin D1, Rb1, Rbl1, Rbl2 and Lats2. C-Myc upregulates miR-290 family, -302 family, -141, -200, -429, and -17-92 which target cell 
cycle repressors Cdkn1a, Cyclin D1, Rb1, Rbl1, Rbl2, Lats2 and p57. Involved in the inhibition of pluripotency; miR-134, -296 and -470 negatively regulate Nanog, 
miR-134, -296, -470, -200c, -203, -183 and -145 repress Sox2, miR-134, -296, -470, and -145 target Oct4 and miR-200c, -203, -183 and -145 decrease expression of 
Klf4. 
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The proliferation defect observed in Dicer1-knockout hESCs also highlights a 
potential role for miRNAs in cell cycle, with several of the predicted targets of 
the miR-302 family involved in cell cycle regulation (Greer Card et al., 2008). In 
mice, research to elucidate the pathways involved in the failure of Dicer 
knockout ESC to successfully differentiate reveals incomplete promoter 
methylation, leading to deficient silencing of Oct4 expression in these cells 
(Sinkkonen et al., 2008, Benetti et al., 2008). 
Included in the ESCC miRNA group, the miR-302 family share a similar seed 
sequence to those other miRNAs that are prevalent in pluripotent hESC (Stadler 
et al., 2010). This suggests that there is some crossover between genes 
regulated by the ESCC miRNA and is evidence of the high level of redundancy 
often reported in miRNA regulated processes (Wang et al., 2008b). As previously 
mentioned, the transcription factors Sox2 and Oct 4 are essential for the 
maintenance of pluripotency in hESC. It has been shown that Sox2 and Oct 4 
bind to the promoter region of the miR-302 family, and that expression is 
dependant on Sox2 and Oct4 (Figure 1.6). During embryogenesis, Oct4 and miR 
302 family are co-expressed in a spatial and temporal manner during 
development (Greer Card et al., 2008). The miRNA-302 family are highly 
expressed in pluripotent hESC in comparison to other differentiated cell types 
(Suh et al., 2004). Expressed as a long transcript containing (in order 5’ to 3’) 
miR-302b, miR-302c, miR-302a, miR-302d and miR-367, this family shares an 
identical seed sequence and are 89% homologous in the mature miRNA form 
(Barroso-del Jesus et al., 2009). As with most miRNA, there is a high degree of 
conservation of the transcript miR-302 and targets between species.  
In differentiated or lineage-committed cells, the cell cycle displays a longer G1 
phase than the S phase. In pluripotent hESC it is the opposite; with the G1 phase 
shorter than the S phase (Wang et al., 2008b). This accounts for the fast self 
renewal which is one of the defining characteristics of the pluripotent hESC (Qi 
et al., 2009). These differences in cell cycle can be attributed to changes in 
expression of regulatory molecules, such as an increase in expression of cyclin 
D2/CDK4 before the transition of G1 to S phase (Becker et al., 2007). miR-302 
members are predicted (by targetscan) to target several regulators of cell cycle. 
miR-302a translationally represses cyclin D1 in hESC, without degradation of 
mRNA levels. When miR-302 is inhibited in pluripotent hESC, an accumulation of 
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cells in G1 phase can be observed (Greer Card et al., 2008). The overexpression 
of miR-302 in differentiated cell types causes a decrease in G1 phase cells with 
an increase in S phase, associated with reprogramming towards iPS cells (Lin et 
al., 2011). 
Several other miRNA polycistrons, including that of miR-302, were shown to be 
occupied at the predicted promoter region by Oct4, Sox2, Nanog and Tcf3, 
indicating a previously unknown regulatory mechanism (Figure 1.6) (Marson et 
al., 2008). It is thought that stem cell-related transcription factors can, and do, 
activate these miRNAs, which in turn regulate the levels of proteins involved in 
both pluripotency and differentiation. Examples of proteins regulated include 
Lefty1 ,which is involved in transcriptional activity in pluripotent ESC, and DNA 
methyltransferases 3a and 3b, which are essential for differentiation (Marson et 
al., 2008, Nakatake et al., 2006, Sinkkonen et al., 2008). 
In addition, Sox2, Oct4 and Nanog associate with the predicted promoter regions 
of tissue-specific miRNAs, which remain silenced in ESC (Marson et al., 2008). 
The binding of these transcription factors to promoter regions suggests they are 
primed for upregulation when differentiation is begun, but silencing is achieved 
by co-habitation of the transcription factors with inhibitory polycomb protein 
Suz12, which remodels chromatin (Marson et al., 2008). 
C-Myc, another essential gene involved in stem cell self renewal, also forms a 
regulatory negative feedback loop with the miRNA let-7, where mature let-7 
biogenesis is inhibited by c-Myc activating Lin28 (Chang et al., 2009). Mature let-
7 can also inhibit c-Myc expression (Melton and Blelloch, 2010). In a study using 
DGCR8 knockout mESC, it was shown that whilst ESCC miRNA rescued the cell 
cycling defect, the introduction of let-7 family miRNAs induced cellular 
differentiation (Melton and Blelloch, 2010). However, Introducing let-7 family 
miRNAs into wildtype mESC had no effect, suggesting ESCC miRNAs can redress 
the balance (Melton and Blelloch, 2010). 
Further investigation of ESCC miRNAs produced data showing c-Myc is able to 
bind to the promoter of the miR-290 family in mESC  but not the miR-302 family 
(Chen et al., 2008b), which is also expressed in hESC where miR-290 is not. It is 
thought c-Myc indirectly promotes expression of miR-302 however the 
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mechanism of action remains unknown (Lin et al., 2009). C-Myc has also been 
shown to occupy the promoter regions and promote expression of miR-141, miR-
200 and miR-429. Upon overexpression in mESC these miRs prevented 
differentiation when cells were exposed to differentiation inducing conditions 
(Lin et al., 2009). The miR-17-92 family of miRNAs is expressed in pluripotent 
stem cells, as well as several cancers, and have seed sequences remarkably 
similar to those in the ESCC group (Laurent et al., 2008, Marson et al., 2008, 
Mendell, 2008, Wang et al., 2008b and Judson et al., 2009). Although the 
function in ESC has not yet been elucidated, c-Myc has been shown to stimulate 
expression of miR-17-92 cluster in tumour cells (O'Donnell et al., 2005). These c-
Myc miRNAs also appear to play an important role in stem cell self-renewal 
(Smith et al., 2010). Also miR-92b has been shown to repress the Cdk inhibitor 
p57, again promoting the G1 to S phase transition (Sengupta et al., 2009). When 
Marson et al conducted their investigation of transcription factor binding sites in 
mESC, it was shown that Sox2 and Oct4 could occupy the promoter region of 
miR-92b, which suggests it is also important in pluripotency maintenance in 
mESC. 
ESCC miRNAs and the let-7 family of miRNAs are thought to be important 
regulators of ESC function (Melton and Blelloch, 2010). The let-7 promoter 
region is occupied by Sox2, Oct4 and Nanog, with high levels of pri-let-7 
transcripts regulated by the expression of Oct4, however, expression of mature 
let-7 miRNAs is not detected in pluripotent ESC (Melton and Blelloch, 2010). The 
conversion of pri-let-7 to its mature form is inhibited by RNA binding protein, 
and reprogramming factor, Lin28, preventing both Drosha (Viswanathan et al., 
2008) and Dicer (Rybak et al., 2008) processing. Lin 28 and let-7 form a negative 
feedback loop where let-7 inhibits expression of Lin28 (Rybak et al., 2008) which 
is also necessary for the translation of Oct4 (Qiu et al., 2010). 
As discussed previously, miRNA deficient ESC are unable to silence pluripotency 
markers during differentiation (Kanellopoulou et al., 2005, Wang et al., 2007a). 
For successful silencing of pluripotency markers DNA methylation must occur 
(Feldman 2006) but in Dicer deficient cells DNA methyltransferases, Dnmt3a and 
Dnmt3b, are lacking (Benetti et al., 2008, Sinkkonen et al., 2008). However, this 
could be restored via overexpression of the miR-209 family. Interestingly, when 
dicer knockout cells were further investigated, it was determined that the 
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transcriptional repressor Rbl2 was a target of the miR-290 family (Benetti et al. 
2008; Sinkkonen et al. 2008). These results indicate that in the absence of miR-
209 family, levels of Rbl2 are increased resulting in transcriptional repression of 
DNA methyltransferases leading to poor silencing of the pluripotency markers 
and inefficient differentiation observed in these Dicer null cells. 
Other miRNAs have been shown to be required for differentiation of ESC; in 
differentiating mESC miR-134, miR-296 and miR-470 are expressed targeting 
Nanog, Oct4 and Sox2 (Tay et al., 2008) and targeting Sox2 and Klf4 are miR-
200c, miR-203 and miR-183 (Wellner et al., 2009). In hESC undergoing 
differentiation miR-145 is expressed, targeting Oct4, Sox2 and Klf4 (Xu et al., 
2009). Therefore, tight regulation of ESC pluripotency is achieved through a 
complex network of transcription factors and DNA methylation, with miRNAs 
adding a further layer of precision control. 
Research performed on the development of knockout Dicer mice suggested 
miRNAs play a role in development of endothelium, when the embryos displayed 
reduced blood vessel formation, altered expression of VEGF, Flt1, Kdr and Tie1 
and died between days 12.5 and 14.5 of gestation (Yang et al., 2005). To further 
assess the importance of miRNAs in endothelial cells, Suárez et al. Knocked 
down Dicer using a siRNA approach and examined the cell phenotype. They 
found differential expression of several endothelial associated genes including 
Tie-2, Kdr, and Tie-1, and increased activity of the endothelial nitric oxide 
synthase pathway. It was also noted that cells had reduced capability to form 
tubes in a matrigel assay and had reduced proliferation (Suarez et al., 2007). 
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Figure 1.8: MiRNAs and targets involved in endothelial cell function and angiogenesis. 
As yet, there are no named miRNA regulating endothelial differentiation. Involved in endothelial function, miR-126 inhibits expression of Spred-1, PI3KR2 and VCAM-1. 
Implicated in angiogenesis; miR-17-92 targets Tsp-1, CTGT, TIMP-1, HIF-1α, miR-130a represses GAX and homeobox A5, miR-181a negatively regulates Prox1, miR-
210 suppresses HIF and Ephrin-A3, direct targets of miR-296 are unknown and miR-378 downregulates SuFu and Fus-1.  
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In Dicer mutant zebrafish endothelial cells were still present but the circulatory 
system was disrupted (Giraldez et al., 2005). In mice, endothelial cell – specific 
knockdown of Dicer did not result in lethality (probably due to incomplete 
excision of the Dicer gene) but a decreased VEGF-induced angiogenesis and 
retarded recovery after ischaemic challenge were observed (Suárez et al., 
2008).  
The first miRNA reported to be expressed at high levels in mesodermal 
progenitors derived from ESC was miR-126 (Figure 1.7) (Ivey et al., 2008b), 
which in the human genome is situated within the epidermal growth factor like-7 
gene. Found to be essential in maintaining the integrity of vessels in both 
zebrafish and mice (Fish et al., 2008, Wang et al., 2008a), morpholino antisense 
to miR-126 didn’t affect endothelium morphology in zebrafish, but vessels were 
leakier and haemorrhages more frequent (Fish et al., 2008). In mice, the 
targeted knockdown of miR-126 resulted in a similar phenotype, along with 
attenuated cell migration, proliferation and angiogenesis (Wang et al., 2008a). 
That the deletion of miR-126 did not result in embryonic lethality suggests that 
miR-126 does not play a crucial role in differentiation of endothelial cells, and 
this is corroborated by findings showing miR-126 does not control differentiation 
of ESC to the endothelial cell lineage, instead playing a role in the integrity and 
function of the vessel (Fish et al., 2008). Sprouty-related proteins (Spreds) act as 
inhibitors of growth factor-induced ERK activation, as can be brought about by 
VEGF and bFGF (Wakioka et al., 2001). MiR-126 is predicted to target Spred-1 
(Figure 1.7) (Fish et al., 2008). PI3 kinase regulatory subunit 2 (PI3KR2/p85) 
which in turn negatively regulates PI3 kinase, is also a target of miR-126 (Figure 
1.7). In EC with suppressed miR-126 levels, a siRNA knockdown of PIK3R2 
rescued the VEGF-dependent Akt/PKB phosphorylation (Fish et al., 2008). miR-
126 has also been shown to negatively regulate VCAM-1 in a post-translational 
manner in endothelial cells (Figure 1.7) (Harris et al., 2008). 
Fish et al. repeated that miR-146b (known to negatively regulate NF-kB activity 
in studies of cancer (Hurst et al., 2009)), miR-625 (no reported function) and 
miR-197 (reported to induce proliferation in follicular thyroid  carcinoma (Weber 
et al., 2006)) were upregulated in their CD31+ cell population compared to 
CD31- cells, but as miR-126 was the most dramatic change, their function in 
endothelial cells was not studied further. 
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As well as having a potential role in pluripotent ESC, the miR-17-92 family are 
upregulated in tumour angiogenesis; promoting cell proliferation, inhibiting cell 
apoptosis and promoting angiogenesis, which is heightened in Myc-induced 
tumours (Figure 1.7) (Dews et al., 2006). MiR-17-92 members are predicted to 
target anti-angiogenic thrombospondin-1 (Tsp-1), connective tissue growth 
factor (CTGF), and tissue inhibitor of metalloproteinase 1 (TIMP-1) as well as 
HIF1-alpha (Dews et al., 2006, Ohtsuka and Dalton, 2008, Taguchi et al., 2008). 
In mouse models, which displayed impaired angiogenesis due to Dicer deficiency, 
partial restoration of vascularisation could be seen following an injection of miR-
17-92 member, miR-17-5p (Ohtsuka and Dalton, 2008). 
Also previously mentioned, the Let-7 family play a role in angiogenesis and 
endothelial cell biology, and are highly expressed in endothelial cells (Ohtsuka 
and Dalton, 2008). With a role in control of EC proliferation and motility by 
targeting TIMP-1 suggested for Let-7b (Ohtsuka and Dalton, 2008) and let-7f 
promoting sprout formation in vitro, the Let-7 family represent more 
functionally important miRNAs, but their role in differentiation of endothelial 
cells from ESC remains unknown. 
Present in cycling endothelial cells (Chen and Gorski, 2008) and endothelial cells 
derived from hESC (Kane et al., 2010a), the role of miR-130a in differentiation 
of endothelial cells is unclear, but its role in angiogenesis has been extensively 
studied. With its 3’ UTR containing 2 seed sequences for miR-130a, growth arrest 
specific homeobox (GAX) inhibits angiogenesis and regulates EC phenotype along 
with homeobox A5, and expression of both these genes appear to be modulated 
in response to expression of miR130a (Chen and Gorski, 2008). 
Also expressed in hESC derived endothelial cells as well as adult endothelial 
cells, miR-210 is involved in migration and cell survival (Fasanaro et al., 2008) 
stimulating VEGF-driven cell migration and tubule formation on Matrigel when 
overexpressed; when absent these processes were inhibited. miR-210 is thought 
to achieve this by targeting HIF and ephrin-A3 which, when downregulated 
changes the angiogenic response to hypoxia, a key determinant of tissue 
pathology during tumour development (Fasanaro et al., 2008). Although never 
reported in endothelial cells derived from ESC, miR-378 has been implicated in 
angiogenesis, tumour cell survival and growth through repression of tumour 
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suppressors suppressor of fused (SuFu) and Fus-1 (Lee et al., 2007). miR-296 has 
also been suggested as an important part of the angiogenic process, although has 
not been characterised in ESC-EC (Würdinger et al., 2008). 
A key gene involved in lymphatic endothelial cell identity, Prox1, has been 
shown to be bound by miR-181a, and as levels of miR-181a increased, so too did 
the number of cells which switched phenotype towards a blood vascular lineage 
in vitro (Figure 1.7) (Kazenwadel, Michael, and Harvey, 2010). 
Although these miRs have been demonstrated to be expressed in EC, ESC or 
both, the role played in the differentiation of EC from ESC remains unknown and 
warrants further investigation. 
Regulation of cardiomyocyte differentiation from ESC involves miR-1 and 133, 
which were first described in skeletal muscle (Chen et al., 2006) and then 
cardiac muscle (Figure 1.8) (Ivey et al., 2008b). Transcriptionally controlled by 
key regulators of muscle lineage commitment SRF, MyoD and Mef2; miR-1 and 
133 are bicistronic (Kwon et al., 2005a, Zhao et al., 2007a, Rao et al., 2006). 
miR-1 supports differentiation of cardiac progenitor cells and exit from the cell 
cycle in both mammals and drosophila (Kwon et al., 2005a, Zhao et al., 2007a), 
whereas miR-133 has an inhibitory effect on skeletal myoblast differentiation 
whilst maintaining the cells’ capacity for proliferation (Figure 1.8) (Chen et al., 
2006). 
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Figure 1.9: MiRNAs and targets involved in Cardiomyocyte differentiation and function.  
Involved in the differentiation of cardiomyocytes, miR-1 targets HDAC4 and Dll-1 and miR-133 targets SRF and CyclinD2. MiRNAs with a role in the function of 
cardiomyocytes are miR-499 that represses Sox6 and miR-17-92 for which the cardiomyocyte specific targets are unknown. 
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Although co-transcribed, there are differences in the modus operandi of miR-1 
and 133. MiR-1 acts by suppressing non muscle genes and upregulating homeobox 
protein NK2 transcription factor related, locus 5 (Nkx2.5), an early mesoderm 
marker in both mESC and hESC (Ivey et al., 2008b). MiR-1 also increases the 
number of beating areas in adult cardiac progenitor cells, as well as upregulating 
several cardiac genes (Sluijter et al., 2010). In hESC embroid bodies, miR-1 has 
also been shown to upregulate myosin heavy chain (Wilson et al., 2010), 
although the timing of miR-1 upregulation is likely to be crucial (Takaya et al., 
2009a). Direct targets are thought to include histone deacetylase 4 (HDAC4) and 
Notch ligand Delta-like 1 (Dll-1) (Figure 1.8) (Chen et al., 2006, Ivey et al., 
2008b). Targeted deletion of one of the two allelles of miR-1-2 in mice resulted 
in defects in cardiac morphogenesis, electrical conduction and cell cycle (Zhao 
et al., 2007a). 
miR-133 appears to act in a different way to its bicistronic partner. 
Overexpression in either hESC or mESC inhibits expression of cardiac genes and 
stimulated myoblast proliferation by repression of SRF and cyclin D2 (Ivey et al., 
2008b, Takaya et al., 2009a, Chen et al., 2006). Deletion of either of the miR-
133a genes resulted in phenotypically normal mice, but deletion of both caused 
abnormalities in cardiomyocyte proliferation and in the ventricular septum, 
leading to neonatal or late embryonic lethality (Liu et al., 2008). 
The actions of miR-1 and miR-133 are not thought to be confined to cardiac 
lineage commitment, but are also involved in cardiac disease (Condorelli et al., 
2010). 
MiR-208 has an important role in the stress adaptation of the adult heart, and 
shares several common gene targets with miR-499 (van Rooij and Olson, 2007), 
which has recently been reported to be expressed in both adult cardiac 
progenitors and hESC (Sluijter et al., 2010, Wilson et al., 2010). Upon 
overexpression of miR-499 in mESC and hESC, expression of myosin heavy chain 
genes and cardiac transcription factors increase (Sluijter et al., 2010, Wilson et 
al., 2010) whilst downregulation of miR-499 inhibited cardiac differentiation 
(Sluijter et al., 2010). 
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Members of the miR-17-92 cluster may also play a role in cardiac differentiation, 
as knockout mice display retardation of cardiovascular development (Ventura et 
al., 2008), although the phenotype has not yet been fully characterised (Bonauer 
et al., 2009).  
That miRs play an essential role in regulating ESC self renewal and commitment 
to lineages is highly likely, and indeed a hot topic for research. Several studies 
have mapped specific miR expression to a defined role in maintenance of 
pluripotency or differentiation of ESC, with miRs shown to regulate expression of 
transcription factors, cell cycle proteins, epigenetic modifiers and other proteins 
with regulatory roles (Figure 1.8).  
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Figure 1.10: Summary of MiRNAs involved in Pluripotency and Cardiovascular 
Differentiation and Function.  
MiRNAs found in pluripotent ESC include miR-290 cluster, -320 cluster,-17-92 cluster, -141, -200, -
429 and -92b. Endothelial cell associated miRNAs include miR-126, -17-92, -Let-7, -130a, -210, -
378, -296 and -181a. MiRNAs present in vascular smooth muscle cells are miR-1, -143/145, -25 
and  -221. MiR-1, -133, -499 and -17-92 cluster are present in cardiomyocytes cells. 
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The negative regulation of whole pathways of genes made possible by miRNAs 
make for a precision tool able to fine tune gene expression patterning. However, 
knockout of single miRNAs in mice rarely results in embryonic lethality, 
suggesting miRNAs are used to refine differentiation, rather than being the 
master control. 
 
1.3 Aims of thesis 
 
The aims of this thesis were to observe the effect of miRNA modulation during 
differentiation of hESC to cardiomyocytes and to gain insight into the role gene 
expression, microRNAs and epigenetic status played in both primary human 
endothelial cells and hESC derived endothelial cells. It was the overall aim of 
this study to uncover new information on the “master control” mechanisms that 
govern hESC differentiation to cardiovascular lineages. 
These aims were addressed by the following studies: 
 Optimisation and delivery of miRNA-overexpressing lentiviruses to hESC 
undergoing cardiac differentiation. 
 MicroRNA, gene expression and epigenetic characterisation of primary 
endothelial cells and hESC derived endothelial cells. 
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Chapter 2: Materials and 
Methods 
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2.1 General Laboratory Practice 
Laboratory reagents and equipment were of the highest commercially available 
grades. Unless otherwise stated, all chemicals were supplied by Sigma-Aldrich, 
Dorset, UK. Hazardous chemicals were handled as described in the Control Of 
Substances Hazardous to Health (COSHH) guidelines, with a laboratory coat and 
powder-free nitrile gloves worn throughout and using laboratory spectacles, 
facemask or fumehood if appropriate. 
2.2 Cell biological methods 
All tissue culture was performed in biological safety class II vertical laminar flow 
cabinets under sterile conditions. Cells were cultivated at 37°C in a humidified 
incubator atmosphere maintained at 5% CO2.  
2.2.1 Stem Cell culture 
2.2.1.1 Maintenance 
Human embryonic stem cells (hESC) were cultured as a monolayer using feeder- 
and serum free systems with media replaced every 24 or 48 h. Studies were 
performed on SA461 cells (Cellartis, Dundee, UK), RC10 (Roslin Cells Ltd., Roslin, 
UK) and H1 cells (WiCell, Madison, USA).  
SA461 hESC were maintained pluripotent as described previously (Kane et al., 
2010a) in maintenance medium composed of equal parts of a chemically defined 
media  (Liu et al., 2006) comprising DMEM/F12, N-2 supplement (Invitrogen 
(Gibco), Paisley, UK) and B-27 supplement , 1 mM L-glutamine, penicillin (50  
µg/mL), streptomycin (50 µg/mL)and 0.1 mM β-mercaptoethanol (Invitrogen) 
with human Umbilical Wharton Inner Layer media (huWil) (Cellartis) and 10 
ng/mL basic fibroblast growth factor (bFGF) (R&D systems, Abington, UK) and 
routinely passaged at approximately 90%. To passage SA461, cells were washed 
in PBS, incubated in 500 µL Tryple Select (Invitrogen) and observed under a light 
microscope until the cells showed defined borders. Tryple Select activity was 
neutralised by addition of 3 mL Pluripotency Media containing 10 µM ROCK 
Inhibitor Y-27632 (Calbiochem, Merck Chemicals Ltd., Nottingham, UK). Cells 
were detached from the growth surface using a cell scraper (Corning, Corning BV 
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Life Sciences, Amsterdam, Netherlands), resuspended homogenously and seeded 
out into T25 flasks for maintenance or plates pre-coated with fibronectin at 1 
mg/mL (Merck Chemicals Ltd.) at a density of 50,000 cells/cm2.  
RC10 and H1 were later introduced to the laboratory and were routinely 
passaged in corning 6 well dishes pre-coated with Cell Start™ matrix (Invitrogen) 
at approximately 80% confluence to prevent cells from spontaneous 
differentiation through overgrowth. Due to discontinuation of huWil media and a 
move toward animal contaminant free culture systems both cell lines were 
maintained in StemPro™ media (Invitrogen) with the addition of 20 ng/mL bFGF. 
For routine passage of RC10 or H1, cells were washed in PBS, fresh maintenance 
media added and colonies created with the EZ-passage tool (Invitrogen). The 
floating colonies were cluster seeded into StemPro™ maintenance media.  
 
2.2.1.2 Differentiation towards mesoderm/vascular endothelial cell lines 
(EC) 
Experiments often required single cells in which case confluent hESC were 
treated with Tryple Select™ and cells were counted using a haemocytometer 
before plating to ensure accurate seeding density. Cells were differentiated in 
12-well plates at 2 x 104 cells per well, 24-well plates at 1 x 104 cells per well, 
or in T25cm3 flasks at a density of 1.25 x 107 cells per flask. 
To direct cells towards endothelial differentiation, cells were incubated with 
Large Vessel Endothelial growth media (500 mL) with the addition of Large 
Vessel Endothelial cell growth supplement singles pack (final concentrations: 
hydrocortisone, 1 mg/mL; human epidermal growth factor, 10 ng/mL; basic 
fibroblast growth factor, 3 ng/mL; and heparin, 10 mg/mL) (TCS CellWorks, 
Buckingham, UK). This will be referred to as “Endothelial differentiation 
media”. 
During endothelial differentiation media was replaced every 24 h for day 1-4, 
and every 48 h onwards. 
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2.2.1.3 Differentiation towards cardiomyocytes (CM) 
Differentiation towards CM required single cells as described in section 2.1.1.2. 
H1 were seeded onto Matrigel™ (BD Biosciences, San Jose, CA)-coated 48-well 
plates at 3x104 cells per well and infected with a lentivirus with Spleen Focus 
Forming Virus (SFFV) promoter driving either Green Fluorescent Protein (GFP) 
expression, pre-miR-1 or pre-miR-133 as described in 2.1.2.4. The CM 
differentiation protocol is an optimised version of the published by LaFlamme et 
al (Laflamme et al., 2007). After transduction with lentivirus the cells recovered 
for one day. The medium was then changed to RPMI 1640 and 1x of a 50x B27 
stock (RPMI/B27) (Invitrogen) with the addition of 100 ng/mL Activin A (R&D 
systems, Abington, UK). After 24 h the media was changed to RPMI/B27 with 10 
ng/mL BMP4 (R&D systems, Abington, UK) and left for 4 days without media 
change. On day 5 a new medium, advanced RPMI/B27 was used as it was found 
to be more beneficial for cell survival. Media change was then performed every 
48 h until the cells were harvested for total RNA at day 14. At around 7-10 days 
after initiation of the protocol spontaneous beating was observed. 
2.2.1.4 Differentiation towards neuronal lines 
Differentiation towards neuronal cells was performed as reported by Gerrard et 
al. and required single cells as described in section 2.1.1.2 (Gerrard et al., 
2005). H1 were seeded onto Matrigel™ (BD Biosciences) coated 12 well plates at 
1x105 cells per well in N2B27 media (1:1 mix of D-MEM/F12 supplemented with 
N2, and Neurobasal medium supplemented with B27 (all from Invitrogen) 
supplemented with 100  ng/mL mouse recombinant noggin (R&D Systems) 
(Gerrard et al., 2005). Media was replenished every 48 h with samples being 
harvested for total RNA at days 0, 4, 7, 10 and 14. 
 
2.2.1.5 Differentiation towards haematopoetic lines 
Haematopoetic samples were kindly provided by Dr Angela McCahill, Institute of 
Cardiovascular and Medical Sciences. Differentiation towards haematopoetic 
cells was performed as reported by Yung et al. and required single cells as 
described in section 2.1.1.2 (Yung et al., 2011). 
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2.2.2 Tissue culture 
2.2.2.1 Human saphenous vein endothelial cells (HSVEC) 
Saphenous veins were obtained from patients with Coronary Artery Disease (CAD) 
undergoing coronary bypass graft at the Golden Jubilee National Hospital, or 
control patients undergoing elective varicose vein stripping at the Glasgow 
Gartnaval General. These collections were covered by the Glasgow West Ethics 
Co mMittee VASCAB and all participants gave their written informed consent 
prior to participation.  
HSVEC were isolated on the day of surgery by collagenase digestion. Briefly, the 
saphenous vein was removed from the sterile saline solution and gently flushed 
with wash medium (Dulbecco’s Modified Eagle’s Medium (DMEM), 100 IU/ mL 
penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine (Invitrogen, Paisley, 
UK)). The vessel was clamped at one end using a small artery clip and filled with 
a solution of filter-sterilised collagenase (2 mg/mL in wash medium (Sigma-
Aldrich)) clamped at the top and incubated in a sterile petri dish for 15 min at 
37°C in 5% CO2. The vein was then flushed with wash medium and the flow-
through containing endothelial cells collected. A second collagenase digestion 
was performed for 10 min, flow-through collected and cells sedimented by 
centrifugation for 5 min at 2,000 x g at RT. Cells were resuspended in 
endothelial differentiation media and placed into a T25cm2 flask, incubated for 
24 h at 5% CO2 followed by a media change. 
Primary human saphenous vein endothelial cells (HSVEC) cells were cultured in 
endothelial differentiation media (TCS CellWorks) with the addition of 20% heat 
inactivated foetal calf serum (FCS) (Invitrogen). Cells were passaged no more 
than 6 times before use to avoid loss of endothelial phenotype in culture 
(Scoumanne et al., 2002).  
 
2.2.2.2 Human Embryonic Kidney 293T (HEK293T) 
HEK293T cells (ATCC, Teddington, UK) were maintained in HEK293T standard 
medium comprised of Dulbecco’s modified Eagle’s medium (DMEM) 
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supplemented with 10% FCS, penicillin (100 µg/mL), streptomycin (100 µg/mL), 
L-Glutamate (2 mM) and sodium pyruvate (1 mM) (Invitrogen, Paisley, UK). When 
60-70% confluent, HEK293T were passaged using 1x citric saline (10x: 100g KCl, 
44g sodium citrate (both Sigma-Aldrich) in 1L distilled H2O, autoclaved) up to 1:6 
for maintenance or 1:2 for transfection of lentiviral producing plasmids the 
following day. The cells were used for Lentivirus production between passage 
10-30. 
 
2.3 Lentiviral vectors 
 
Lentiviral vectors were second-generation, self-inactivating (SIN), HIV-1 based 
and produced as described previously (Demaison et al., 2002a, Buckley et al., 
2008).  
 
2.3.1 Production of lentivirus 
 
Lentiviral vectors were produced by triple transient transfection of HEK293T 
cells with a packaging plasmid (pCMVΔ8.74), a plasmid encoding the envelope of 
vesicular stomatitis virus (VSVg) (pMDG) (Plasmid Factory, Bielefeld, Germany) 
and an expression plasmid (pHR’SIN-cPPT-SFFV-eGFP-WPRE) containing the 
desired gene under the control of the SFFV promoter (kind gift of Prof. Adrian 
Thrasher, Institute of Child Health, University College London, London, UK). The 
transfection reagent polyethylenimine (PEI; Sigma-Aldrich) was used as 
previously described (Demaison et al. 2002). Per T150 flask of 70% confluent 
HEK293T, 17.5g envelope plasmid, 32.5 g packaging plasmid and 50 g of 
expression plasmid were added to 5 mL OptiMEM I reduced serum media with 
GlutaMax™ I (plus 2400 mg/l sodium bicarbonate, HEPES, sodium pyruvate, 
hypoxanthine, thymidine, trace elements, growth factors and 1.1 mg/l phenol 
red) (Invitrogen), filter-sterilised through a 0.22 µM filter and combined with 
(sterile-filtered) 5 mL OptiMEM containing 1 l of 10 mM PEI. The mixture was 
left for 20 min in the flow cabinet with the light off at RT to allow formation of 
polyplexes, which give efficient DNA binding, have endosomolytic activity and 
are protected from lysosomal degradation. The culture MEM was removed from 
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HEK293T cells and they were washed with 10 mL of OptiMEM. 10 mL of DNA/PEI 
polyplexes were added to each flask and the cells placed back in the incubator 
at 37°C in 5% CO2 for 4 h, after which the transfection mix was removed and 
replaced with 25 mL of fresh HEK293T standard medium (2.1.2.3). At 48 h post-
transfection, the media containing lentiviral particles was taken off, sterile-
filtered through a 0.22 µM  filter unit and kept at 4°C with a further 25 mL 
HEK293T standard medium added (2.1.2.3). At 72 h post transfection the media 
containing lentiviral particles was taken off, sterile-filtered through a 0.22  µM  
filter unit and kept at 4°C for a maximum of 24 h prior to concentration.  
 
2.3.2 Concentration of lentivirus 
Lentiviruses were concentrated by ultracentrifugation before storage and use. 
Media containing lentiviral particles was added to sterile 14 mL ultra-clear 
centrifuge tubes (Beckman Coulter Ltd, Buckinghamshire, UK) which in turn 
were loaded into a SW-32.1 Ti rotor bucket (Beckman Coulter) and placed in the 
SW32 Ti rotor (Beckman Coulter) in an Optima L-80 XP Ultracentrifuge (Beckman 
Coulter). Lentiviral particles were subjected to ultracentrifugation at 92752 x g 
for 1 h and 7 min at 4°C. Immediately after centrifugation the supernatant was 
decanted carefully to avoid disruption to the lentivirus pellet, and the procedure 
repeated until no media remained. The tubes were drained carefully by placing 
them upside down on fresh tissue paper for 2 min, then turned right way up and 
50 µL of OptiMEM added per tube. The tubes were then covered with bijou lids 
and placed on ice for 20 min. Each tube had the volume of OptiMEM pipetted up 
and down the walls of the tube to resuspend the lentivirus pellet thoroughly, 
before aliquots of 20 µL of concentrated lentivirus were stored at -80°C until 
required. 
 
2.3.3 Determination of functional lentiviral titre 
Lentiviral titres were determined by TaqMan® quantitative real-time PCR (qRT-
PCR) detecting  linear double-stranded DNA pre-integration complex as 
previously described (Butler et al., 2001) using the following primer and probe 
sequences: forward, 5’-TGTGTGCCCGTCTGTTGTGT-3'; reverse, 5'-
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GAGTCCTGCGTCGAGAGAGC-3'; probe, 5'-(FAM)-CAGTGGCGCCCGAACAGGGA-
(TAMRA)-3'. Briefly, HEK293T cells were seeded into a 12-well plate at a density 
of 5x104 cells per well in standard media and left overnight at 37°C 5% CO2 to 
attach. Freeze-thawed lentivirus was serially diluted and added as indicated in 
Figure 2.1. The transduction was left for 72 h, cells washed once with PBS, 200 
µL of PBS was added to each well and the plate stored at -20°C for minimum 30 
min. Plates could be stored for several weeks at this stage. The plate was then 
subjected to DNA extraction (see chapter 2.2.1). Serial dilutions of the 
expression plasmid were used to generate a standard curve ranging from 1 x 1012 
to 1 x 100 plasmid copy number. The most concentrated standard was calculated 
from the following equations: 
 To determine the molecular weight of the expression plasmid: 
(bp) x (330 Daltons x 2nt/bp)= Daltons 
Daltons = g/mole 
 To determine the weight of one copy of plasmid: 
(g per mole ÷ Avogadro’s Constant) = g per molecule. 
 To determine the copy number of plasmids per  mL in the plasmid stock: 
(concentration of plasmid in g per  mL ÷ g per molecule) = copy number of 
plasmid per  mL. 
 To prepare the top standard: 
(copy number of plasmid per mL ÷ top standard required) = initial dilution for 
top standard. 
(1000 ÷ initial dilution factor for top standard) =  µL of plasmid stock required to 
make 1 mL of top standard. 
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 Titres ranged from 1 × 108 to 1 × 109 transducing functional U/ mL. Multiplicity 
of Infection (MOI) is the ratio of virus to cells, and ranged between 20 and 200. 
Viral dosing was calculated from the following equation: 
((Cell number) x MOI x No. Of Replicates) ÷ Viral titre = Volume of virus to use ( 
µL) 
Virus suspension aliquots were stored at -80°C, thus avoiding repeated freeze 
thaw cycles. Thawed aliquots were briefly centrifuged and kept on ice.  
 
2.3.3.1 Lentiviral infection protocol 
hESC were seeded into 24 well plates coated with fibronectin (SA461) or 
Matrigel™ (H1) with the addition of ROCK Inhibitor (see section 2.1.1.1.) and 
allowed to attach overnight at 37°C, 5% CO2 in a humidified incubator. Lentivirus 
was added to appropriate pluripotency maintenance media along with 4 μg/ mL 
polybrene (Sigma-Aldrich) and cells incubated overnight in the incubator. The 
media containing lentivirus was then removed and fresh pluripotency 
maintenance media added for 24 h to allow cells to recover.  Cells could then 
either be maintained in pluripotency (section 2.1.1.1.) or directed to 
differentiate to the lineage of choice. 
 
2.3.4 Cryo-preservation and recovery of cell lines 
Cells were collected as detailed above and resuspended in 1 mL pluripotency 
maintenance media for SA461 or StemPro™ for RC10 and H1 with the addition of 
10% dimethyl sulphoxide (DMSO) and 30% FCS per T-25 cells culture flask of cells. 
1 mL of the cell suspension was aliquoted into cryo-preservation vials and 
subjected to cooling using isopropanol at a constant -1°C per minute to -80°C. 
Vials were stored under liquid nitrogen indefinitely. Recovery of cryo-preserved 
cells was performed by adding media pre-warmed to 37°C to the frozen cell 
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suspension, then adding this drop wise to a pre-coated flask (SA461) or plate 
(RC10 or H1). Media was replenished the following day. 
 
2.4 Molecular biology 
2.4.1 Extraction of DNA from cells 
Total cellular DNA was extracted from cells using the QIAamp DNA Mini and 
Blood Mini kit (Qiagen, Crawley, UK) as per manufacturer’s instructions. DNA 
binds to the silica of the QIAamp Mini Spin Column which was washed to remove 
contaminants. Cells were washed in PBS, 200 µL PBS added to each well of a cell 
culture plate and cells detached from the growth surface using a rubber 
policeman. The cell suspension was transferred to a clean 1.5 mL 
microcentrifuge tube and cells sedimented by centrifugation at 300 x g for 5 
min. The supernatant was discarded, the cell pellet resuspended in 200 µL PBS, 
20 µL QIAGEN proteinase K added, 200 µL buffer AL added and the sample pulse-
vortexed for 15 sec. Buffer AL contains chaotropic salt guanidine hydrochloride, 
allowing the nucleic acids to adsorb to the silica membrane of the column while 
the polysaccharides and proteins do not bind and are washed away. The sample 
was incubated at 56°C in a waterbath for 10 min, 200 µL ethanol added and 
mixed by pulse-vortexing for 15 sec. The sample mixture was applied to a 
QIAamp Mini Spin Column and centrifuged for 1 minute at 6000 x g. The spin 
columns were washed with 500 µL of buffer AW1 (containing guanidine 
hydrochloride and ethanol) and then 500 µL of buffer AW2 (containing ethanol) 
was added and subjected to centrifugation for 3 min at 20, 000 x g followed by 
another centrifugation step for 1 minute at 20, 000 x g to eliminate likelihood of 
buffer AW2 carryover. The column was placed into a clean 1.5 mL 
microcentrifuge tube, 50 µL sterile distilled nuclease-free water added directly 
to the membrane, incubated for 1 minute at RT and then centrifuged at 6, 000 x 
g for 1 minute. This was repeated with the eluate to ensure highest possible 
yield. Extracted DNA was stored at -20°C. 
 
78 
2.4.2 Total RNA Extraction 
Using the miRNAeasy Mini Kit (Qiagen, Crawley, UK), total cellular RNA was 
extracted with DNA contamination removed by treatment with TurboDNase™ 
(Ambion, Applied Biosystems, Warrington, UK) as per manufacturer protocols. 
Briefly, 700 µL QIAzol™ Lysis Reagent was added to the cell monolayer which was 
then scraped using a cell scraper, 200 µL pipette tip or a rubber policeman. 
Phenol and guanidine based, QIAzol™ allows efficient lysis of cells and chaotropic 
disruption allows the RNA to adsorb to the column membrane. The cell lysate 
was added into a nuclease-free 1.5 mL microcentrifuge tube and vortexed for 1 
minute to ensure complete homogenisation. Allowing the sample to stand on the 
benchtop at RT for 5 min to promote dissociation of nucleoprotein complexes, 
140 µL chloroform was then added and the tube shaken vigorously for 15 sec. 
The tube was placed on the benchtop at RT for 2-3 min and then centrifuged at 
12,000 x g at 4°C for 15 min to allow the sample to separate into an upper, 
colourless phase containing total RNA, a white interphase containing DNA and a 
lower pink phase containing organic chemicals and proteins. The upper 
colourless phase was transferred to a fresh nuclease-free 1.5 mL microcentrifuge 
tube and 1.5 volumes 100% ethanol added and pipetted up and down 3 times to 
provide optimal conditions for RNA molecules greater than 18 nucleotides to 
bind to the silica-gel membrane of the column. Up to 700 µL of the sample was 
then loaded onto a RNeasy Mini spin column in a 2 mL collection tube and 
centrifuged at ≥8000 x g for 15 sec at RT with the flow-through discarded. This 
was repeated until the entire sample had passed through the spin column and 
then 700 µL of Buffer RWT (containing guanidine hydrochloride and ethanol) 
added and centrifuged at ≥8000 x g for 15 sec to wash. Following this, the spin 
column was washed twice with 500 µL Buffer RPE (a mild washing buffer 
containing ethanol), the first wash performed for 15 sec at ≥8000 x g and the 
second wash performed for 2 min at ≥8000 x g , both at RT. The spin column was 
then placed in a fresh 2 mL collection tube and centrifuged at full speed (13100 
x g) for 1 minute at RT to eliminate any possible carryover of Buffer RPE. The 
spin column was  transferred to a fresh 1.5 mL nuclease-free microcentrifuge 
tube, 30 µL nuclease free water added directly to the membrane and then 
centrifuged at ≥8000 x g for 1 minute with the eluate passed through the spin 
column again at ≥8000 x g for 1 minute to increase yield of RNA. The 
concentration of RNA was then determined by a NanoDrop™ (ND-1000 
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spectrophotometer, Labtech International, Ringmer, UK). At this point the RNA 
could be stored at -80 °C. 
 
2.4.3 DNase Digestion 
DNase digestion was performed using the TURBO DNA-free™ kit (Ambion). The 
reaction mixture for a 30 µL RNA sample comprised 3.5 µL 10x TURBO DNase 
buffer, 1 µL TURBO DNase (2 units/ µL) and 0.5 µL of nuclease-free water. This 
was placed at 37°C for 30 min, after which 5 µL DNase inactivation reagent was 
added and incubated at RT for 2 min. Following this, the sample was centrifuged 
at 6000 x g for 2 min at RT and the supernatant containing the DNase treated 
RNA carefully aspirated off and stored at -80 °C. 
 
2.4.4 cDNA synthesis 
To allow analysis of mRNA, cDNA was prepared from DNAse treated Total RNA 
using random primers and the TaqMan® Reverse Transcription Reagents (Applied 
Biosystems, Warrington, UK). Up to 1 µg of RNA was diluted in nuclease-free 
water to a volume of 7.7 µL. The following reagents were added to create a 
reaction volume of 20 µL: 2 µL of 10x Buffer, 4.4 µL of 25 mM MgCl2 (5 mM), 4 µL 
of dNTPs mix (500 µM each), 1 µL of Random Hexamers (2.5 µM ), 0.4 µL of 
RNase Inhibitor and 0.5 µL of MultiScribe. Samples were placed in a MJ Research 
PTC Gradient Cycler set to 25°C for 10 min to allow pre-annealing, 48°C for 30 
min for reverse transcription, 95°C for 5 min to inactivate reverse transcription 
and then held at 12°C. cDNA was stored at -20°C. 
 
2.4.5 mRNA TaqMan® qRT-PCR analysis  
TaqMan® qRT-PCR was used to quantify the relative gene expression levels of 
genes of interest (Table 1). Based on the detection of a fluorescent signal 
produced proportionally during amplification of a PCR product, the intensity of 
fluorescence released during the amplification cycle is directly proportional to 
the concentration of product produced in each cycle. Short primer sequences 
are designed against a target DNA sequence, between which a probe can anneal. 
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The probe is labelled at the 5’ end with a reporter fluorophore and a quencher 
fluorophore at the 3’ end. When intact, the quencher suppresses all 
fluorescence by the reporter. When the target sequence is present, the probe 
anneals and when the target sequence is amplified by the forward and reverse 
primers during the PCR, the probe is cleaved by AmpliTaq Gold. This means the 
quencher is separated from the reporter, resulting in a detectable increase in 
fluorescence. The fluorescence can be measured directly or relative to a control 
sample. Data is acquired whilst PCR is in the exponential phase and is measured 
when the reporter dye emission intensity rises above a background level, called 
the cycle threshold (Ct). A housekeeping gene which would remain stable and 
constant allows for corrections due to RNA concentration to be made. The ΔCt is 
the difference between the gene Ct and the housekeeper Ct, allowing the signal 
to be corrected against the total RNA content. The mean ΔCt between the 
triplicates on the 384 well PCR plate was calculated which was then used to 
calculate the ΔΔCt which relates the amount of cDNA of the target gene to the 
ΔCt value and the control sample within the experiment. The 2
-ΔΔCt shows the 
fold increase or decrease in gene expression of each sample in comparison to the 
appropriate biological control, which has the value 1 (Livak and Schmittgen, 
2001). 
 QRT-PCR reactions were carried out in 384-well plates in technical triplicate, 
using TaqMan® probes (Table 2.1) and normalised to 18s or GAPDH housekeeping 
genes (Applied Biosystems). Briefly, the reaction mixture of a 10 µL reaction 
comprised 5 µL of 2x Taqman Mastermix, 0.5 µL of probe, 3 µL of water and 1.5 
µL of cDNA. This was added per well of the 384-well plate and run on an ABI 
Prism® 7900Ht sequence Detection System (Applied Biosystems) and mean values 
used in subsequent analyses. 
81 
Table 2.1: List of TaqMan® qRT-PCR Gene Expression Assays. 
List of gene expression assays used in this study, with RefSeq Gene Identifiers and Applied 
Biosystems Assay Identifiers. 
Gene RefSeq Gene ID Assay ID 
18S N/A Hs99999901_s1 
ACTN2 NM_001103.2 Hs00153809_m1 
ANKRA2 NM_023039.4 Hs00969413_g1 
ASCL2 NM_005170.2 Hs00944285_s1 
CXXC1 NM_001101654.1 Hs00969406_g1 
DNMT3L NM_175867.1 Hs01081364_m1 
EHMT2 NM_006709.3 Hs00938384_g1 
FOXA2 NM_021784.4 Hs00232764_m1 
GABPB1 NM_002041.4 Hs01065385_m1 
GAPDH NM_002046.3 Hs02758991_g1  
HDAC5 NM_001015053.1 Hs01108316_g1 
L3MBTL2 NM_031488.4 Hs01002038_g1 
 MLL3 NM_170606.2 Hs01005539_m1 
MNT NM_020310.2 Hs00947071_g1 
NKX2.5 NM_004387.3 Hs00231763_m1  
RAX2 NM_032753.3 Hs00262109_m1 
RBM4 NM_006328.3 Hs01056358_m1 
RFX1 NM_002918.4 Hs00958823_m1 
SNAPC4 NM_003086.2 Hs00967025_g1 
SRA1 NM_001035235.2 Hs00398296_g1 
T NM_003181.2 Hs00610080_m1  
TAF6L NM_006473.2 Hs01008038_m1 
TFAP4 NM_003223.2 Hs01558245_m1 
TNNT2 NM_000364.2 Hs00165960_m1  
TSC22D3 NM_001015881.1 Hs00608272_m1 
UBTF NM_001076683.1 Hs00610733_g1 
USF2 NM_003367.2 Hs01100995_g1 
ZNF35 NM_003420.3 Hs01071488_m1 
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2.4.6 MicroRNA (miRNA) TaqMan® qRT-PCR analysis  
MiRNA expression was assayed by using specific miRNA primers included with the 
TaqMan® microRNA Expression Assays (Applied Biosystems) to reverse transcribe 
sample Total RNA using the miRNA Reverse Transcription Kit. Briefly, in a 7.5 µL 
reaction, 0.075 µL of dNTPS, 0.5 µL of multiscribe, 0.75 µL of 10x RT buffer, 
0.095 µL of RNA inhibitor, 2.08 µL of water, 1.5 µL of 5x RT primer and 2.5 µL of 
Total RNA diluted to 2 ng/µL were added to 1 well of a 96-well plate. This was 
then run on a thermal cycler at 16°C for 30 min, 42°C for 30 min, 85°C for 5 min 
and held at 12°C before being stored at -20°C. 
To perform the qRT-PCR portion of the experiment, 5 µL of 2x TaqMan 
Mastermix, 0.5 µL of specific miRNA probe, 3.835 µL of water and 0.67 µL of 
miRNA RT product were assembled in 1 well of a 384-well plate. Samples were 
normalised to RNU48 housekeeping assay, run in technical triplicate on an ABI 
Prism® 7900Ht sequence Detection System (Applied Biosystems) and mean values 
used in subsequent analyses. A list of assays used can be found in Table 2.2. 
Relative Quantification (RQ) was  calculated using the 2-Ct  method previously 
described in Section 2.2.5 (Livak and Schmittgen, 2001), where each miRNA was 
compared to RNU48 and a control sample. 
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Table 2.2: TaqMan® MicroRNA expression assays. 
List of qRT-PCR TaqMan® MicroRNA expression assays used in this study, including miRNA 
name, MIRBASE accession number and Applied Biosystems Identifier. 
 
Gene 
MIRBASE 
Accession Assay ID 
hsa-miR-1-1 MIMAT0000416 002222 
hsa-miR-23a MIMAT0000078 000399 
hsa-miR-23b MIMAT0000418 000400 
hsa-miR-99b MIMAT0000689 000436 
hsa-miR-125a-5p MIMAT0000443 002198 
hsa-miR-133b MIMAT0000770 002247 
hsa-miR-181a MIMAT0000256 000480 
hsa-miR-181b MIMAT0000270 001098 
RNU48 N/A 001006 
 
2.4.7 miRNA microarray 
SA461 hESC were assayed for miRNA expression using a 2-channel human miRNA 
microarray (LC Sciences, Houston, TX, USA). Total RNA was extracted and DNase 
treated as detailed previously. The miRNA probes were designed around miRBase 
version 10.1 (miRBase, University of Manchester, UK). To assess significance in 
the resulting intergroup comparisons within the dataset Rank Products were 
utilised  as previously described (Breitling et al., 2004) (Caruso et al., 2010) 
allowing statistical significance to be established at a False Discovery Rate (FDR) 
of <0.05.  
2.4.8 Northern Blotting 
miRNA expression was further quantified by Northern Blotting. Briefly, 10μg 
total RNA was run overnight at RT on a 15% denaturing polyacrylamide gel and 
then transferred for 90 min using a Biorad semidry transfer system onto a nylon 
membrane (Hybond, GE Healthcare Life Sciences, UK). Nylon membranes are 
most appropriate as they have a positive charge and the negatively charged 
nucleic acid backbone has a high affinity for them. Following 1-Ethyl-3-[3-
dimethylaminopropyl] carbodimide hydrochloride (EDC) crosslinking at 60°C for 
60 min, the membrane was subject to pre-hybridisation in hybridisation buffer 
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(50% formamide), for 60 min before hybridisation overnight with digoxigenin-
labelled probe specific to each miRNA (Exiqon, Denmark). Formamide lowers the 
annealing temperature of the probe, preventing RNA degradation associated 
with higher temperatures. The membranes were washed with low and high 
stringency wash buffer (Ambion). A mouse anti-digoxigenin antibody (Sigma) was 
then used and bands visualised by development with CDP-
StarChemiluminescent Substrate (Invitrogen). 
2.4.9 Illumina whole genome expression microarray 
Amplification of sample RNA for the Illumina array was achieved by using the 
Illumina® TotalPrep RNA Amplification Kit (AMIL1791) as per manufacturer’s 
instructions. The kit generates biotinylated, amplified RNA for hybridization with 
Illumina arrays. The RNA amplification protocol is based on the method 
developed in the laboratory of James Eberwine (Van Gelder et al., 1990). The 
method included reverse transcription with an oligo(dT) primer bearing a T7 
promoter using Array Script, a reverse transcriptase (RT) designed to yield higher 
concentrations of first strand cDNA than wild-type enzymes which resulted in the 
synthesis of virtually full-length cDNA. The cDNA was then subjected to second 
strand synthesis and cleanup, where it became a template for in vitro 
transcription (IVT) with T7 RNA polymerase. IVT along with biotin-UTP was used 
to generate hundreds to thousands of biotinylated copies of antisense RNA. This 
labelled antisense RNA (cRNA; aRNA) was then hybridised to Illumina Beadchips.  
Starting RNA was subjected to QC checks by NanoDrop to ensure no 
contaminating proteins, DNA, phenol ethanol and salts remained after miRneasy 
RNA isolation. The Agilent® 2100 bioanalyser was employed to ensure RNA 
sample integrity. RNA Integrity Number (RIN) of 8.0+ was deemed acceptable for 
samples to go forward for microarray analysis. In a non-stick, sterile, RNase-free 
tube, 350 ng of Total RNA (50-500 ng is recommended) was brought to 11 µL with 
nuclease-free water. Separately, Reverse Transcription Master Mix was 
assembled at RT in a nuclease-fee tube. For a single 20 µL reaction, 1 µL of T7 
Oligo(dT) Primer, 2 µL of 10X First Strand Buffer, 4 µL of dNTP Mix, 1 µL of 
RNase Inhibitor and 1 µL of ArrayScript were mixed gently, centrifuged briefly 
and placed on ice. 9 µL of Reverse Transcription Master Mix was transferred to 
each RNA sample and the sample mixed by pipetting up and down 2-3 times then 
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flicking the tube 3-4 times with brief centrifugation to bring the sample to the 
bottom of the centrifuge tube. The reactions were then placed in a thermal 
cycler set to 42°C for 2 h, after which the samples were centrifuged and placed 
on ice. On ice, a Second Strand Master Mix was prepared in a nuclease-free tube 
comprising, in order, 63 µL nuclease-free water, 10 µL 10X Second Strand Buffer, 
4 µL dNTP Mix, 2 µL DNA Polymerase and 1 µL RNase H for a single 100 µL 
reaction. This was mixed gently and briefly centrifuged. 80 µL of Second Strand 
Master Mix was added to each sample, the sample mixed by pipetting up and 
down 3-4 times and centrifuged briefly, put in a thermal cycler set to 16°C for 2 
h and placed on ice. 250 µL of cDNA Binding Buffer was added to each sample, 
mixed by pipetting up and down 2-3 times and flicking the tube 3-4 times with 
brief centrifugation and the sample loaded onto the cDNA Filter Cartridge. The 
cDNA cartridge was centrifuged at 10000 x g for 1 minute at RT and the flow-
through discarded. 500 µL Wash Buffer was added to the cDNA Filter Cartridge 
and centrifuged at 10,000 x g for 1 minute with the flow-through discarded and 
the empty cDNA Filter Cartridge centrifuged for an additional minute to remove 
all traces of Wash Buffer. The cDNA Filter Cartridge was transferred to a cDNA 
Elution Tube. 20 µL of pre-heated nuclease-free water at 55°C was added to the 
centre of the filter in the cDNA Filter Cartridge and left at RT for 2 min. The 
cDNA Filter Cartridge was centrifuged for 1 minute at 10,000 x g, leaving the 
double stranded cDNA in the eluate. The cDNA was stored overnight at -20°C at 
this point, as directed by the protocol. Each cDNA sample was transferred to a 
0.5 mL nuclease-free microcentrifuge tube and at RT an IVT Master Mix 
assembled, comprising 2.5 µL T7 10X Reaction Buffer, 2.5 µL T7 Enzyme Mix and 
2.5 µL Biotin-NTP Mix per 25 µL reaction. This was mixed gently, centrifuged 
briefly and placed on ice. 7.5 µL of IVT Master Mix was added to each cDNA 
sample, mixed by pipetting up and down 2-3 times and flicking the tube 3-4 
times with brief centrifugation, placed in a thermal cycler set to 37°C for 14 h. 
The reaction was stopped by the addition of 75 µL Nuclease-free water to each 
cRNA sample, bringing the final volume to 100ul. 350 µL of cRNA Binding Buffer 
was added to each cRNA sample, 250 µL of ACS reagent grade 100% ethanol 
added to sample and the mixture pipetted up and down 3 times. The mixture 
was immediately added to the centre of the filter of a cRNA Filter Cartridge, 
centrifuged at 10,000 x g for 1 minute and the flow-through discarded. 650 µL 
Wash Buffer was then added to the cRNA Filter Cartridge and centrifuged at 10, 
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000 x g for 1 minute, the flow-through discarded and the cRNA Filter Cartridge 
centrifuged for an additional minute to remove all trace of Wash Buffer. The 
cRNA Filter Cartridge was transferred to a fresh cRNA Collection Tube, 200 µL 
nuclease-free water heated to 55°C added to the centre of the filter in the cRNA 
Filter Cartridge and placed in a hybridisation oven at 55°C for 10 min. The cRNA 
Filter Cartridge was centrifuged at 10, 000 x g for 1.5 min, eluting the cRNA. At 
this stage samples were subjected to Nanodrop analysis to ascertain cRNA 
concentration was at least 150ng/µL, if not then samples were concentrated by 
vacuum centrifugation.  
The resultant samples were then hybridised to the Illumina® HumanHT-12 v3 
Expression BeadChip as per manufacturers protocol (cat number BD-901-1002). 
Briefly, the cRNA was pre-heated to 65°C for 5 min, vortexed, pulse centrifuged 
at 250 x g and allowed to cool to RT and 750ng pipetted into a microcentrifuge 
tube with the appropriate volume of nuclease-free water added to bring the 
sample to 5 µL. 10 µL of HYB was added to the sample and the Hyb Chamber 
assembled with 200 µL of HCB in each humidifying buffer reservoir. The sample 
was pipetted onto the centre of each inlet port on the beadchip, the beadchip 
placed into the Hyb chamber and the Hyb chamber placed into an illumina 
Hybridisation over at 58°C for 14 h. The beadchips were removed from the Hyb 
chambers, submerged in diluted wash E1BC buffer and the cover-seal removed. 
Following this the beadchips were placed in a slide rack submerged in a glass 
staining dish containing diluted wash E1BC then transferred to a Hybex 
Waterbath containing High-Temp Wash buffer at 55°C for 10 min. The slide rack 
was placed into a staining dish containing 250 mL fresh Wash E1BC buffer and 
plunged in and out of the solution 5-10 times before being put back into the 
staining dish and placed on an orbital shaker for 5 min at RT at medium speed. 
The beadchips were subsequently moved to a new staining dish containing 250 
mL fresh 100% Ethanol, the sliderack plunged in and out of the solution 5-10 
times and the staining dish placed on an orbital shaker for 10 min at RT. The 
beadchips were transferred back to the original staining dish containing 250 mL 
Wash E1BC buffer, plunged in and out of the solution 5-10 times and placed on 
an orbital shaker for 2 min at RT. The beadchips were subsequently put face up 
into a beadchip wash tray with 4 mL Block E1 buffer and placed on a rocker 
mixer at medium speed for 10 min at RT. The beadchips were transferred to 
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another wash tray containing 2 mL Block E1 buffer and 1:1,000 dilution of Cy3-
Streptavidin and placed on a rocker mixer at medium speed for 10 min at RT. 
Subsequently, the beadchips were transferred to fresh Wash E1BC, plunged in 
and out of the solution 5 times before being placed submerged in Wash E1BC and 
placed on an orbital shaker at  medium-low for 5 min at RT. The slide rack 
containing the beadchips was then transferred to a centrifuge and subjected to 
1,400 x rpm for 4 min at RT after which they were imaged on an Illumina® 
BeadArray Reader. 
Whole genome gene expression was determined for SA461 hESC differentiating to 
endothelial lineage as per design of the miRNA microarray, with data quantile 
normalised and exported from Genome Studio (Illumina, CA, USA) for uploading 
to Partek (Partek Inc., MO, USA) where the data was subjected to transformation 
by Principle Components Analysis (PCA). An analysis of variance (ANOVA) model 
was then created with step-up false discovery rate (FDR), taking into account 
chip effects and allowing pairwise comparisons. The data were then uploaded to 
Ingenuity Pathway Analysis (IPA, CA, USA, www.ingenuity.com) and pathways 
with the most significantly different genes interrogated, as well as dynamic 
expression of genes expressed at specific timepoints. In addition, a primary 
bivalency dataset from H9 hESC (Ku et al., 2008) was integrated with the data 
from the Illumina, allowing a prediction of bivalent status to be made for around 
~2,500 genes. 
2.4.10 Immunocytochemistry 
Cells in culture plates were washed 3 times in PBS and fixed with 4% 
paraformaldehyde (PFA) for 15 min at RT. The PFA was removed and cells 
washed 3 times in PBS, and could be stored with a volume of PBS covering the 
cells at 4°C before continuing with the staining protocol. Cells were then 
exposed to permeabilising/blocking solution (P/B) (PBS, 10% donkey serum, 1% 
BSA and 0.1% Triton-X-100) for 30 min at RT. Primary antibodies were diluted in 
P/B solution as indicated in table X and incubated for 4 h at RT. Excess primary 
antibody was removed by 3 x 5 minute washes with PBS. Cells were subsequently 
incubated with the appropriate secondary antibody diluted in P/B solution as 
indicated in table x for 1 h. Plates were protected from light to prevent photo 
bleaching of sample. Cells were washed for 5 min with PBS on a rocker 3 times 
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to remove excess secondary antibody, a drop of ProLong Gold with DAPI 
(Invitrogen) added to the cell surface and a glass coverslip placed over the top. 
Cells were imaged using a Zeiss Axiovert 200M. 
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Table 2.3: Primary Antibodies. 
Primary antibodies used for Immunocytochemistry studies, with information of the species raised in, dilution used, catalogue number and the supplier. 
 
Protein Species Raised In 
Dilution 
Used 
Catalogue 
Number Company 
Oct 4 Mouse 1 in 200 SC5279 Santa Cruz 
FOXA2 Goat 1 in 50 AF2400 R&D Systems 
Troponin T Rabbit 1 in 200 AB45932 Abcam 
NKX2.5 Rabbit 1 in 100 SC14033 Santa Cruz 
Sarcomeric α-actinin Mouse 1 in 400 A7811 Sigma 
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Table 2.4: Secondary Antibodies 
Secondary antibodies used for immunocytochemistry studies, with information of the species raised 
in, dilution used, catalogue number and the supplier. 
 
Fluorophore Species Raised In Dilution Used 
Catalogue 
Number Company 
Alexafluor-555 Goat Anti-Mouse 1 in 400 A21424 Invitrogen 
Alexafluor-488 Donkey Anti-Goat 1 in 400 A11055 Invitrogen 
Alexafluor-488 Goat Anti-Rabbit 1 in 400 A11008 Invitrogen 
Alexafluor-555 Goat Ant-Rabbit 1 in 400 A21428 Invitrogen 
 
2.4.11 DNA Cloning 
Eukaryotic expression plasmids were employed to create miRNA and 
transcription factor overexpression lentiviruses as well as reporter viruses driving 
GFP. 
2.4.12 Small Scale Plasmid DNA Purification: QIAprep Mini 
Prep kit 
Single bacterial colonies were picked from Luria Agar plates in the morning and 
used to inoculate starter cultures grown in 10 mL Luria Broth containing 100 
µg/mL ampicillin at 37°C in a shaking incubator for 7 h. 2 mL of this was 
aliquotted and stored at 4°C for DNA extraction by QIAprep Mini Prep Kit, 
diagnostic restriction endonuclease digestion and sequencing to ensure cloning 
success.  
Small scale plasmid purification was achieved by using the QIAprep Mini Prep kit 
(Qiagen, Crawley, UK). The kit works based on the alkaline lysis of bacterial cells 
and the binding of DNA to a silica membrane in the presence of high salt buffer 
followed by elution in low salt buffer. Bacteria were harvested by centrifugation 
at 6800 x g, for 3 min at RT. The bacterial pellet was then resuspended in 250 µL 
buffer P1 (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 µg/mL RNase A), 250 µL of 
buffer P2 (200 mM NaOH, 1% SDS) was added to break down the bacterial cell 
wall and denature proteins, lysing the cells. The lysis was then neutralised by 
the addition of 350 µL buffer N3 (proprietary) and allowed high salt binding and 
precipitation of SDS, cellular debris and chromosomal DNA. Samples were then 
centrifuged at 17,900 x g for 10 min at RT and the supernatant applied to a 
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QIAprep spin column containing a silica membrane. The QIAprep spin column was 
then centrifuged at 17, 900 x g for 1 minute and the DNA bound to column 
washed with 500 µL buffer PB to remove endonucleases. A further wash with 750 
µL of buffer PE removed salts and incubation of the column with 50 µL sterile 
nuclease-free water followed by centrifugation 18,000 x g for 1 minute eluted 
plasmid DNA. Plasmid DNA was routinely stored at -20°C. 
2.4.13 Large Scale Plasmid DNA Purification: Qiagen Plasmid 
Maxi Kit 
Large scale plasmid purification was achieved by using the Qiagen Plasmid Maxi 
Kit. The kit is also based on the alkaline lysis principle but DNA is bound to the 
column using an anion-charge membrane. In summary, a single colony of 
transformed bacteria was grown in 10 mL of Luria broth as previously detailed. 
After diagnostics performed to ensure correct clone selected, the starter culture 
was transferred to a conical flask containing 500 mL Luria broth and placed in an 
oscliating incubator overnight at 37°C. Bacteria were collected by centrifugation 
at 6, 000 x g for 15 min at 4°C (centrifuge model). The resulting pellet was then 
resuspended with 10 mL of P1 buffer (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 
µg/mL RNase A) and 10 mL of buffer P2 (200 mM NaOH, 1% SDS) added and 
incubated for 5 min at RT. SDS disrupts the bacterial membrane and NaOH 
denatures the chromosomal DNA and proteins. 10  mL of chilled buffer P3 (3M 
potassium acetate at pH5.5) was then added to neutralise lysis of the bacterial 
cells, mixed vigorously and incubated on ice for 20 min. The precipitated lysate 
was then subjected to centrifugation at 4°C for 30 min at 20, 000 x g and the 
supernatant applied to a QIAGEN-tip 500 column pre-wetted with 10 mL buffer 
QBT (750 mM NaCl, 50 mM 3-morpholinopropanesulfonic acid pH7 (MOPS), 15% 
isopropanol, 0.15% Triton-X 100). The QIAGEN-tip 500 was allowed to empty by 
gravity flow,  washed twice with 30 mL with buffer QC (1M NaCl, 50 mM MOPS 
pH7, 15% isopropanol) and DNA eluted with 15 mL of buffer QF (1.25M NaCl, 50 
mM Tris pH8.5, 15% isopropanol) into a round bottom polypropylene centrifuge 
tube. Eluted DNA was desalted, precipitated by addition of 10.5 mL of 
isopropanol and subjected to centrifugation for 30 min at 15, 000 x g at 4°C. The 
resulting DNA pellet was washed with 5 mL of 70% ethanol and centrifuged for 10 
min at 15, 000 x g at 4°C, the ethanol carefully removed and the DNA pellet 
allowed to air dry before resuspension in 300 µL sterile water. 
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2.4.14 Restriction Digestion 
Digestion of double stranded plasmid DNA was achieved by use of Restriction 
Endonuclease Enzymes. This allowed insertion of specific DNA sequences 
(inserts) into plasmid backbones for expression. Both inserts and plasmid 
backbones were digested with appropriate restriction enzymes to generate 
compatible ends suitable for ligation. Briefly, plasmid DNA was digested with 
restriction endonucleases in either a small scale 20 µL reaction for diagnostic 
purposes (containing 100-200ng of DNA, 2 µL of restriction endonuclease, 2 µL of 
buffer, 1 µL of BSA and made to 20 µL with sterile water, incubated for 1-2 h at 
37°C), or a larger scale 50 µL reaction for isolation and subsequent purification 
of insert or plasmid backbone (comprising 10-20 µg of DNA, 5 µL of restriction 
endonuclease, 5 µL of buffer, 5 µL of BSA and made up to 50 µL with sterile 
water, incubated overnight at 37°C). Reactions were then subjected to analysis 
by agarose gel electrophoresis. 
2.4.15 Agarose gel electrophoresis 
Gel electrophoresis separates nucleic acids or proteins by using a crosslinked 
polymer exposed to an electrical current. This works to separate nucleic acids or 
proteins as they have a negative charge and run towards a positive electrode or 
anode. As the samples migrate through the polymer, pores of the gel allow 
separation dependant on size. Restriction endonuclease digests were 
electrophoresed through an appropriate percentage (0.6-2% w/v) agarose gel 
(Invitrogen) in 1x Tris/Borate/EDTA (TBE) (10 mM Tris, 10 mM boric acid, 10 mM 
EDTA, pH 8.3) with ethidium bromide (Sigma-Aldrich) added at 10 ng/mL. 
Samples and DNA marker ladders (100 bp or 1 Kb) (Promega, Southampton, UK) 
were mixed with 6x blue/green loading dye (Invitrogen) before being loaded 
onto the gel and electrophoresed at a constant voltage of 30-100 V with 1x TBE 
used as running buffer. Bands on the gel were visualised using trans UV 
illumination on a ChemiDoc XRS+ Imaging System (Bio-Rad Laboratories, Hemel 
Hempstead, UK). 
2.4.16 Gel Extraction of DNA 
The Wizard® SV Gel and PCR Clean-Up System is based on the ability of DNA to 
bind to silica membranes in the presence of chaotropic salts. To purify 
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restriction endonuclease digested DNA, samples were electrophoresed on an 
agarose gel and resultant bands localised using UV illumination as described in 
agarose gel elctrophoresis. The bands were excised using a clean scalpel blade 
and placed into a clean, pre-weighed 1.5 mL microcentrifuge tube. DNA was 
extracted from the agarose using the Wizard® SV Gel and PCR Clean-up System 
(Promega, Southampton, UK) following the manufacturers protocol. Briefly, 10 
µL of Membrane Binding Solution (4.5 M guanidine isothiocyanate, 0.5 M 
potassium acetate, pH 5.0) per 10 µg of gel was added and mixed thoroughly 
before being placed in a 65°C waterbath until the gel was dissolved fully. The 
melted gel mixture was then transferred to a silica column where it was 
incubated for 1 minute at RT and then subjected to centrifugation at 16, 000 x g 
for 1 minute at RT. The column was washed twice with membrane wash solution 
(10 mM potassium acetate pH 5, 80% ethanol, 16.7μM EDTA pH 8.0) with 700 µL 
and then 500 µL respectively and centrifuged at 16, 000 x g for 1 minute at RT. 
The column was then centrifuged for 16, 000 x g for 5 min to ensure no ethanol 
carry over. The purified DNA was eluted from the column by addition of 50 µL 
sterile nuclease-free water to the column membrane and centrifugation at 16, 
000 x g for 1 minute and the eluate passed through the column a second time to 
ensure the highest possible yield. DNA was stored at -20°C. 
 
2.4.17 Dephosphorylation of plasmid DNA 
To prevent re-circularisation of plasmid backbone DNA after restriction 
endonuclease digestion, dephosphorylation was performed using the Antartic 
Alkaline Phosphatase (New England Biolabs UK Ltd (NEB), Hertfordshire, UK) 
according to manufacturer protocol. Briefly, 1-5µg of restriction endonuclease 
digested DNA was added to 1/10 volume of 10x Antartic Phosphatase Reaction 
Buffer, 1 µL Antartic Phosphatase and the reaction volume made up with sterile 
water. Following incubation at 37°C for 15 min the reaction was heated to 65°C 
for 5 min to inactivate the enzyme. 
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2.4.18 Ligation of insert into plasmid backbone 
To ligate inserts into dephosphorylated plasmid backbone, T4 ligase (NEB) was 
used as per manufacturer instructions. In summary, ligation reactions were 
carried out at a range of molar ratios to increase the likelihood of the correct 
clone being present. Ratios of 5:1, 3:1 and 1:1 were routinely used.  The formula 
for calculating molar ratios was: 
  ng of Insert: (ng of vector) x (Kb size of insert) x (molar ratio) 
     Kb size of vector 
DNA for ligation, 1 µL of T4 ligase, 1 µL of 10x T4 ligase buffer were added to a 
clean 0.5 mL microcentrifuge tube and reactions were made up to 10 µL using 
sterile water. Reactions were incubated for 1-4 h at RT or overnight at 4°C. 
Ligations could then be transformed.  
2.4.19 Transformation of Chemically Competent Bacteria 
Both JM109 and Top10 chemically competent Escherichia coli (E. coli) bacteria 
(Invitrogen, Paisley, UK) were used as hosts for plasmids detailed in this study. 
The plasmids used had ampicillan resistance to allow for selection of clones. To 
transform, 40 µL of competent cells per transformation were thawed on ice and 
2ng of intact plasmid or 5 µL of ligated plasmid/insert mixes were added. After 
gentle mixing, cells were left on ice for 30 min before being heat-shocked at 
42°C for 30 sec and returned to ice for 2 min. 250 µL of Super Optimal broth 
with Catabolite repression (SOC) medium (2% tryptone, 0.5% yeast extract, 10 
mM sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 
mM magnesium sulphate and 20 mM glucose per 1L)(Invitrogen) was added and 
tubes placed in a shaking incubator (incubator model here) at 37°C for 1 h, 180 
oscillations per minute. Transformation mixtures were plated out onto Luria 
Agar plates containing 100 µg/mL ampicillin (Sigma); for all transformations 20 
µL and 200 µL were plated. Cultures were allowed to dry, plates inverted and 
placed into a 37°C incubator (Heraeus) overnight, and checked for resultant 
bacterial colonies. 
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2.4.20 DNA sequence analysis 
DNA sequences were analysed by dideoxy sequencing. Based on the use of 
dideoxynucleotides labelled with a different fluorophore at the 3’ end with 
missing hydroxyl groups so that another nucleotide cannot bind, this method 
generates a series of different size DNA fragments each with a fluorescently 
labelled dNTP as its terminal nucleotide. This can then be translated by 
excitation with a laser and recording of the wavelength each fluorophore emits, 
building up nucleotide by nucleotide the sequence information.  
Sequencing of cloned plasmids was performed routinely to check for cloning 
efficiency. DNA was prepared as previously detailed and 300ng used as template 
for the sequencing reaction. Briefly, 2nM of forward or reverse primers were 
used (see table for primer sequences), 0.5 µL of Ready Reaction Mix (Applied 
Biosystems, UK), 3.5 µL Sequencing buffer were added to template DNA and 
sterile water to result in a 20 µL volume. This was subjected to 25 PCR cycles of 
96°C for 50 sec, 50°C for 20 sec and 60°C for 3 min. The PCR products were 
then cleaned with CleanSEQ (Agencourt Bioscience Corporation, MA, USA) 
following manufacturers protocol. The resultant sample was then analysed using 
an ABI 3730 automated sequencer and SeqScape v2.0 software (Applied 
Biosystems). 
 
2.4.21 Promoter activity assay 
SA461 hESC were infected with GFP-expressing lentiviruses, either under control 
of a CytoMegaloVirus (CMV) or spleen focus-forming virus (SFFV) promoter with 
the control experiment of uninfected cells of the same passage number. The 
cells were either maintained in pluripotency (section 2.1.1.1), underwent 
directed differentiation to vascular endothelial cells (section 2.1.1.2) , were 
allowed to passively differentiate by addition of untreated MEM media 
(Invitrogen, Paisley, UK), or underwent directed to cardiomyocyte lineage 
(section 2.1.1.3). Visual analysis of promoter-driven GFP was assessed on a daily 
basis. 
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Cellular protein was harvested at 2 days and 7 days post infection by washing in 
PBS twice, 0.2% Triton-X-100 in PBS (v/v) added and cells scraped from the 
growth surface using a rubber policeman. Plates were placed at -20°C to ensure 
complete cell lysis and could be stored indefinitely before protein samples were 
subjected to a Green Fluorescent Protein (GFP) luminescence assay and protein 
quantification by BCA assay. 
 
2.4.21.1 Green Fluorescent Protein (GFP) Luminescence assay 
Cells were prepared as detailed in 2.2.21. Dilutions of recombinant eGFP 
(Clontech, Basingstoke, UK) in cell lysis buffer were used to create a standard 
curve as follows: 1 µg/mL, 0.5 µg/mL, 0.25 µg/mL, 0.1 µg/mL, 0.05 µg/mL and 
0.01 µg/mL. 20 µL of each standard was added in duplicate and of each sample 
in triplicate to a pre-chilled black 96-well plate with 80 µL of cell lysis buffer. 
The plate was then analysed immediately on a Wallac Victor2 plate reader 
spectrophotometer (Wallac, Turku, Finland) at absorbance 507 nm. For both 
standards and samples average relative fluorescent units (RFU) were calculated 
and a linear standard curve generated. Expression of eGFP was normalised to 
total protein amount determined by BCA assay (2.2.21.2) and results shown as 
RFU/mg of protein (Nicklin et al., 2001). 
2.4.21.2 Determination of protein concentration 
Protein concentration in cellular samples was quantified using a colourimetric 
detection protocol, the bicinchoninic acid (BCA) Protein Assay Kit (Pierce, 
Rockford, Illinois, USA) following manufacturer’s instructions. In summary, a 
standard curve from the following Bovine Serum Albumen (BSA) dilutions was 
created: 2 mg/mL, 1.5 mg/mL, 1 mg/mL, 750 µg/mL, 500 µg/mL, 250 µg/mL, 
125 µg/mL and 25 µg/mL. Working reagent (WR) is created by mixing 50 parts of 
BCA Reagent A with 1 part of BCA Reagent B with 200 µL of WR added to 25 µL of 
standard or sample in duplicate in a 96-well plate. The plate was incubated for 
30 min at 37°C in the dark and then analysed at absorbance 570 nm using a 
Wallac Victor2 plate reader spectrophotometer (Wallac). Results were 
extrapolated by plotting the unknown samples onto the standard curve created 
by the standard BSA dilutions. 
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2.4.22 Manipulation of miRNA expression – overexpression 
A library of human pre-miRNA clones was obtained (under MTA from Reuven 
Agami, Netherlands Cancer Institute) that encode for over 350 human miRNAs. 
These are in retroviral and lentiviral clones under the control of the CMV 
promoter.  
The miRNA’s of interest were cloned in intermediate pri-miRNA form from the 
retrovirus plasmid to lentiviral expression vector under control of the SFFV 
promoter via the intermediate vector pCDNA3.1/Zeo(+) (Figure 5). The success 
of the cloning was verified by sequencing, diagnostic gels and TaqMan® miRNA 
expression assay. 
The revised microRNA overexpression strategy involved designing inserts 
containing individual pre-miRNA stem loop sequences between appropriate 
restriction endonuclease sites, kozak sequence and stop codon (Figure ??). These 
were then chemically synthesised by GeneArt® (Life Technologies, Warrington, 
UK) and subjected to step-wise cloning by restriction endonuclease digestion to 
liberate from the GeneArt® plasmid, ligation into PCDNA3.1+/Zeo (Invitrogen) 
followed by ligation into a lentivirus expression plasmid, pSFFV-MCS. Success of 
cloning was verified by sequencing, diagnostic agarose gel electrophoresis and 
TaqMan® miRNA expression assay. 
2.4.23 Chromatin ImmunoPrecipitation 
In order to ascertain which methylation signature the transcriptional start site 
(TSS) of FOXA2 had, chromatin immunoprecipitation (ChIP) was performed. 
Adherant hESC either maintained pluripotent or differentiated using endothelial 
differentiation media were first subjected to cross-linking by the addition of 1% 
w/v formaldehyde (Sigma-Aldrich) diluted in culture media with flasks placed on 
a rocker for 15 minutes at room temperature. To quench the cross-linking 
reaction, glycine was added to a final concentration of 125 mM with a further 5 
minutes rocking at room temperature. The media was discarded and cells 
washed twice in standard PBS (Gibco). PBS with protease inhibitor cocktail 
(Roche, Hertfordshire, UK) was used to scrape cells from the growth surface, 
before samples were centrifuged at 500 x g for 5 minutes at 4°C. The 
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supernatant was carefully aspirated and cell pellets were snap frozen and stored 
at -80°C indefinitely until required. 
To prepare chromatin, cell pellets were resuspended in Sarkosyl lysis  buffer 
(SLB, 10mM TRIS pH 8.0, 0.5% w/v Sarkosyl, 5mM EDTA, 2.5mM EGTA) plus 
protease inhibitors and incubated on ice for 10 minutes. Cells were then 
collected by centrifugation at 200 x g, for 5 minutes at 4°C, the supernatant 
carefully aspirated and the pellet resuspended in SLB again. 5 µL of the cell 
suspension was placed onto a glass slide and checked by microscope to ensure 
cells were homogenously resuspended. The cells were then aliquotted into 2 mL 
microcentrifuge tubes and subjected to sonication in a Diagenode Bioruptor XL 
on H, 2 seconds on, 2 seconds off for 15 minutes at 4°C. After sonication, 5µL of 
the sample was placed on a glass slide and visualised by Olympus IX51 
microscope to ensure sonication of cells a success. Samples were subjected to 
centrifugation at 13,100 x g for 5 minutes at 4°C twice with the supernatant 
moved to fresh tubes in between centrifugations. The supernatant was carefully 
collected and identical chromatin samples pooled into fresh tubes. The samples 
were measured by Qubit dsDNA kit (Invitrogen) and diluted with lysis buffer used 
to normalise the concentration of the samples. After that sonicated chromatin 
was diluted at 1:4 with Immunoprecipitation Dilution Buffer (IPDB; 20mM Tris 
pH8.0; 1mM EDTA pH8.0; 1mM EGTA pH8.0; 1% Triton X100; 0.01%SDS; 150mM 
NaCl) to prepare input. 
For immunoprecipitation, 200µL of magnetic Dynabeads® M-280 Sheep anti-
Rabbit IgG (Invitrogen) were simultaneously washed and blocked with 0.5% w/v 
BSA in PBS twice, then 2mL of 0.5% w/v BSA in PBS added to the beads to 
resuspend and 500µL of bead suspension aliquotted for each IP. 2.5µg of total H3 
antibody (AB1791, Abcam), H3K27me3 antibody (C36B11, Cell Signalling, NEB) or 
H3K4me3 antibody (AB8580, Abcam) was added to beads and incubated for 1 
hour at room temperature with agitation. The beads were washed in IPDB 3 
times before 450µL of chromatin sample being added to each tube, and samples 
placed at 4°C for 2-3 hours with agitation. The beads were then washed twice 
with IPDB, once with high salt wash (20mM Tris pH8.0; 1mM EDTA pH8.0; 1% 
Triton X100; 0.01%SDS; 500mM NaCl), once with IPWB2 (10mM Tris pH8.0; 1mM 
EDTA pH8.0; 1% NP40; 1% Na-DOC; 250mM LiCl) and twice with TE buffer (10mM 
Tris pH8.0; 1mM EDTA). 50 μL of 10% Chelex-100 suspension (BioRAD ) was then 
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added per IP, vortexed, and incubated for 15 min at 97C. The IPs were vortexed, 
briefly centrifuged and 450μL of nuclease-free water added before being 
vortexed and spun down again ready for PCR.  
To perform qPCR using primer pairs directed at TSS of the gene of interest 
FOXA2 (Table 2.5), the DyNAmo ColorFlash kit (Finnzymes, Thermo Scientific, 
Fisher Scientific UK Ltd, Leicestershire, UK) was used. Briefly, 5µL of chromatin, 
10µL of F416 Mastermix, 2µL of primer pair mix (2.5µM) and 3µL of water were 
added per well of a 96 well white PCR plate. Samples were run in quadruplicate 
along with a NTC and input control on a Bio-Rad Chromo 4 machine and qPCR 
data analysed using Opticon3 software. Data are shown normalised to 2% input 
sample, which represents the amount of chromatin used in the ChIP. 
 
Table 2.5: Primers used for FOXA2 ChIP. 
Sequences of forward and reverse primers used at the FOXA2 TSS. 
Region Forward Primer Reverse Primer 
2 5'-AAGGCCTTGCTCAAAGTTCC-3' 5'-TCACTTTTCCATCCCCTCTG-3' 
7 5'-TTTCAGTCACAACCGAGGTG-3' 5'-TCAACTCCATATGCCCCATC-3' 
10 5'-TGGAAAAGACGAGCGCTTAC-3' 5'-TTGCTGGTCGTTTGTTGTG-3' 
17 5'-CCGAGTCTGTTTCATTCAGG-3' 5'-TCTAGAATCTGGGCGAGGTG-3' 
 
 
2.4.24 Statistical Analyses 
Where appropriate, values were presented as mean ± standard error of the mean 
(SEM). Analysis of experiments with multiple treatment groups was performed by 
repeated measures analysis of variance (ANOVA). Significant differences were 
determined by Tukey post-hoc testing and significance was cut off at p<0.05. 
Specific software suites were used in data analysis, including GraphPad Prism 
and Partek. 
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Chapter 3: Optimisation and 
delivery of miRNA 
overexpressing lentiviruses to 
hESC undergoing cardiac 
differentiation. 
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3.1 Introduction 
After an MI, the death of cardiomyocytes impairs the pump capacity of the 
heart, which, if left untreated, can (and often does) lead to heart failure. 
Current treatments are limited, with transplantation being the only treatment 
which addresses the loss of cardiac tissue directly. The amount of transplants 
carried out is severely limited by lack of healthy donor tissue available, and an 
alternative source of tissue would go some way to address this issue. HESC have 
been proposed and investigated as such a potential therapy, with their 
properties of indefinite self renewal and capacity to differentiate to any cell 
type found in the human proving extremely attractive. Several laboratories have 
studied cardiac differentiation in hESC, although no standardised protocol to 
generate functional cardiomyocytes exists (Laflamme et al., 2007, Ivey et al., 
2008a, Xu et al., 2002, Graichen et al., 2008, Yang et al., 2008).  
MicroRNAs have been proposed to regulate several physiological and pathological 
processes, including cardiac differentiation and development (Ivey et al., 2008a, 
Elia et al., 2009), angiogenesis, arrhythmias, hypertrophy and remodelling (van 
Rooij et al., 2006, van Rooij et al., 2007, Zhao et al., 2007b, Care et al., 2007). 
As part of the same transcriptional unit, miR-1 and miR-133 have been shown to 
have specialised roles in cardiac development, disease and differentiation. MiR-
1, which is widely conserved between species, is muscle specific and has been 
previously studied in cardiac development (Kwon et al., 2005b, Zhao et al., 
2007b, Zhao et al., 2005). The relationship between miR-1 expression and 
cardiac differentiation has been further understood by studies which show its 
regulation of several cardiac markers such as Hand2, MyoD, Mef2, Nkx2.5, cyclin-
dependant kinase-9, α-actin, myogenin and myosin heavy chain (Chen et al., 
2006, Takaya et al., 2009a, Zhao et al., 2005).  
MiR-133 has also been reported to be associated with muscle and cardiac 
function and disease. Double deletion of miR-133a-1 and miR-133a-2 in mice 
resulted in cardiac morphogenetic defects and a proliferative phenotype of 
cardiomyocytes, however single deletion resulted in a normal phenotype being 
observed, suggesting that these miRNAs function in concert and that if 25% of 
the normal levels of miR-133 are present, then the organism has no ill effects 
(Liu et al., 2008).  
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In a previous publication, Ivey et al. reported that miR-1 and miR-133 were 
enriched in hESC-derived cardiomyocytes when differentiated using an embryoid 
body formation protocol (Ivey et al., 2008a). Interestingly, over-expression of 
these miRNAs elicited opposing effects, with miR-1 over-expression resulting in 
promotion of cardiac lineage commitment, and miR-133 over-expression 
appearing to block specification to cardiac muscle, suggesting that miR-1 and 
miR-133 are critically important miRNA in mesoderm and cardiac differentiation 
(Ivey et al., 2008a). 
HESC are refractory to several transfection methods, and due to their potent 
self-renewal capacity long lasting and stable expression would be useful qualities 
in any miRNA modulation approach. Useful due to their ability to integrate into 
the host genome providing long term gene expression (Naldini et al., 1996), 
lentiviruses provide opportunities for long lived and efficient microRNA 
manipulation. Lentiviruses are a member of the retrovirus family retroviridae, 
and include human immunodeficiency virus 1 (HIV-1), feline immunodeficiency 
virus (FIV) and simian immunodeficiency virus (SIV). Other advantages to using 
lentiviral technology include their ability to transduce both dividing and non 
dividing cells, the ease at which the transgene or promoter can be modified and 
their relatively simple production (Naldini et al., 1996). Lentiviral technologies 
used in this study were based on HIV-1 Self Inactivating vectors, that is, they 
were unable to replicate and form new infectious virus particles. Lentiviral 
vectors have been produced by deletion of viral genes gag, pol and env and 
replacement with a transgene of interest under the control of a promoter of 
choice. Most of these self inactivating vectors are produced by transient triple 
transfection of a packaging plasmid, an expression plasmid containing the 
promoter driving the transgene of interest and a vesicular stomatitis virus 
glycoprotein (VSV-g) envelope plasmid in the presence of polyethylenimine (PEI) 
(Sinn et al., 2005, Cockrell and Kafri, 2007). VSV-g remains a common choice for 
a lentiviral vector envelope protein as it has broad cell tropism (Seganti et al., 
1986). The lentiviral vectors used in this study are known as “second generation” 
vectors; that is they had vif, vpr, vpu and nef deleted from the packaging 
plasmid thereby ensuring if mutation or recombination events had occurred, the 
viral particles would not have contained virulence factors. These modifications 
have also been shown to have no significant effect on efficiency or vector titres 
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(Zufferey et al., 1997). The expression plasmid had further modifications for 
improved biosafety profile, namely the deletion of key transcriptional regulatory 
sequences including the homogenous viral enhancer-promoter unit. This has 
been achieved by a deletion within the U3 region of the 3’ Long Terminal Repeat 
(LTR) of the DNA transcript. This was reverse transcribed conferring the deletion 
to the 5’ LTR of the proviral DNA. Transcriptional activity was therefore 
sufficiently hampered so that no full length viral RNA could be produced 
(Zufferey et al., 1998). Modifications created to increase the overall 
functionality of the lentiviral vectors included the introduction of the rev-
responsive regulatory element (RRE), the central polypurine tract (cPPT) 
element and woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE). RRE is important as it allowed the Rev-mediated shuttle of mRNA from 
the nucleus to the cytoplasm for translation to occur and as such is also present 
on the packaging plasmid (Cochrane et al., 1990, Dull et al., 1998). The cPPT 
element enhanced the nuclear translocation, degree of vector genome 
integration into the host genome and had also been shown to increase the 
achievable titre (Demaison et al., 2002a, Logan et al., 2004, VandenDriessche et 
al., 2002). The WPRE improved viral genome transcript packaging, regulated the 
stability of transgene mRNA by polyadenylation, increased RNA export from the 
nucleus and enhanced translation of transgene mRNA (Zufferey et al., 1999, 
Demaison et al., 2002a).  
It was previously assumed that integrating lentiviruses were not suitable for 
clinical therapies due to their propensity to integrate semi-randomly but with 
some common integration sites (CIS) within oncogenes. However, upon further 
study it was discovered that for the most part the CIS lie in benign genes  
(Modlich et al., 2009, Cavazzana-Calvo et al., 2010, Biffi et al., 2011) and there 
are current studies using lentivirus in patients with Wiscott-Aldrich syndrome 
(Scaramuzza et al., 2012). Lentiviral vectors remain very useful tools in 
preclinical studies, allowing interrogation of the miRNA involved in hESC lineage 
commitment.  
The aim of this chapter was to design and produce suitable lentiviral vectors for 
miRNA overexpression, to allow interrogation of miR-1 and miR-133b in cardiac 
lineage commitment in a feeder-free monolayer hESc culture system (Figure 
3.1). 
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Figure 3.1: Schematic of cardiac differentiation and lentivirus infection of hESC.  
Lentiviruses were generated by triple transfection of a packaging plasmid (p8.74) an envelope 
plasmid (pMGD) and a microRNA expression plasmid (LNT-SFFV-miR) in the presence of PEI in 
HEK293T cells. Lentiviruses were collected in the cell media at 48 and 72 hours before being 
sterile filtered, concentrated by ultracentrifugation and subjected to titration to determine functional 
virus titre. Lentiviral transduction in the presence of polybrene was then carried out in pluripotent 
hESC, after which cells were maintained pluripotent as shown by Oct 4 staining, or differentiated 
towards cardiac lineage as shown by positive staining of TNNT2 and TPM1. 
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3.2 Results 
3.2.1 Lentiviral infection does not alter hESC pluripotency or 
differentiation 
To understand what effect, if any, transduction with lentiviral vectors may have 
on hESC, SA461 cells were infected with a lentivirus expressing green fluorescent 
protein (GFP) under the spleen focus forming virus promoter at an MOI of 100 in 
the presence of 4 μg/mL of polybrene for 72 hours. 
DAPI staining for intact nuclei in blue shows the location of cells (Figure 3.2, 
Panel I). Cells infected with a lentivirus expressing GFP under the SFFV promoter 
showed GFP positive cells indicating successful transduction (Figure 3.2, Panel 
II). Oct4 staining in red indicated the cells were indeed pluripotent (Figure 3.2, 
Panel III). The merged image of hESC infected with lentivirus expressing GFP and 
also expressing Oct 4 demonstrates lentivirally transduced cells remained 
pluripotent (Figure 3.2, Panel IV). Transduced hESC were still able to undergo 
embryoid body formation (Figure 3.2, Panel V) and passively differentiate to all 
3 germ layers as confirmed by Taqman qRT-PCR for α-fetoprotein (AFP), β-
tubulin and α-actin cardiac muscle (Figure 3.2, Panel VI). 
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Figure 3.2: Lentiviral transduction of hESC does not affect pluripotency.  
Panel I shows DAPI staining for intact nuclei in blue, in panel II cells infected with a lentivirus 
expressing GFP under SFFV promoter show GFP positive cells. Panel III shows Oct 4 expressed 
by transduced cells in red as detected by ICC. Panel IV shows a merged image of transduced 
hESC and positive expression of Oct 4. Panel V shows that the hESC were able to undergo 
embryoid body formation and passively differentiate to all 3 germ layers as confirmed by Taqman 
qRT-PCR for α-fetoprotein (AFP), β-tubulin and α-actin cardiac muscle shown in graph in panel VI. 
Scale bars panel I-IV = 50 µm. Scale bar panel V = 500 µm. 
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3.2.2 Spleen focus forming virus promoter achieves superior 
transgene expression in hESC 
In order to choose the best promoter for high transgene expression from 
lentiviral vectors in hESC, two lentiviruses were compared; one which expressed 
GFP under the popular cytomegalovirus (CMV) promoter or one which expressed 
GFP under the SFFV promoter. Although it had previously been described that 
CMV was not an ideal choice for transgene overexpression in hESC (Liew et al., 
2007), we received a large plasmid library of miRNAs under the CMV promoter 
that we wished to use in hESC. Therefore, cells were seeded in a 24 well plate at 
1x104 cells/well and either left uninfected (UI), infected with a lentivirus 
expressing GFP from a CMV promoter and compared to cells infected with a 
lentivirus expressing GFP from a SFFV promoter (LNT-GFP-SFFV), both at 150 MOI 
and all conditions had polybrene. Cells were then either maintained pluripotent, 
subjected to endothelial differentiation media, subjected to a cardiac 
differentiation protocol, or allowed to passively differentiate in 10% MEM. In 
cells harvested 2 days post infection, GFP expression relative to mg of protein 
was highest in those cells tranduced with the LNT-GFP-SFFV. The highest 
transgene expression relative to milligrams of protein was found in the 
endothelial and passive differentiation conditions. Additionally, expression was 
still relatively high under pluripotency and cardiac conditions (Figure 3.3). In 
cells harvested 7 days post infection again LNT-GFP-SFFV proved to be much 
more efficient at expressing GFP (Figure 3.3). 
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Figure 3.3: Analysis of CMV and SFFV promoters in hESC.  
HESC were uninfected (UI), transduced with a lentivirus expressing GFP from a CMV promoter or 
transduced with a lentivirus expressing GFP from a SFFV promoter (LNT-GFP-SFFV), both at 150 
MOI. Cells were then either maintained pluripotent, subjected to endothelial differentiation media, 
allowed to passively differentiate in 10% MEM or subjected to a cardiac differentiation protocol and 
analysed at day 2 and day 7 of differentiation. * = p<0.05 vs UI, **= p<0.01 vs UI, ***= p<0.001 vs 
UI. 
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3.2.3 Design optimisation of miRNA overexpressing lentiviral 
vectors 
To create miRNA overexpression lentiviral vectors a sub-cloning strategy was 
designed and employed. A retroviral library of 350 pri-miRNA clones was kindly 
gifted from Reuven Agami at the Netherlands Cancer Institute. As the retroviral 
plasmid (pMSCV-Blast-miR) which contained each miRNA was driven by CMV, it 
was necessary to subclone the miRNA inserts into the LNT-MCS-SFFV plasmid, 
which has the same design as the LNT-SFFV-GFP plasmid but with no GFP tag. 
The restriction endonuclease sites used to excise the insert from the retroviral 
plasmid pMSCV-Blast-miR were BamHI and EcoRI. As the LNT-SFFV-GFP plasmid 
does not contain an EcoRI restriction endonuclease site, it was necessary to add 
the correct restriction endonuclease sites to the miRNA insert. In order to do 
this, the miRNA insert was subcloned into the PCDNA3.1(+)/Zeo  multiple cloning 
site  by digesting both plasmids with BamHI and EcoRI. PCDNA3.1(+)/Zeo was 
then subjected to dephosporylation before the miRNA insert of choice was 
ligated using T4 ligase into PCDNA3.1(+)/Zeo. At this stage diagnostic restriction 
endonuclease digests were run on an agarose gel and visualised and 
dideoxynucleotide sequencing was carried out showing that the miRNA insert had 
been successfully incorporated. 
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Figure 3.4: Cloning scheme of miR-1 and miR-133 overexpression lentiviruses. 
Expression vector maps of GeneArt plasmid, PCDNA3.1/Zeo(+) and LNT-SFFV-MCS and sequences of miRNA pre-miR inserts as synthesised by GeneArt. 
 
 
Pre-miR
5’ AAGCTT GGATCC   ACCATGG TGGGAAACATACTTCTTTATATGCCCATATGGACCTGCTAAGCTATGGAATGTAAAGAAGTATGTATCTCA TAG TTTTTT CTCGAG GATATC 3’
3’ TTCGAA CCTAGG TGGTACC ACCCTTTGTATGAAGAAATATACGGGTATACCTGGACGATTCGATACCTTACATTTCTTCATACATAGAGT  ATC AAAAAA GAGCTC CTATAG 5’
MiR-1 construct
MiR-133 construct
5’ AAGCTT GGATCC ACCATGG CCTCAGAAGAAAGATGCCCCCTGCTCTGGCTGGTCAAACGGAACCAAGTCCGTCTTCCTGAGAGGTTTGGTCCCCTTCAACCAGCTACAGCAGGGCTG
GCAATGCCCAGTCCTTGGAGA TAG TTTTTT CTCGAG GATATC 3’
3’ TTCGAA CCTAGG TGGTACC GGAGTCTTCTTTCTACGGGGGACGAGACCGACCAGTTTGCCTTGGTTCAGGCAGAAGGACTCTCCAAACCAGGGGAAGTTGGTCGATGTCGTCCCGAC
CGTTACGGGTCAGGAACCTCT ATC AAAAAA GAGCTC CTATAG 5’
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Figure 3.5: Cloning of miRNA overexpression lentiviruses.  
(A) Diagnostic agarose gel electrophoresis of restriction endonuclease digests. Lane 1 is 100bp  
ladder, lane 2 is 1kb ladder, lane 3 is uncut LNT-SFFV-miR-1, lane 4 is LNT-SFFV-miR-1 cut with 
A 
B 
C 
** 
*** 
*** ** 
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BamHI and XhoI, lane 5 is uncut LNT-SFFV-miR-133 and lane 6 is LNT-SFFV-miR-133 cut with 
BamHI and XhoI. (B) Transfection by lipofectamine 2000 of PCDNA3.1 + miR-1 and PCDNA3.1 + 
miR-133 expression vectors into HeLa cells. (C) Transduction of HeLa cells with LNT-SFFV-GFP, 
LNT-SFFV-miR-1 and LNT-SFFV-miR-133 and qRT-PCR for miRNA expression. ** = p<0.01, *** = 
p<0.001. 
 
As PCDNA3.1(+)/Zeo drives transgene expression under a CMV promoter and hESC 
cells are refractory to conventional transfection methods, correct expression of 
mature miRNA was assessed by transfection using Lipofectamine 2000 into HeLa 
cells, which were then miRNeasy extracted and subjected to miRNA TaqMan 
using appropriate primer and probe sets for each miRNA of interest. Expression 
levels compared to that of the original pMSCV-Blast-miR plasmids were similar 
for miR-133b, however miR-1-1 did not evoke as high levels of expression. 
Upon further investigation, it was discovered that the large 500-700 bp pri-miR 
inserts containing pri-miRNA sequences were not only expressing the chosen 
miRNA, but contained fragments of other miRNAs too. This was most likely due 
to the nature of construction of the pri-miR library, where large sections of 
sequence surrounding the miR of interest were preserved in an effort to ensure 
correct biological processing upon expression. In order to simplify cloning by 
reducing the insert size and have a more targeted approach, a redesign of the 
strategy for specific overexpression of miRNAs of interest was carried out. The 
pre-miRNA stem loop sequences were obtained from miRbase (University of 
Manchester) and used to design new inserts for creation by GeneArt (Life 
Technologies) (Figure 3.4). In addition to the pre-miRNA stem loop, the inserts 
also contained multiple flanking restriction endonuclease sites so that the pre-
miRNAs could be cloned into several different vectors and kozak and stop 
sequences to ensure correct processing (Figure 3.4). The pre-miRNA constructs 
were received in a standard plasmid with ampicillin resistance, grown up in 
E.coli under selection of ampicillin, restriction endonuclease digested and 
electrophoresed on a 2% agarose gel to isolate the inserts, gel extracted and 
ligated into PCDNA3.1. The plasmids were then subjected to diagnostic 
restriction endonuclease digests, dideoxynucleotide sequencing and transfection 
into Hela cells to quantify expression of mature miRNA as detailed previously 
(Figure 3.5). Once the pre-miRNA constructs passed these quality control checks, 
they were restriction endonuclease digested using BamHI and XhoI and ligated 
into the LNT-SFFV-MCS expression plasmid ready for lentiviral vector production. 
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Diagnostic endonuclease digestion (Figure 3.5) and dideoxynucleotide 
sequencing was then performed to ensure correct insertion of the pre-miRNA 
contructs, and lentivirus produced. 
3.2.4 Cardiac differentiation optimisation 
Discovering the most successful route of deriving cardiomyocytes from hESC 
involved optimisation of a previously published cardiac protocol (Laflamme et 
al., 2007) as detailed in section 2.1.1.3. SA461 cells were seeded on Matrigel™ 
and subjected to cardiac differentiation. Despite culture under these conditions 
for up to 28 days, no spontaneous beating could be observed. At day 7, 
moderate expression of tropomyosin, myosin heavy chain, α-actinin and troponin 
T could be observed however, upon further culture at day 14 this expression 
appeared to be lost (Figure 3.6). Therefore, SA461 did not exhibit enough 
cardiogenic potential to be used in cardiac differentiation studies.  
We then went on to test H1 hESC for cardiogenic potential by the modified 
Laflamme cardiac differentiation protocol for 14 days (Laflamme et al., 2007). 
Cells were then fixed and ICC performed or harvested for total RNA extraction 
by miRneasy and subjected to qRT-PCR. H1 hESC were found to be an excellent 
choice for cardiac differentiation. Spontaneous beating occurred at 
approximately day 9 and by day 14, expression of of troponin T, tropomyosin, 
NKX2.5 and α-actinin cardiac markers and expression of  for alpha actinin-2 
(ACTN2), Brachyury (T), NK2 homeobox 5 (NKX2.5) and troponin T type 2 
(cardiac) (TNNT2) could be observed (Figure 3.7) 
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Figure 3.6: SA461 subjected to cardiac differentiation.  
After 7 and 14 days of cardiac differentiation, ICC was performed for DAPI in blue, tropomyosin (green), myosin heavy chain (MHC) (red), α-Actinin (red), Troponin T 
(green) and control IgG. Scale bar 200 µm. 
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Figure 3.7: H1 cardiac differentiation. 
(A) H1 hESC subjected to cardiac differentiation for 21 days. Dotted ellipse denotes beating area. 
(B) ICC performed for DAPI (blue), Troponin T (green), Tropomyosin (red), NKX2.5 (green) and α-
actinin (red). Scale bars = 10 µm. 
 
3.2.5 Overexpression of miR-1-1 and miR-133b in cardiac 
differentiation of hESC 
These experiments were conducted to ascertain whether forced over-expression 
of miR-1-1 or miR-133b had an impact on monolayer cardiac differentiation in H1 
hESC cells.  
H1 hESC were seeded into 48-well plates pre-coated with Matrigel™ at 3x104 
cells per well, and either maintained pluripotent, or differentiated towards 
cardiac lineage. In addition to differing media conditions, cells were either 
uninfected or transduced with LNT-SFFV-GFP, LNT-SFFV-pre-miR-1 or LNT-SFFV-
pre-miR-133b, all at 25 MOI in the presence of 4 μg/mL of polybrene. The cells 
were allowed to differentiate for 14 days, with spontaneous beating observed 
from day 9. The samples were subjected to miRNA qRT-PCR to ensure the 
A 
B 
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overexpression of both miRNAs from the lentiviruses (Figure 3.8) and gene 
expression qRT-PCR for Oct 4 as a marker of pluripotency, and cardiac markers 
alpha actinin-2 (ACTN2), Brachyury (T), NK2 homeobox 5 (NKX2.5) and troponin 
T type 2 (cardiac) (TNNT2) (Figure 3.9). 
Oct 4 expression was significantly downregulated between pluripotent samples 
and those subjected to cardiac conditions, with no statistically significant 
difference observed between samples transduced with GFP, miR-1 or miR-133b 
overexpression viruses (Fig9 A). ACTN2 was significantly upregulated in the 
sample group transduced with GFP-expressing lentivirus under cardiac 
conditions, and was significantly downregulated in those samples transduced 
with miR-133b lentivirus compared to the GFP virus control (Fig 9 B). Brachyury 
expression did not attain significance in any of the test groups, although it 
appeared to be upregulated in the GFP lentivirus transduced cardiac group and 
the miRNA-133b overexpression lentivirus transduced cardiac group (Fig 9 C). 
NKX2.5 was significantly upregulated in cardiac GFP lentivirus group as 
compared with pluripotent samples. NKX2.5 was also significantly downregulated 
in those cardiac samples transduced with miR-133b overexpressing lentivirus 
compared to the GFP virus control (Fig 9 D). TNNT2 was the most upregulated 
gene of those tested, with all cardiac samples showing significant increase over 
pluripotent samples, however miR-133b overexpressing lentivirus tranduced 
samples showed significant downregulation compared to GFP virus control (Fig 9 
E). 
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Figure 3.8: Expression of miR-1 and miR-133b from lentiviruses.  
Samples maintained pluripotent or cardiac differentiated for 14 or 21 days, uninfected (control), 
LNT-SFFV-GFP control virus (GFP), LNT-SFFV-MiR-1 transduced (miR-1) or LNT-SFFV-MiR-133 
transduced (miR-133). * = p<0.05 vs pluripotent control, ** = p<0.01 vs pluripotent control, *** = 
p<0.001 vs pluripotent control, # = p<0.05 vs pluripotent GFP, + = p<0.05 vs cardiac control, ++ = 
p<0.01 vs cardiac control, +++ = p<0.001 vs cardiac control, $ = p<0.05 vs cardiac GFP, $$ = 
p<0.01 vs cardiac GFP and $$$ = p<0.001 vs cardiac GFP. 
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Figure 3.9: Overexpression of miR-1 and miR-133 in hESC during cardiac differentiation.  
Samples were maintained pluripotent or subjected to cardiac differentiation and were either uninfected or transduced with LNT-SFFV-GFP, LNT-SFFV-pre-miR-1 or 
LNT-SFFV-pre-miR-133b. The samples were subjected to qRT-PCR after 14 days to ensure gene expression for Oct 4, alpha actinin-2 (ACTN2), brachyury (T), NK2 
homeobox 5 (NKX2.5) and troponin T type 2 (cardiac) (TNNT2) (n=2, p<0.05). * = p<0.05 vs pluripotent control, ** = p<0.01 vs pluripotent control, *** = p<0.001 vs 
pluripotent control, # = p<0.05 vs pluripotent GFP, + = p<0.05 vs cardiac control, ++ = p<0.01 vs cardiac control, +++ = p<0.001 vs cardiac control, $ = p<0.05 vs 
cardiac GFP, $$ = p<0.01 vs cardiac GFP and $$$ = p<0.001 vs cardiac GFP. 
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3.3 Discussion 
In this study, it was found that targeted overexpression of single pre-miRs was 
achievable in H1 hESC, that SA461 hESC were less cardiogenic than H1 hESC 
under cardiac differentiation conditions, and that the role of miR-1 and miR-133 
overexpression in altering cardiac differentiation was unclear. 
To interrogate of the role of miRNAs miR-1-1 and miR-133 in cardiac 
differentiation a lentiviral strategy was required. With hESC reportedly resistant 
to most transfection methods, lentiviral vectors offered an attractive alternative 
to allow overexpression of genes of interest with the VSVG envelope broad cell 
tropism coupled with the ability to infect non-dividing cells. Initially it was 
important to ascertain whether lentivirus infection in itself had an effect on 
hESC pluripotency or differentiation. As previously reported, lentiviruses 
integrate into the host genome in a semi-random fashion, often in proto-
oncogenes (Modlich et al., 2009, Cavazzana-Calvo et al., 2010). So that this 
effect could be accounted for, a control lentivirus expressing GFP from a SFFV 
promoter was employed. It was observed that lentivirus infection has no effect 
on the hESC expression of pluripotency marker Oct 4, with cells expressing GFP 
also staining red for Oct4 expression. Importantly, upon embryoid body 
formation, the GFP expressing hESC could still differentiate to form 
representative cell types of all three germ layers, α-fetoprotein (AFP) for 
endoderm, β-tubulin 3 for ectoderm and cardiac muscle actin for mesoderm. 
This confirms the pluripotent nature of hESC is not adversely affected by 
lentiviral infection. 
As the existing library of pre-miRs was in a retrovirus format under the CMV 
promoter, the next experiments were designed to show whether CMV promoter 
could be active in hESC, as it had been previously reported that CMV promoter 
was not ideal for use in stem cells with inactivation of more than 95% of eGFP 
transgenes reported in H1 and H9 hESC (Liew et al., 2007, Xia et al., 2007). A 
lentivirus driving GFP under a CMV promoter and a lentivirus driving GFP under a 
SFFV promoter were employed, with SA461 hESC infected and either maintained 
as pluripotent or differentiated using an endothelial protocol, early cardiac 
protocol or placed in standard 10% DMEM to allow passive differentiation. There 
was also a no virus control. At both day 2 and day 7, it was observed that that 
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SFFV was a much more efficient promoter at driving GFP expression compared to 
the CMV promoter in all conditions tested although expression of the transgene 
was considerably lower at day 7 compared to day 2. This showed that to 
successfully overexpress miRNAs of interest in hESC, an SFFV promoter 
containing lentivirus expression plasmid would be the vector of choice. Low 
transgene expression in hESC can be attributed to poor transduction efficiency 
or gene inactivation (Xia et al., 2007). As successful transgene expression could 
be observed from the SFFV promoter, the poor transgene expression seen in 
those samples transduced with LNT-CMV-GFP can be attributed to promoter 
suppression as previously described (Xia et al., 2007). Rather than traditional 
silencing, where expression falls off over time, it has been reported that the 
mechanism to involve transgene blockage occurrs very soon after viral 
transduction and integration (Xia et al., 2007). Additionally, promoter 
suppression appeared to be associated with viral transduction, as transient 
transfection delievered transgenes were not observed to be suppressed (Xia et 
al., 2007). However, silencing of CMV-driven transgene expression after 
transient transfection was observed during further studies which reported the 
mechanism of suppression to be mediated through epigenetic modification 
(Meilinger et al., 2009). It was shown that CMV promoter suppression was 
dependant upon Np65 (also known as Uhrf1), a nuclear protein that recruits DNA 
methyltransferases Dnmt3a and Dmnt3b to hemi-methylated sites (Meilinger et 
al., 2009). ESC which were deficient in the 3 major DNA methyltransferases, or 
deficient in Np65 displayed no silencing of GFP or mRFP driven by CMV (Meilinger 
et al., 2009). We therefore used the LNT-SFFV-MCS lentivirus expression plasmid 
(kindly gifted by Prof. Thrasher, UCL, UK) for miRNA overexpression construct 
engineering.  
Subsequently, a strategy was designed to subclone the pri-miRNA sequences to 
the LNT-SFFV-MCS expression plasmid. Further investigation of the initial cloning 
strategy sequencing data for the pri-miR-1-1 and pri-miR-133b showed that each 
insert not only contained the miRNA of choice, but other miRNA sequences. As 
such, a new miRNA overexpression strategy was required. On the basis of shRNA 
work, it was decided that the stem loop precursor miRNA would be sufficient to 
drive expression of each miRNA in a smaller, more precise construct (Fire et al., 
1998, Paul et al., 2002). The sequence of each stem loop pre-miR was taken 
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from miRbase (http://www.mirbase.org/, (Griffiths‐Jones, 2004)) and placed 
between a kozak and stop sequence along with appropriate restriction 
endonuclease digest sites to allow cloning of the pre-miRs into several different 
plasmid vectors. Both miR-1 and miR-133b LNT-SFFV vectors expressed mature 
miRNA as detected by TaqMan qRT-PCR, although miR-1 was expressed at lower 
levels then miR-133b. It is not known whether miR-1-1 undergoes more strict 
criteria for processing than miR-133b or that there is perhaps some sort of 
inhibition leading to a decreased level of expression. It has been reported that 
miR-1 is under the transcriptional control of muscle differentiation regulators 
including serum response factor (SRF) (Zhao et al., 2005) and therefore there is 
a possibility that this pathway is responsible for the lower levels of miR-1 
observed. Interestingly, although the kozak sequence is thought to enhance 
protein expression (Kozak, 1987) and should therefore not be required for miRNA 
processing, constructs omitting the sequence did not produce detectable mature 
miRNA. 
It has been proposed that different hESC lines display differing capacities for 
differentiation to each germ layer (Hong et al., 2011, Rooney et al., 2010, Wu et 
al., 2007, Pal et al., 2009) and reviewed in (Allegrucci and Young, 2007). 
Differences in cardiac potential between hESC lines were also reported 
previously (Burridge et al., 2007). SA461 hESC were subjected to a previously 
published protocol capable of generating beating clusters in other hESC lines 
(Laflamme et al., 2007). However, SA461 were unable to generate beating 
clusters regardless of length of time cells were subjected to culture conditions. 
H1 hESC had previously been reported to successfully differentiate to cardiac 
phenotype cells (Moore et al., 2008, Xu et al., 2002). When H1 hESC were tested 
in our laboratory, they consistently displayed ~30% beating clusters per well by 
day 14 of differentiation. The decision was made to switch to H1 hESC for 
cardiac differentiation experiments due to their ready ability to differentiate to 
beating cells which stained positive for tropomyosin, myosin heavy chain, α-
actinin and troponin T.  
To investigate whether the role of miR-1-1 and miR-133b was specific to 
embryoid body differentiation to cardiomyocytes, a monolayer cardiac 
differentiation protocol was employed along with miRNA overexpression 
lentiviruses. As expected, Oct 4 expression is present in those samples 
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maintained pluripotent, with no significant difference seen between different 
virus groups and the uninfected samples. This would suggest that, as previously 
shown in SA461 hESC, infection with a lentivirus has no effect on pluripotency 
genes, and that overexpression of miR-1 or miR-133b was not sufficient to 
initiate differentiation when cells remain under pluripotent media conditions. To 
date, no studies have shown miRNA overexpression under pluripotent conditions 
to be powerful enough to direct cells to a particular lineage, but rather it has 
been shown miRNAs can refine differentiation during embryoid body or directed 
differentiation (Ivey et al., 2008a, Kane et al., 2012, Tzur et al., 2008). It has 
recently been reported in mice, that overexpression of miR-1, -133, -208 and -
499 in fibroblasts can induce differentiation of cardiac-like cells, both in vitro 
and in vivo (Jayawardena et al., 2012). ACTN2 appeared to be significantly 
upregulated in those samples transduced with LNT-SFFV-GFP control virus 
compared with uninfected cells. There has been no previously published 
information on lentiviral infection in itself having an impact on cardiac 
differentiation in hESC, or indeed any other system. As the hallmark of a 
retrovirus (and indeed a lentivirus) is the ability to integrate into the host cell 
genome in a semi-random fashion, it is not excluded that the virus could 
integrate into an area which causes disregulation of genes involved in cardiac or 
mesodermal differentiation. This possibility is of course increased with using a 
higher MOI, and previous studies in our laboratory have shown transduction with 
LNT-SFFV-GFP control virus to be powerful enough to create iPSC like cells from 
fibroblasts at a MOI of 200 (Kane et al., 2010b). However, in this case, the cells 
were transduced at an MOI of 20. ACTN2 is significantly downregulated in 
samples transduced with miR-133b overexpression lentivirus. As ACTN2 is not 
reported or predicted to be a direct target of miR-133b, it is likely that the 
downregulation is caused by a general inhibition of cardiac commitment as 
previously reported (Ivey et al., 2008a). Brachyury is encoded by the T gene in 
humans, is a member of the t box transcription factor family and an early 
marker of mesoderm (Wilkinson et al., 1990, Showell et al., 2004). Brachyury 
expression was significantly different with GFP, miR-1 and miR-133 
overexpression in those samples maintained pluripotent however did not reach 
significant levels compared to either uninfected control or SFFV-GFP lentivirus 
control in the cardiac differentiated samples. These results suggested that 
lentiviral transduction had some effect on the expression of Brachyury in hESC 
123 
maintained pluripotent, but the levels did not reach that of the cardiac 
differentiated samples. 
 NKX2.5 is known as an early cardiac marker, involved in cardiac commitment, 
and is significantly upregulated in the SFFV-GFP control virus group compared to 
uninfected. NKX2.5 is also significantly downregulated in cardiac samples 
transduced with miR-133b overexpressing virus compared to LNT-SFFV-GFP 
control virus transduced samples, however there was no significant difference 
when compared to uninfected controls. This is consistent with findings 
previously reported, although in this setting it is not known whether this effect 
is due to a generally lower level expression of NKX2.5 per cell or a lower number 
of cells expressing NKX2.5 (Ivey et al., 2008a, Takaya et al., 2009b). TNNT2 
expression achieved the highest levels of those genes tested, with all samples 
subjected to cardiac media conditions displaying significant increase over 
matched pluripotent samples. A significant decrease in TNNT2 levels was 
observed in miR-133 overexpression samples compared to SFFV-GFP control 
samples. 
MiR-1 overexpression did not, as previously reported, appear to enhance cardiac 
differentiation of H1 hESC in a monolayer system. In all of the genes tested, 
those transduced with miR-1 overexpression virus showed no significant 
improvement over SFFV-GFP virus control or no virus control. 
In previously published work, miR-133 overexpression appeared to inhibit 
cardiogenesis in an embryoid body cardiac protocol (Ivey et al., 2008a). Our 
results show a down regulation of cardiac genes in samples transduced with LNT-
SFFV-miR-133 but only when compared to samples transduced with LNT-SFFV-
GFP . In comparison to uninfected control samples no significant difference in 
cardiac potential could be ascertained by qRT-PCR. That miR-1 did not appear to 
potentiate cardiac differentiation could be due to the differences in culture 
technique (embryoid body vs monolayer), hESC line used or the fact our hESC 
were maintained under feeder-free conditions. Therefore the expected action of 
miR-1 and miR-133 in H1 hESC monolayer cardiac differentiation does not appear 
to be defined between protocols and laboratories. 
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In summary, we successfully showed generation of pre-miR overexpression 
lentiviruses for miR-1 and miR-133 in a construct using the SFFV promoter, that 
SA461 hESC were unsuitable for cardiac differentiation, and that using a 
modified version of the LaFlamme protocol in a monolayer system resulted in 
beating cells with a cardiomyocyte phenotype (Laflamme et al., 2007). However 
our investigation into miRNA refinement of cardiac differentiation from hESC 
was inconclusive. We were unable to confirm the findings published previously 
(Ivey et al., 2008a) and due to time constraints could not investigate the 
hypothesis further. 
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Chapter 4: MicroRNA, gene 
expression and epigenetic 
characterisation of primary 
endothelial cells and hESC 
derived endothelial cells. 
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4.1 Introduction 
Endothelial cells provide an essential interface between the blood and the 
tissues. The revascularisation of the infarcted heart would play a major 
beneficial role in a regenerative medicine strategy to treat myocardial 
infarction. The differentiation of vascular endothelial cells in clinically relevant 
numbers for injection into the ischaemic area could stimulate angiogenesis, 
rescuing at risk myocytes, thus limiting the development of scar tissue and 
improving cardiac function. Similarly, for peripheral ischaemia, injection of cells 
into the ischaemic regions to create/stimulate new blood vessel growth could be 
beneficial.  
Although successful generation of functional endothelial-like has been 
demonstrated (Wang et al., 2007b, Kane et al., 2010a, Strahl and Allis, 2000, 
Kane et al., 2012), very little is understood about the early commitment of 
pluripotent hESC to mesoderm and subsequently to the endothelial-like lineage. 
How mesodermal tissues are formed during development remains a difficult area 
to study due to lack of specific markers of early mesodermal commitment 
(Evseenko et al., 2010). Differentiation of hESC in vitro recapitulates early 
embryogenesis, and although hESC are increasingly studied, research is usually 
focussed on defined, intermediate to late differentiated cell products (Murry 
and Keller, 2008). As such, many questions remain about the initial processes 
involved as the hESC becomes more specified towards a chosen lineage. 
At present, methods of generating stem cell-derived vascular endothelial cells 
differ greatly between laboratories and hESC lines used. Upon differentiation, 
cell morphology changes along with expression of various markers of 
differentiation which can be used to classify cell populations. Embryoid body 
(EB) differentiation, in which cells are encouraged to aggregate in culture, 
allows spontaneous differentiation to endothelial cells as well as potentially all 
cell-types from mesodermal, ectoderm and endoderm germ layers. The shortfalls 
of this technique include low efficiency of differentiation with just 1-3% 
endothelial cells reported (Levenberg et al., 2002, Li et al., 2009, Cho et al., 
2007) and the technically difficult cell isolation procedures needed to obtain a 
homogenous cell population, such as fluorescence activated cell sorting (FACS) 
or magnetic activated cell sorting (MACS) (Levenberg et al., 2002, Li et al., 
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2009). Recent modifications to EB differentiation include culture under hypoxic 
conditions (Prado-Lopez et al., 2010), the introduction of VEGF-A to the culture 
media (Nourse et al., 2010), and inhibition of the TGF-β signalling pathway 
(James et al., 2010). These changes have improved the yield of an appropriate 
cell population, however issues such as animal contamination through use of 
serum and scale-up of production to produce a clinically relevant number of 
cells, still remain. Alternative endothelial cell differentiation strategies include 
a 2-D system involving co-culture with mouse embryonic fibroblast feeder layers 
followed by MACS sorting for CD34 positive EPC-like cells and further expansion 
of this population (Wang et al., 2007b). Further functional assays confirmed this 
cell population isolated was able to form structurally normal vessels in vivo, 
although the efficiency for this method remains at 10% (Wang et al., 2007b). 
Improvements to this method involving serum free media conditions was 
reported to yield ~50% CD31 and VE Cadherin positive cells within 6-7 days, 
although no in vivo functional characterisation was carried out (Lagarkova et al., 
2008). Previous research from our group described a method to generate 
functional endothelial-like cells by directed differentiation without the need for 
serum or a feeder cell layer (Kane et al., 2010a). Cells derived using this 
protocol were ~80% positive for CD31 and VE Cadherin after 21 days and 
significantly improved neogenesis in a mouse model of hindlimb ischaemia 
following injection (Kane et al., 2010a). 
MiRNAs have been implicated in primary endothelial cell function and involved in 
the regulation of formation of blood vessels in the developing embryo (Nicoli et 
al., 2010). Research performed on Dicer knockout (KO) mice suggested that 
miRNAs play a role in development of endothelium, with embryos displaying 
reduced blood vessel formation, altered expression of VEGF and endothelial-
associated genes Flt1, Kdr and Tie1 and knockouts were embryonic lethal 
phenotype between days 12.5 and 14.5 of gestation (Yang et al., 2005). To 
further assess the importance of miRNAs in endothelial cells, Suárez et al. 
knocked down Dicer using a siRNA approach and examined the cell phenotype of 
human umbilical vascular endothelial cells (HUVECs) (Suarez et al., 2007). They 
reported differential expression of several endothelial-associated genes 
including Tie-2, Kdr, and Tie-1, and increased activity of the endothelial nitric 
oxide synthase pathway. It was also noted that Dicer KO cells had reduced 
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capability to form tubes in a tube forming assay and exhibited reduced 
proliferation (Suarez et al., 2007). Similar results were demonstrated in Dicer 
mutant zebrafish, where endothelial cells were present but the circulatory 
system was disrupted (Giraldez et al., 2005). Specific knockdown of Dicer in 
murine endothelial cells did not result in a lethal phenotype (likely owing to 
incomplete excision of the Dicer gene) however, a decreased VEGF-induced 
angiogenesis and retarded recovery after ischemic challenge were observed 
(Suárez et al., 2008). 
Epigenetic control of the poised state classically associated with hESC is due to 
changes at the chromatin level, where post translational modification of 
histones can “prime” a gene for activation or repression dependant on which 
modification has occurred (Berger, 2007). ~3000 genes are thought to be primed 
for both repression and activation and have both tri-methylation of lysine 27 of 
histone H3 (H3K27Me3) for repression and tri-methylation of lysine 4 of histone 
H3 (H3K4Me3) for activation present (Bernstein et al., 2006)(Figure 1.4). Owing 
to both types of chromatin being present, the gene is termed bivalent, meaning 
they can be rapidly activated upon differentiation or remain silenced if 
committing to a lineage which does not require expression of that particular 
gene (Bernstein et al., 2006). Unsurprisingly, genes with these bivalent marks 
have been proposed as highly important cell fate deciders, and the role of these 
genes in cardiovascular differentiation remains to be investigated. 
With the control of hESC differentiation so complex, a strategic dissection of 
regulation is required. The studies discussed in this chapter were designed to 
create a microRNA and gene expression profile, in addition to epigenetic status 
of hESC-EC and primary HSVEC. 
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4.2 Results 
4.2.1 microRNA profile of SA461 hESC during endothelial-like 
differentiation 
To allow characterisation of miRNA expression in SA461 hESC undergoing a 
mesodermal endothelial differentiation (Kane et al., 2010a), a LC Sciences 2 
channel microarray was initially employed. Samples were collected from cells 
undergoing differentiation for 2, 4 and 10 days with pluripotent control samples 
collected at day 0 (initiation of differentiation) as well as at each of the 
timepoints (Figure 4.1). Of the 374 mature miRNAs tested, hsa-miR-99b, hsa-
miR-181a and hsa-miR-181b showed a reproducible and statistically significant 
increase in expression over time in the endothelial differentiated samples 
(Figure 4.2A)(n=3, p<0.05). These findings were subsequently validated by 
miRNA TaqMan qRT-PCR (Figure 4.2B) and Northern blotting (Figure 4.2C), 
confirming the expression of hsa-miR-99b, hsa-miR-181a and hsa-miR-181b 
human embryonic stem cell-derived endothelial-like cells (hESC-EC)(n=3, 
p<0.05). These miRNAs were subsequently termed “novel endothelial-associated 
miRNA”. 
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Figure 4.1: Schematic of microarray experimental design.  
All SA461 hESC samples were derived from “Pluripotent Control”. SA461 hESC were differentiated 
in “endothelial differentiation media” for 2, 4 and 10 days with cells maintained in pluripotency 
harvested at the same timepoints. Comparisons between groups are indicated by arrows. 
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Figure 4.2: MicroRNA characterisation of hESC derived ECs.  
Panel A depicts the normalised intensity log ratio from a LC Sciences microRNAs microarray of miR-99b (i), miR-181a (ii) and miR-181b (iii) in pluripotent Day 0 
samples, pluripotent Day 2 samples labelled Pluripotent 1, pluripotent day 4 samples labelled Pluripotent 2, pluripotent day 10 samples labelled Pluripotent 3, 
endothelial differentiation day 2 samples labelled Endothelial 1, endothelial differentiation day 4 samples labelled Endothelial 2 and endothelial differentiation day 10 
samples labelled Endothelial 3.  Panel B shows validation of the microarray results by TaqMan qRT-PCR for miR-99b (i), miR-181a (ii) and miR-181b (iii) with D0 
representing pluripotent day 0, P D2 representing pluripotent day 2, P D4 representing pluripotent day 4, P D10 representing pluripotent day 10, E D2 representing 
endothelial differentiation day 2, E D4 representing endothelial differentiation day 4 and E D10 representing endothelial differentiation day 10. All data normalised to 
pluripotent D0. ** = p<0.01 vs D0, *** = p<0.001 vs D0  
A (i) (ii) (iii) 
B (i) (ii) (iii) 
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Figure 4.3: Northern Blotting validation of miRNA in hESC-EC. 
Northern blots for miR-99b, miR-181a, miR-181b and control U6. Lanes are numbered 1 to 13, with 1 being Pluripotent Day 0, 2 being pluripotent day 2, 3 being 
endothelial differentiation day 2, 4 being pluripotent day 4, 5 being endothelial day 4, 6 being pluripotent day 7, 7 being endothelial day 7, 8 being pluripotent day 10, 9 
being endothelial day 10, 10 pluripotent day 14, 11 being endothelial day 14, 12 being pluripotent day 21 and 13 being endothelial day 21. 
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4.2.2 Expression of novel “endothelial-associated miRNA” in 
other mesoderm cell types 
To further investigate the expression of the novel endothelial-associated miRNA, 
miR-99b, -181a and -181b were analysed in a selection of other mesodermal cell 
types including primary human vascular cells and H1 hESC subjected to a defined 
haematopoetic differentiation protocol. These were compared to SA461 hESC-EC 
and H1 hESC-EC by TaqMan qRT-PCR (Figure 4.4). Compared to day 10 hESC-EC 
from both SA461 and H1, expression of novel endothelial associated miRNAs 
were at the highest levels in human saphenous vein endothelial Cells (HSVEC) 
from both patients undergoing elective varicose vein stripping and considered 
otherwise healthy (Control) and HSVEC from patients undergoing saphenous vein 
dissection for coronary artery bypass graft as a vascular disease phenotype 
(CABG). Substantial levels of miR-99b, miR-181a and miR-181b expression 
compared to H1 and SA461 pluripotent day 0 and hESC-EC day 10 were observed, 
with miR-181b expression reaching the highest relative levels (Figure 
4.4C)(p<0.01). There was a small but statistically significant difference in 
expression of miR-181b between control HSVEC and CABG HSVEC by ANOVA 
(p<0.05) (Figure 4.4).  
Expression of novel endothelial associated miRNAs in human saphenous vein 
smooth muscle cells (HSVSMC) from control patients compared to H1 and SA461 
day 0 and day 10 hESC-EC samples was also investigated. For miR-99b, 
expression was slightly higher in HSVSMC than in day 0 samples, however, this 
did not attain significance (Figure 4.4A). For miR-181a, expression was 
significantly higher in HSVSMC than in hESC day 0 (p<0.05) (Figure 4.4B). For 
miR-181b, expression was also significantly higher in HSVSMC compared to 
pluripotent H1 hESC (p<0.05) (Figure 4.4C). Additionally, miRNA expression data 
was collected from human pulmonary artery endothelial cells (HPAEC). 
Expression of miR-99b in HPAEC appears to be increased compared to 
pluripotent day 0 H1 hESC, but this trend did not reach significance (Figure 
4.4A). MiR-181a expression in HPAEC was significantly higher than H1 hESC as 
was miR-181b expression (p<0.05) (Figure 4.4B and C). In H1 hESC subjected to 
haematopoetic differentiation, miR-99b was significantly expressed in day 10 
samples compared to day 0 samples (p<0.05) (Figure 4.4A). MiR-181a and miR-
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181b expression in day 10 hESC-haem compared to day 0 was also significant 
(p<0.001) (Figure 4.4B and C).  
 
4.2.3 MiR-99b, miR-181a and miR-181b appear to be mesoderm-
specific 
In order to investigate whether these miRNA were specific to the mesoderm 
lineage, miRNA expression was assessed in representative cell types of the other 
germ layers, ectoderm and endoderm. To investigate the ectoderm lineage, H1 
hESC were subjected to a defined, neuronal differentiation protocol as described 
(Gerrard et al., 2005) and samples collected for analysis at 0, 4, 7, 10 and 14 
days post initiation of differentiation (Figure 4.5). TaqMan qRT-PCR was 
subsequently performed to quantify miRNA expression levels. Expression of miR-
99b, miR-181a or miR-181b did not reach levels of significance compared to day 
0 pluripotent control (n=2, p>0.05). 
To ascertain expression of miR-99b, miR-181a and miR-181b in cells from the 
endoderm lineage, we required the generation of endodermal cells from hESC or 
access to endodermal tissue. Neither of these options were available to this 
study. Instead, liver hepatocellular carcinoma HepG2 cells were used. There was 
no significant expression of miR-99b, miR-181a or miR-181b from the HepG2 cells 
tested (Figure 4.5)(n=3, p>0.05). 
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Figure 4.4: Expression of miR-99b, miR-181a and miR-181b in other mesodermal cell types. 
TaqMan® qRT-PCR results of miR-99b, miR-181a and miR-181b expression in H1 hESC at day 0 and day 10 endothelial differentiation, SA461 hESC at day 0 and 
day 10 endothelial differentiation, control HSVEC from 5 age and sex-matched patients, CABG HSVEC from 5 age and sex-matched patients, HSVSMC from 3 age 
and sex-matched control patients, pooled HPAEC from healthy patients and H1 hESC at day 0 and day 10 haematopoetic differentiation. HESC data normalised to 
appropriate day 0 population; HSVEC, HSVSMC and HPAEC data normalised to H1 hESC-EC day 0. * = p<0.05 vs H1 hESC-EC D0, *** = p<0.001 vs H1 hESC-EC 
D0, +++ = p<0.001 vs SA461 hESC-EC D0, # = p<0.05 vs H1 hESC-haem D0 and ### = p<0.001 vs hESC-haem D0. 
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Figure 4.5: Expression of miR-99b, miR-181a and miR181b in ectoderm and endoderm cell types. 
QRT-PCR results of miR-99b, miR-181a and miR-181b expression in H1 hESC at day 0 and day 10 endothelial differentiation, SA461 hESC at day 0 and day 10 
endothelial differentiation, H1 hESC at day 0 and day 10 neuronal differentiation (ectoderm) and HepG2 cells (endoderm). *** = p<0.001 vs H1 hESC-EC D0, +++ = 
p<0.001 vs SA461 hESC-EC D0. 
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4.2.4 MiR-99b, miR-181a and miR-181b are not altered by 
“vascular disease stimuli” in vitro 
In an attempt to dissect the regulation of novel endothelial associated miRNAs, 
HSVEC were subjected to a range of physiologically relevant agents to mimic 
human endothelial disease. Angiotensin II was used at a final concentration of 1 
µM, as it had been previously shown to inhibit the growth and migration of 
endothelial cells through the AT2 receptor at this concentration (Stoll et al., 
1995, Benndorf et al., 2003), carbachol was used to stimulate nitric oxide 
production at a final concentration of 10 µM as had been shown previously to 
effectively induce a measurable response using ELISA (Kane et al., 2010a), 
Endothelin-1 is a potent vasoconstrictor and also induces nitric oxide production 
at a final concentration of 1 µM (Tsukahara et al., 1994, Calo et al., 1996), 
glucose at a final concentration of 25 mM to mimic diabetes as had previously 
been shown to elicit modulation in miRNA levels in endothelial cells (Caporali et 
al., 2011), L-NAME is an inhibitor of endothelial nitric oxide synthase (eNOS) at a 
final concentration of 100 µM (Pfeiffer et al., 1996) and ox-LDL at a final 
concentration of 50 µg/ml and 100 µg/ml to cause superoxide production 
measureable by fluorometric probes as had been previously reported (Cominacini 
et al., 2000). Samples were collected at 24, 48 and 72 h and total RNA 
extracted. Expression of miR-99b (Figure 4.6A), miR-181a (Figure 4.6B) and miR-
181b (Figure 4.6C) were ascertained by TaqMan qRT-PCR. Angiotensin II, 
carbachol, endothelin-1, glucose, L-NAME or oxidised-LDL treatment did not 
elicit any statistically significant difference in miR-99b, miR-181a or miR-181b 
expression at any of the time-points studied (Figure 4.6).  
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Figure 4.6: MicroRNA expression in HSVEC in response to pathophysiological 
stimuli. 
HSVEC were plated and exposed for 24, 48 or 72 h to normal media (Control), angiotensin II 
(AngII) at 1µM, carbachol at 10µM, endothelin-1 at 1µM, glucose at 25µM, L-NAME at 100µM and 
ox-LDL at 100µg/ml and expression of miR-99b(A), miR-181a(B) or miR-181b(C) relative to 
timematched control and RNU48 ascertained. There were no significant changes in expression of 
miRNAs tested.
A 
B 
C 
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4.2.5  Illumina Gene expression analysis of endothelial 
differentiation 
In order to interrogate dynamic gene expression changes, cells were subjected 
to directed differentiation using the endothelial protocol (Kane et al., 2010a) 
and an Illumina whole genome expression microarray was employed. SA461 hESC 
subjected to endothelial-like differentiation were collected at day 0, 2, 4 and 10 
as per sample collection for the LC Sciences microRNA microarray and analysed 
by Illumina gene expression microarray (Figure 4.1). In parallel HSVEC samples 
were also analysed to act as a positive control. 
Principle Component Analysis (PCA) is a mathematical method to transform 
several closely related variables into uncorrelated variables termed principal 
components. This transformation allows the first principle component to account 
for the highest degree of variance which accounts for as much of the variability 
in the data as possible. The following components are assigned the next highest 
variance, orthogonal to the last component. Information provided allowed the 
visualisation of sample groups clustered together (Figure 4.7) and was used to 
build the ANOVA model. The PCA analysis showed acceptable separation of the 
groups, with primary HSVEC cells distinct from everything hESC-derived (Figure 
4.7A). HESC-EC day 4 and day 10 also appear separate from all other samples 
derived from hESC (Figure 4.7B). Analyses of datasets have shown a large 
number of significantly differentially expressed probes at each time point: Day 2 
of endothelial differentiation compared to Day 0 pluripotent control showed 
1040 (of which IPA mapped 974) significant differentially expressed probe 
changes, Day 4 of endothelial differentiation compared to Day 0 pluripotent 
control showed 2400 (of which IPA mapped 2264) significant differentially 
expressed probe changes and Day 10 of endothelial differentiation compared to 
Day 0 pluripotent control showed 2157 (of which IPA mapped 2023) significant 
differentially expressed probe changes (all FDR<0.05) (Figure 4.8B). Comparison 
of HSVEC with hESC-EC Day 10 reveals 6133 significantly differentially expressed 
probes (FDR <0.05) suggesting that day 10 hESC-EC remain markedly different 
compared to primary HSVEC (Figure 4.8A). 
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Figure 4.7: Principle component analysis.  
Principle component analysis of Illumina microarray. (A) HSVEC (pink) were distinct from hESC 
and hESC-EC. (B) HESC-EC day 4 (green) and 10 (red) were separate from hESC-EC day 2 
(deep blue) and pluripotent time-matched samples at day 0 (purple), day 2 (light blue), day 4 
(brown) and day 10 (gold). 
  
A 
B 
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Figure 4.8: Summary of significantly differentially expressed probes from 
Illumina microarray. 
Summary schematic detailing key significant probe expression comparisons. There were 2157 
significantly different expressed probes between hESC-EC day 0 (Pluripotent Day 0) and hESC-EC 
day 10 (Endothelial differentiation Day 10). There were 6133 significantly differentially expressed 
probes between hESC-EC day 10 (Endothelial differentiation Day 10) and HSVEC (Primary Adult 
endothelial cells). Between hESC-EC day 0 (Endothelial differentiation Day 10) and HSVEC 
(Primary Adult endothelial cells) there were 7801 significantly differentially expressed probes (all 
FDR<0.05) (A). Venn diagram of significantly different probe expression changes, all corrected to 
hESC-EC day 0 (Pluri D0) (FDR<0.05) (B). 
 
A 
B 
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4.2.6 Analyses of hESC-EC day 10 compared to primary 
endothelial cells 
As the latest time-point investigated, day 10 hESC-EC from pluripotent day 0 
hESC had 2157 significantly differentially expressed probes, however between 
HSVEC and hESC-EC day 10 there were 6133 statistically significant probe 
expression changes (FDR <0.05)(Figure 4.8A). In order to visualise which 
endothelial associated genes present in adult HSVEC remain at lower levels in 
day 10 hESC-EC, IPA was employed. Levels of key endothelial genes chemokine 
(C-X-C motif) receptor 4 (CXCR4), intercellular adhesion molecule 1 (ICAM1), 
selectin E (SELE), fms-related tyrosine kinase 4 (FLT4), C-type lectin domain 
family 11, member A (CLEC11A), catenin (cadherin-associated protein), beta 1 
(CTNNB1), T, brachyury homolog (T), Kruppel-like factor 6 (KLF6), melanoma 
cell adhesion molecule (MCAM), intercellular adhesion molecule 2 (ICAM2), 
cadherin 5, type 2 (vascular endothelium) (CDH5), bone morphogenetic protein 2 
(BMP2), CD34 molecule (CD34), selectin P (SELP), fms-related tyrosine kinase 1 
(vascular endothelial growth factor/vascular permeability factor receptor) 
(FLT1), von Willebrand factor (VWF), kinase insert domain receptor (KDR), TEK 
tyrosine kinase, endothelial (TEK), fibroblast growth factor (Fgf) and v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) in hESC-EC day 10 
compared to day 0 samples were studied and significant changes observed 
(Figure 4.9). HESC-EC day 10 compared to HSVEC were also studied (Figure 
4.10). KLF6, FGF9 and TEK were the only probes statistically significantly 
upregulated by hESC-EC day 10 compared to day 0 (Figure 4.9), whereas CXCR4, 
SELE, CLEC11A, KLF6, MCAM, ICAM2, CDH5, BMP2, CD34, VWF, KDR and TEK were 
statistically significantly expressed in HSVEC compared to hESC-EC day 10 (FDR 
<0.05) (Figure 4.10). Pluripotency markers such as Oct4 and Sox2 were 
significantly downregulated in hESC-EC day 10 compared to hESC-EC day 0 
(Figure 4.11) however levels were significantly lower in HSVEC compared to 
hESC-EC day 10 (Figure 4.12). 
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Figure 4.9: Significant expression of endothelial associated probes in hESC-EC day 10 compared to hESC-EC day 0. 
Expression of endothelial associated genes in hESC-EC day 10 vs hESC-EC day 0. Red denotes higher expression in hESC-EC day 10 compared to hESC-EC day 0 
and green denotes lower expression in hESC-EC day 10 compared to hESC-EC day 0. Numbers underneath genes correspond to FDR, fold-change and prediction of 
bivalency. 
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Figure 4.10: Significant expression of endothelial associated probes in primary HSVEC compared to hESC-EC. 
Expression of endothelial associated genes in HSVEC vs hESC-EC day 10. Red denotes higher expression in HSVEC compared to hESC-EC day 10 and green 
denotes lower expression in HSVEC compared to hESC-EC day 10. Numbers underneath genes correspond to FDR, fold-change and prediction of bivalency. 
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Figure 4.11: Expression of pluripotency associated genes in hESC-EC day 10. 
IPA pathway with expression data of pluripotency associated probe levels compared to hESC-EC day 0. 
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Figure 4.12: Expression of pluripotency associated genes in HSVEC compared to hESC-EC day 10. 
IPA pathway with expression data of pluripotency associated probe levels in HSVEC compared to hESC-EC day 10. 
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4.2.7 Transient transcription factor expression observed at day 2 
hESC-EC differentiation 
Ingenuity Pathway Analysis was employed to process the data into the key 
biological comparisons from the Illumina microarray. It facilitates the 
interrogation of large datasets for related genes and pathways represented in 
the expression data. It subsequently displays each probe as an individual symbol 
based upon the known function. It also displays by colour whether a probe is 
statistically significantly up (red) or down-regulated (green) compared to 
another dataset, including the false discovery rate (top number) and fold-change 
information (middle number). In addition, information from a chip-SEQ dataset 
identifying bivalent domains on ~2500 genes in H9 hESC (Ku et al., 2008) was 
also integrated to the SA461 hESC datasets to give an in silico prediction of 
bivalent status, which is detailed as the bottom number.  
When hESC-EC day 2 was investigated further, it was noted from the Venn 
diagram that hESC-EC day had 223 unique significant probe-set expression 
changes (Figure 4.8). Upon further analysis using IPA, a transient induction of 
several transcription factors unique to endothelial differentiation day 2 were 
observed, accounting for approximately 13% of expression changes specific to 
this time point (Figure 4.13A and B). 
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Figure 4.13: HESC-EC day 2 specific genes. 
Pie chart of gene ontology classification of significantly differentially expressed genes specific to 
hESC-EC day 2 (FDR<0.05) (A). IPA output of significant transcription factor expression unique to 
hESC-EC day 2 (B). 
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Table 4.1: Transcription Factors specific to hESC-EC day 2. 
List of transcription factors unique to hESC-EC day 2, with FDR, fold-change and Illumina probe ID. 
Symbol 
Fold 
Change FDR 
Illumina Probe 
ID 
Ankyrin repeat, family A (RFXANK-like), 2 (ANKRA2) -1.64468 0.00550105 ILMN_1687351 
Achaete-scute complex homolog 2 (Drosophila) (ASCL2) 1.24413 0.0473781 ILMN_1723412 
CXXC finger protein 1 (CXXC1) 1.81781 0.0174628 ILMN_1691276 
DNA (cytosine-5-)-methyltransferase 3-like (DNMT3L) 1.29018 0.0129366 ILMN_2406634 
Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) 1.45772 0.0159592 ILMN_1751081 
Forkhead box A2 (FOXA2) 1.50997 1.80E-05 ILMN_1668052 
GA binding protein transcription factor, beta subunit 1 (GABPB1) -1.46947 0.0193597 ILMN_1761147 
Histone deacetylase 5 (HDAC5) 1.21127 0.0269061 ILMN_1810856 
L(3)mbt-like 2 (Drosophila) (L3MBTL2) 1.36717 0.0289989 ILMN_2336109 
Myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3) 1.2788 0.00554164 ILMN_1725300 
MAX binding protein (MNT) 1.49585 0.0210798 ILMN_1792910 
Retina and anterior neural fold homeobox 2 (human) (RAX2) 1.569 0.0443982 ILMN_1653412 
RNA binding motif protein 14 (RBM14) 1.72171 0.011002 ILMN_1700604 
Regulatory factor X, 1 (influences HLA class II expression) (RFX1 (includes EG:100038773)) 1.46898 0.0158731 ILMN_1725787 
Small nuclear RNA activating complex, polypeptide 4, 190kDa (SNAPC4) 1.7998 0.0443982 ILMN_1677484 
Steroid receptor RNA activator 1 (SRA1) 1.34046 0.0110232 ILMN_2062754 
TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa (TAF6L) 1.74775 0.0132732 ILMN_1727281 
Transcription factor AP-4 (activating enhancer binding protein 4) (TFAP4) 1.62316 0.0135871 ILMN_1814657 
Upstream binding transcription factor, RNA polymerase I (UBTF) 1.59561 0.015919 ILMN_1806946 
Upstream transcription factor 2, c-fos interacting (USF2) 1.7263 0.037322 ILMN_1756696 
Zinc finger protein 35 (ZNF35) 1.33306 0.0238139 ILMN_1692100 
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4.2.7.1 QRT-PCR validation of transient transcription factor expression 
observed at day 2 hESC-EC differentiation 
To further confirm gene expression of the transcription factors listed in Table 
4.1, we performed TaqMan qRT-PCR. Of these 24 transcription factors, 12 
validated significantly by TaqMan qRT-PCR when subjected to one way analysis 
of variance (ANOVA) (p<0.05); CXXC1, EHMT2, FOXA2, L3MBTL2, MLL3, RBM14, 
TAF6L, TFAP4, TSC22D3, UBTF, USF2 and ZNF35 (Table 4.1). When included in a 
list for analysis by IPA, among the top functions published for these transcription 
factors was cell cycle. 
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Figure 4.14: TaqMan qRT-PCR validation of hESC-EC day 2 specific transcription 
factors. 
Validative qRT-PCR for hESC-EC day 2 specific transcription factors performed in hESC-EC day 0 
(Pluri 0), hESC-EC day 2 (Endo 2) and in HSVEC from 2 patients (HSVEC1, HSVEC2). All data 
normalised to hESC-EC day 0 and 18S ribosomal control (*=p<0.05 vs hESC-EC day 0, **=p<0.01 
vs hESC-EC day 0, ***=p<0.001 vs hESC-EC day 0). 
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4.2.7.2  FOXA2 protein is upregulated at hESC-EC differentiation day 2 
To confirm expression of transcription factors at day 2 at the protein level, 
immunocytochemistry (ICC) was performed for Oct4, FOXA2, L3MBTL2, TFAP4, 
TSC22D3 and UBTF in SA461, H1 and RC10 hESC lines (Figure 4.15, Figure 4.16, 
Figure 4.17). Pluripotent SA461, H1 and RC10 hESC-EC day 0 maintained Oct4 
expression as expected, which was reduced by hESC-EC day 2 (Figure 4.15, 
Figure 4.16, Figure 4.17). FOXA2, although present in a small subset of cells at 
pluripotent day 0, appeared more abundant at day 2 of endothelial-like 
differentiation, and there did not appear to be any co-localisation of Oct4 and 
FOXA2 as evidenced by the merge images (Figure 4.15, Figure 4.16, Figure 4.17). 
The remaining antibodies did not stain successfully under the conditions tested. 
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Figure 4.15: Immunofluorescent validation of FOXA2 and Oct4 in SA461 hESC-EC day 2. 
ICC performed on hESC-EC day 0 (Pluri D0) and hESC-EC day 2 (Endo D2) for DAPI nuclear stain in blue, FOXA2 in green and Oct 4 in red. Goat (green) and mouse 
(red) IgG controls also shown. Scale bars represent 20 µm, 
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Figure 4.16: Immunofluorescent validation of FOXA2 and Oct4 in H1 hESC-EC day 2. 
ICC performed on hESC-EC day 0 (Pluri D0) and hESC-EC day 2 (Endo D2) for DAPI nuclear stain in blue, FOXA2 in green and Oct 4 in red. Goat (green) and mouse 
(red) IgG controls also shown. Scale bars represent 20 µm. 
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Figure 4.17: Immunofluorescent validation of FOXA2 and Oct4 in RC10 hESC-EC day 2. 
ICC performed on hESC-EC day 0 (Pluri D0) and hESC-EC day 2 (Endo D2) for DAPI nuclear stain in blue, FOXA2 in green and Oct 4 in red. Goat (green) and mouse 
(red) IgG controls also shown. Scale bars represent 20 µm. 
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4.2.7.3 The transcriptional start site of FOXA2 is bivalently marked 
Using data from a ChIP-SEQ experiment performed in H9 hESC by Ku et al. a 
prediction was made on bivalent status for every gene, and displayed in IPA (Ku 
et al., 2008) (Figure 4.13B). In pluripotent H9 hESC, FOXA2 was predicted to 
have both H3K4me3 and H3K27me3 histone modifications at its transcriptional 
start site (TSS) allowing rapid activation and repression of the gene (Figure 
4.18). To validate these findings in our culture conditions for both H9 and SA461 
hESC, ChIP-PCR was performed. Using the information within the UCSC genome 
browser, primer pairs were designed to span the TSS (Figure 4.19) (Table 2.5). 
Immunoprecipitations (IPs) with negative control rabbit anti-mouse IgG antibody, 
H3K4me3 antibody, H3K27me3 antibody and positive control total H3 antibody 
were set up with chromatin prepared from pluripotent H9 and SA461 hESC. SYBR 
green qPCR with the designed primer pairs 2, 7, 10 and 17 (Figure 4.19) was then 
performed on the eluate from the IPs along with a 2% chromatin input which had 
not been subjected to IP and a NTC. Data were normalised to IgG negative 
control and are displayed as fold enrichment. The FOXA2 TSS had both H3K4me3 
activation histone modification and H3K27me3 repression histone modification at 
all genomic regions tested in both H9 hESC and in SA461 hESC (Figure 4.20). The 
highest fold enrichment was observed in regions 7 and 10 (Figure 4.20) 
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Figure 4.18: UCSC genome browser visualisation of H3K4me3 and H3K27me3 Chip-SEQ performed in H9 hESC.  
Genome browser output from FOXA2 genomic location showing presence of H3K4me3 and H3K27me3 at the transcriptional start site from Chip-SEQ performed on 
pluripotent H9 hESC (Ku et al., 2008). 
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Figure 4.19: Location of primer pairs designed for FOXA2 ChIP. 
UCSC output showing the genomic location of the optimised primer pairs designed for the FOXA2 TSS. 
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Figure 4.20: Chromatin ImmunoPrecipitation for H3K4me3, H3K27me3 and Total H3 at FOXA2 transcriptional start site. 
Enrichment of H3K4me3, H3K27me3 and control Total H3 histone modifications at each primer site within the TSS of FOXA2. * = p<0.05 vs IgG control 
antibody. 
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Figure 4.21: Chromatin ImmunoPrecipitation for H3K4me3, H3K27me3 and Total H3 normalised to percentage input chromatin at FOXA2 
transcriptional start site. 
Enrichment of H3K4me3, H3K27me3 and control Total H3 histone modifications at each primer site within the TSS of FOXA2. * = p<0.05 vs 2% input control, ** = 
p<0.01 vs 2% input control and *** = p<0.001 vs 2% input control 
.
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4.2.8 Target analysis of miR-99b, miR-181a and miR-181b 
To identify a list of potential gene targets for miR-99b, miR-181a and miR-181b, 
the 3’ UTR of mRNAs were screened for seeds of the miRNAs of interest. The 
seed can be defined as consecutive Watson-Crick base pairing between miRNA 
and mRNA at nucleotide positions 2-7 from the 5’ end. Previously demonstrated 
using an unbiased computational approach applied to high-throughput pulsed 
SILAC data sets, the seed sequence in the 3’ UTR correlates with translational 
repression or mRNA degradation and seed-based target prediction has the 
highest degree of overlap with data from pulsed SILAC experiments (Grimson et 
al., 2008). Adding the filter of evolutionary conservation improves likelihood of 
the prediction being biologically accurate, although the false discovery rate 
remains fairly substantial at 40%. The extent of miRNA regulation upon a mRNA 
depends on the number of seeds and the distance between seeds for the miRNA 
of interest to bind. Seed sequences with less than 40 nucleotides between them 
appear to act synergistically (Selbach et al., 2008, Grimson et al., 2008). 
Furthermore, seed regions for different miRNAs that are within an optimal 
distance appear to cooperatively regulate 1 target (Grimson et al., 2008). The 
target prediction method used is unique in this respect and was used to search 
for mRNAs that have multiple seeds for each miRNA within a short stretch of the 
3’ UTR of mRNA. 
To explore which targets of miR-99b, miR-181a and miR-181b were differentially 
regulated as SA461 hESC were undergoing directed differentiation to an 
endothelial-like lineage, lists of targets were individually uploaded to IPA, added 
to a new “my pathway” and overlaid with gene expression data for hESC-EC day 
10 from the Illumina gene expression microarray. Targets of miR-99b which were 
significantly downregulated by day 10 hESC-EC can are listed inTable 4.2. 
Further analysis of these targets using IPA to find common pathways or processes 
they are involved in suggests they have involvement in cell cycle and 
hepatogenesis.  MiR-181a and miR-181b share the same seed sequence, 
therefore their targets are the same. Targets of miR-181a and miR-181b that are 
downregulated in hESC-EC day 10 are detailed in Table 4.3.  
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Table 4.2: Significantly downregulated miR-99b targets. 
MiR-99b targets that were significantly downregulated at hESC-EC day 10 
Target mRNA Fold Change FDR 
Acetoacetyl-CoA synthetase (AACS) -1.81778 6.01E-05 
ATPase, Na+/K+ transporting, alpha 2 polypeptide (ATP1A2) -1.27601 0.0301848 
Autism susceptibility candidate 2 (AUTS2) -1.67213 0.0086478 
Coenzyme Q2 homolog, prenyltransferase (COQ2) -1.26927 0.0316319 
DCN1, defective in cullin neddylation 1, domain containing 5 (DCUN1D5) -2.33961 0.0296054 
ELOVL family member 6, elongation of long chain fatty acids (ELOVL6) -1.70739 0.0100094 
Frequently rearranged in advanced T-cell lymphomas (FRAT1) -1.33519 5.48E-04 
Golgi to ER traffic protein 4 homolog (GET4) -1.51798 0.0381108 
HEN1 methyltransferase homolog 1 (HEN1MT) -2.63823 3.08E-04 
Huntingtin interacting protein 1 (HIP1) -1.64945 0.0204874 
Major histocompatibility complex, class II, DO alpha (HLA-DOA) -1.30813 0.031312 
Heterogeneous nuclear ribonucleoprotein D-like (HNRPDL) -1.59162 0.0207067 
Opsin 3 (OPN3) -1.30713 0.0467024 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) -2.13913 0.0010091 
Pleckstrin homology domain containing, family B (evectins) member 2 (PLEKHB2) -1.91322 0.0404824 
RAB3A interacting protein (rabin3) (RAB3IP) -4.44999 1.47E-04 
Ras association (RalGDS/AF-6) domain family member 4 (RASSF4) -1.16883 0.0177361 
Sodium channel, nonvoltage-gated 1, gamma (SCNN1G) -1.38647 6.19E-04 
Solute carrier family 39 (zinc transporter), member 1 (SLC39A1) -1.39436 0.0198011 
Sphingomyelin phosphodiesterase, acid-like 3B (SMPDL3B) -2.0343 0.0395251 
Suppression of tumorigenicity 5 (ST5) -1.65595 0.0230849 
Stromal antigen 3-like 1 (STAG3L1) -1.5186 0.0119033 
VAMP (vesicle-associated membrane protein)-associated protein A (VAPA) -1.35521 0.0338819 
Zinc finger protein 483 (ZNF483) -1.34779 0.0076592 
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Table 4.3: Significantly downregulated targets of miR-181a and miR-181b. 
MiR-181a and miR-181b targets that were significantly downregulated at hESC-EC day 10. 
 
Target mRNA Fold Change FDR 
Acid phosphatase, prostate (ACPP) -1.15533 0.0313494 
Activin A receptor, type IIA (ACVR2A) -1.24481 0.00860618 
A kinase (PRKA) anchor protein 7 (AKAP7) -2.11528 2.96E-04 
Adaptor-related protein complex 1, gamma 1 subunit (AP1G1) -1.62345 0.0437767 
Rho GTPase activating protein 19 (ARHGAP19) -1.59107 0.021598 
Armadillo repeat containing 10 (ARMC10) -1.28609 0.0470022 
Arrestin domain containing 4 (ARRDC4) -1.52098 4.86E-05 
ATP synthase mitochondrial F1 complex assembly factor 1 (ATPAF1) -1.27153 0.0209369 
B-cell CLL/lymphoma 11A (zinc finger protein) (BCL11A) -1.46098 0.00345701 
B-cell CLL/lymphoma 6 (BCL6) -1.37126 0.0265635 
BCL2-associated transcription factor 1 (BCLAF1) -1.47122 0.0195685 
Biogenesis of lysosomal organelles complex-1, subunit 2 (BLOC1S2) -1.22854 0.0142713 
Chromosome 1 open reading frame 21 (C1orf21) -1.28984 0.0144568 
Chromosome 3 open reading frame 23 (C3orf23) -1.16191 0.00911217 
Cache domain containing 1 (CACHD1) -1.52894 0.0140239 
Cell cycle associated protein 1 (CAPRIN1) -1.72943 0.0187887 
Cathepsin C (CTSC) -1.78854 0.00486354 
Chemokine (C-X-C motif) ligand 5 (CXCL5) -1.53466 3.34E-05 
DDB1 and CUL4 associated factor 12-like 1 (DCAF12L1) -1.17744 0.0330199 
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DEK oncogene (DEK) -1.96101 0.0126222 
Eukaryotic translation initiation factor 5 (EIF5) -3.16452 0.0397181 
Ethanolamine kinase 1 (ETNK1) -1.39447 9.02E-04 
Frequently rearranged in advanced T-cell lymphomas 2 (FRAT2) -1.74418 6.12E-05 
GTPase activating protein (SH3 domain) binding protein 2 (G3BP2) -3.88471 0.00496549 
Glycine amidinotransferase (L-arginine:glycine amidinotransferase) (GATM) -1.29949 0.0306098 
GC-rich promoter binding protein 1 (GPBP1) -2.39719 0.0463725 
Hairy/enhancer-of-split related with YRPW motif 2 (HEY2) -2.03688 0.00831369 
Heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) -2.00609 0.0165194 
Hermansky-Pudlak syndrome 3 (HPS3) -2.14548 0.00365148 
V-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) (MAF) -1.28121 0.0114694 
Multiple EGF-like-domains 10 (MEGF10) -1.27902 0.00878033 
N-ethylmaleimide-sensitive factor attachment protein, beta (NAPB) -1.31213 0.00481907 
Neurocalcin delta (NCALD) -1.34046 0.00953114 
Pallidin homolog (mouse) (PLDN) -1.60905 0.0201241 
Proteolipid protein 1 (PLP1) -1.58748 6.35E-04 
Peroxiredoxin 3 (PRDX3) -5.70488 0.0375135 
RAB3A interacting protein (rabin3) (RAB3IP) -4.44999 1.47E-04 
RAN, member RAS oncogene family (RAN) -1.73039 0.0033028 
Factor C (activator 1) 3 (RFC3) -1.61046 0.0104135 
RecQ-mediated genome instability protein 2 (RMI2) -1.82678 0.0103454 
Reticulon 1 (RTN1) -1.17173 0.042165 
SAM and SH3 domain containing 1 (SASH1) -1.77383 0.0305972 
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SUMO1/sentrin/SMT3 specific peptidase 2 (SENP2) -1.73987 0.0147492 
TatD DNase domain containing 3 (TATDN3) -2.04778 3.54E-04 
TRNA aspartic acid methyltransferase 1 (TRDMT1) -1.16991 0.0355577 
Vasohibin 2 (VASH2) -1.62406 0.016792 
Zinc finger, AN1-type domain 6 (ZFAND6) -2.61869 0.0338819 
Zinc finger protein 138 (ZNF138) -1.44575 0.0126937 
Zinc finger protein 483 (ZNF483) -1.34779 0.00765915 
Zinc finger protein 589 (ZNF589) -1.76052 0.0103845 
Zinc finger protein 682 (ZNF682) -1.7067 0.00370472 
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4.3 Discussion 
In order to commit to a specified lineage, a pluripotent cell must undergo 
radical transcriptional change. Profiling these changes during cell commitment 
to a mesoderm and endothelial-like fate was the purpose of the body of research 
reported in this chapter. MiRNA profiling in hESC-EC, mesodermal cell type, 
ectodermal cell types and endodermal cell types revealed a distinct expression 
pattern of miR-99b, miR-181a and miR-181b largely unique to the mesodermal 
lineage. Expression of miR-99b, miR-181a and miR-181b did not appear to be 
affected by physiological stimuli used to mimic endothelial disease. Gene 
expression studies carried out in early EC differentiation captured a 
transcriptional shift during lineage commitment over time, which resulted in 
large numbers of significant gene expression changes at each timepoint and 
compared to primary adult EC cells. HESC-EC day 10 show a downregulation of 
pluripotency associated genes, but few endothelial associated genes are present 
at this early time point. Early changes at hESC-EC day 2 included an over-
representation of transcription factors including the transient expression of 
FOXA2, a traditionally endoderm-associated transcription factor. FOXA2 
regulation was hypothesised to be down to epigenetic modification at the TSS, 
and when investigated by ChIP FOXA2 was found to have both the activating 
H3K4me3 mark and H3K27me3 repressive mark. The FOXA2 gene is therefore 
bivalent in both SA461 and H9 hESC at pluripotency, marking it as a potential 
master regulator of lineage commitment. Finally, several predicted targets of 
miR-99b, -181a and -181b are shown to be downregulated in hESC-EC day 10 
compared to hESC-EC day 0, but how these downregulated targets help refine 
differentiation to EC remains unclear. 
Currently, very little is known about miRNA involvement in hESC differentiation 
to endothelial-like cells.  MiRNA control of endothelial differentiation remains a 
hot topic for research, with miRNAs implicated in EC function and angiogenesis 
but not in the differentiation of mammalian ESC in vitro. We have recently 
published data suggesting a role for miRNAs in EC commitment (Kane et al., 
2012). It is therefore likely miRNAs have a role in the process of lineage 
commitment to endothelial cells, and further dissection of these pathways 
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involved would elucidate the extent of miRNA involvement and governance of 
these biological processes. 
Recently, our group reported an EC directed differentiation protocol which was 
capable of generating cells phenotypically and genotypically similar to 
endothelial cells without the need for embryoid body formation (Kane et al., 
2010a). Cells seeded in monolayer differentiated in a uniform and highly specific 
manner, allowing extensive characterisation of cells without the requirement of 
isolation of the cell type of interest. During the course of the endothelial 
differentiation, loss of pluripotency associated miRNA clusters miR-302 and miR-
372/373 (Kane et al., 2012) an induction of miR-99b, miR-181a and miR-181b 
was observed by hESC-EC day 10 (Kane et al., 2012). Our hypothesis was that 
lineage specific miRNAs must play a role in the process of endothelial 
differentiation, especially in early lineage commitment. Pinpointing the role of 
miRNA during differentiation of hESC to EC had not previously been studied to 
the best of our knowledge at the time these studies began. It had been 
previously reported that knockdown of Dicer abrogated the production of nitric 
oxide (NO) in endothelial cells (Suárez et al., 2007). For the first time 
knockdown of Dicer has been shown to result in suppression of NO production 
from hESC-EC and therefore successful endothelial differentiation (Kane et al., 
2012). It had been previously shown that NO was produced as hESC 
differentiated using our feeder-free system and derived cells showed increased 
production of NO in response to carbachol (Kane et al., 2010a). 
The description of miR-99b, miR-181a and miR-181b expression in SA461 hESC 
cells differentiating to endothelial lineages is consistent with previous miRNA 
characterisation studies performed in EC, but not in pluripotent cells 
differentiating to endothelial lineage (Anand et al., 2010, Kazenwadel et al., 
2010, Suárez et al., 2008). MiR-181b has also been reported to be present on 
CD34+ haematopoetic cells derived from hESC (Huang et al., 2011). ECs and 
other mesodermal cell types are also positive for CD34 (Flamme and Risau, 
1992), therefore this would suggest a role for miR-181b in mesodermal 
commitment. During the profiled early timepoints of directed-differentiation in 
SA461 hESC, the induction of expression of miR-99b, miR-181a and miR-181b was 
observed by LC Sciences microarray, TaqMan qRT-PCR and Northern blotting, 
reaching statistical significance by day 10. Expression of these miRNAs during 
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directed differentiation has also been in observed in hESC lines H1 and H9, 
reaching statistical significance by day 10 (Kane et al., 2012). MiR-99b is an 
intergenic miRNA found in cluster with let-7e and miR-125a on chromosome 19. 
MiR-181a and miR-181b can be transcribed from different chromosomal 
locations; miR-181a-1 and miR-181b-1 are co-localised on chromosome 1, within 
the RP11-31E23.1 coding region whereas miR-181a-2 and miR-181b-2 are found 
together on chromosome 9, within the MIR181A2HG coding region. The genes in 
which these miRNA are located as yet have no known function. 
In order to investigate the expression of miR-99b, miR-181a and miR-181b in 
other mesodermal cell types, further characterisation of their expression was 
performed in vascular cell types HSVEC, HSVSMC, HPAEC, and H1 hESC directed 
to haematopoetic lineage (hESC-Haem) by a defined protocol. Expression of miR-
99b was seen to be expressed at significant levels in both control and CABG 
HSVEC compared to day 0 and and similar levels to day 10 hESC-EC, at lower 
levels in HSVSMC, HPAEC and day 10 hESC-Haem differentiated cells. MiR-181a 
was expressed at lower levels in HSVSMC, HPAEC and day 10 hESC-Haem 
differentiated cells. MiR-181b expression is abundant in both control and CABG 
hESC with a significant difference between patient cohorts. Expression can also 
be found in HSVSMC, HPAEC and day 10 hESC-Haem differentiated cells. The 
significant difference between miR-181b expression in HSVEC from control 
patients and patients undergoing CABG suggested disease status could play a role 
in differential miRNA expression.  
To ascertain whether these miRNAs were specific to the mesodermal lineage, 
miRNA qRT-PCR was again employed in representative cells from the ectoderm 
and endoderm germ layers. H1 hESC underwent a defined neuronal 
differentiation to represent the ectodermal lineage in the absence of access to 
primary human neuronal cells. There was no significant expression of miR-99b, 
miR-181a and miR-181b from any of the neuronal differentiated samples tested. 
However, it has recently been reported that miR-99b is expressed in ectodermal 
mammary duct carcinoma cell line HCC193 (Tanic et al., 2011), so expression in 
this lineage could not be ruled out. Unfortunately, we were unable to obtain 
primary human endodermal cells and no protocol for generation of endoderm 
from hESC had been optimised for our culture system. As such, HepG2 liver 
hepatocellular carcinoma cells were the closest cell type to-the endodermal 
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lineage, and were tested for expression of miR-99b, miR-181a and miR-181b. 
Expression of miR-99b, miR-181a and miR-181b was below the detection limit in 
HepG2. This supports the hypothesis that miR-99b, miR-181a and miR-181b are 
largely mesoderm specific miRNAs, however the use of the HepG2 cell line is a 
limitation of this study, and this requires future validation in primary 
endodermal cell types. It is likely that these miRs are expressed as cells 
differentiate through a common mesodermal progenitor (de Bruijn et al., 2002) 
which would also account for miR-181b expression being present in 
haematopetic differentiated hESC (Huang et al., 2011) and in HSVSMC. 
We further interrogated the hypothesis that the novel endothelial associated 
miRNAs were differentially regulated in patients with different health status by 
exposing HSVEC to various physiologically relevant agents in an attempt to mimic 
endothelial disease in a cell culture assay. Changes in miRNA expression have 
been previously reported in a number of diseases including heart disease (van 
Rooij et al., 2006, Cheng et al., 2007, Ikeda et al., 2007, Naga Prasad et al., 
2009, Olivieri et al., 2012) diabetes (Chen et al., 2008a, Caporali et al., 2011) 
and coronary artery disease (Fichtlscherer et al., 2010, Hoekstra et al., 2010). It 
had been previously shown that miR-503 expression in cultured EC changes 
during in vitro recapitulation of diabetes and ischaemia (Caporali et al., 2011) 
therefore we investigated if miR-99b, miR-181a and/or miR-181b could be 
differentially regulated in HSVEC in response to disease stimuli. Samples were 
collected at 24, 48 and 72 h post exposure and total RNA extract samples 
extracted. None of the treatments elicited a significant difference in miRNA 
expression in n=3 experiments. The difference in expression of miRNA in EC from 
patients with coronary artery disease and patients without appears to be 
unrelated to diseased endothelium, or possibly these differences are not able to 
be mimicked in vitro. The mechanism of regulation of miR-99b, miR-181a and 
miR-181b remains unknown. 
To create a gene expression profile of SA461 hESC undergoing directed 
differentiation to EC, an Illumina human whole genome expression microarray 
was carried out. HESC were differentiated to EC and samples collected at day 0, 
2, 4 and 10, as samples were collected for the LC Sciences microarray. In 
addition, HSVEC were added to the array to give a gene expression profile of 
adult EC for comparison. PCA showed the clustering of similar samples in a 3-
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dimensonal graph, and samples showed good separation between sample groups. 
Adult HSVEC remained separated from all other groups plotted on the graph, 
which is unsurprising considering there are 6133 statistically significant 
differential expressed genes between hESC-EC 10 and HSVEC. Large numbers of 
statistically significant gene expression changes were found between sample 
comparisons. Numbers of genes upregulated versus those downregulated are 
roughly equal suggesting a complex transcriptional program at work. As there 
was such a large difference in number of statistically significant differentially 
expressed genes between hESC-EC day 10 and HSVEC, the expression of a 
number of key endothelial and mesodermal genes were investigated with the 
datasets overlayed to give a colour indication of statistically significantly 
upregulated (red) or statistically significantly downregulated (green), along with 
FDR, fold-change and predicted bivalent status in H9 hESC. There were no 
datasets on bivalency in HSVEC that could be added to those data, so HSVEC do 
not display bivalency prediction. HESC-EC day 10 versus day 0 showed that most 
of the endothelial associated genes were not yet present at levels of 
significance. Previously, our group showed hESC-EC day 10 cells derived from the 
same hESC line and culture protocol effectively improved foot perfusion after 
injection into a mouse model of hindlimb ischaemia (Kane et al., 2010a), 
therefore it would appear despite lacking the expected endothelial gene profile, 
the cells remain biologically and clinically relevant. The level of maturation at 
which cells are transplanted appears to be critical to clinical improvement – 
mature adult cells such as hMVEC (Kalka et al., 2000) and immature cell types 
such as (VEGF) R2-positive Tra-1–60–positive differentiating hESC cells (Sone et 
al., 2007) do not result in improved local blood flow in vivo.  
Furthermore, when pluripotency pathways were analysed in the context of hESC-
EC day 10 vs hESC-EC day 0, pluripotency genes were seen to drop significantly 
by day 10. However, when the level of pluripotency markers in HSVEC was 
compared to hESC-EC day 10, they were significantly lower in HSVEC, indicating 
that although expression of Oct4 and Sox2 was reduced there is still much more 
present in hESC-EC day 10 cells than adult EC. This could be due to a 
subpopulation of cells remaining pluripotent within the endothelial 
differentiation, therefore negatively sorting cells for pluripotency markers 
171 
before microarray analysis would have been a useful addition to the 
experimental design to eliminate this possibility. 
When day 2 of EC differentiation was investigated further, transcription factors 
unique to this timepoint were observed, accounting for 13% of the gene 
expression changes to this timepoint. Ingenuity Pathway Analysis was employed 
to discover the known functions of these transcription factors, although there 
was no direct link to endothelial differentiation although cell cycle was a top 
related result. Of these 24 transcription factors found to be significant, CXXC1, 
EHMT2, FOXA2, L3MBTL2, MLL3, RBM14, TAF6L, TFAP4, TSC22D3, UBTF, USF2 
and ZNF35 validated successfully by TaqMan qRT-PCR (ANOVA p<0.05), with 
FOXA2 being the most dramatic change. To investigate whether these 
transcription factors are present at hESC-EC day 2 in other hESC lines, ICC was 
performed with antibodies for Oct4, FOXA2, L3MBTL2, TFAP4, TSC22D3 and UBTF 
in SA461, H1 and RC10 hESC lines. Oct4 expression can be detected in 
pluripotent SA461, H1 and RC10 hESC with expression less abundant at day 2 of 
EC differentiation. However, in SA461 the levels of Oct4 expression in 
pluripotent cells appeared considerably lower than that of the other lines 
tested. Of the antibodies for the transcription factors tested, FOXA2 can be seen 
to be more abundant at day 2 EC differentiation, although some can be detected 
in pluripotent hESC. The remaining antibodies tested did not stain successfully in 
tested samples, and further optimisation is required in order to investigate their 
role in hESC-EC commitment.  
FOXA2 is a hepatocyte nuclear factor and is a “winged helix” member of the 
forkhead class of DNA binding proteins. FOXA2 is reported to be involved in the 
embryonic development of the axial mesoderm from the primitive streak and 
node in day 6.5 mouse embryos (Sasaki and Hogan, 1993, Monaghan et al., 
1993). Interestingly, FOXA2 has been shown to be able to bind directly and open 
compacted chromatin at histones H3 and H4, suggesting its importance as a 
“pioneer” transcription factor in early development (Cirillo et al., 2002). It has 
been linked to endoderm development with FOXA2-deficient mouse embryos 
lacking hepatic specification (Lee et al., 2005) and displaying abnormal 
mesoderm formation lacking notochord although lateral mesoderm, from which 
the blood vessels are  derived, appeared largely normal (Ang and Rossant, 1994). 
FOXA2 had not previously been observed in hESC-EC differentiation at the time 
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of writing. In the developing embryo, it is thought that endoderm and mesoderm 
are derived from a common progenitor which could suggest a role for FOXA2 in 
early EC committment from hESC (Lickert et al., 2002, Kubo et al., 2004). In 
order to elucidate the role of FOXA2 in endothelial differentiation further, 
knockdown using RNA interference and overexpression studies during 
differentiation would allow documentation of the role it plays during EC 
commitment and are currently underway. 
Bivalent genes have been suggested to be master regulators of lineage 
commitment due to their transcriptionally poised status and ablity to undergo 
rapid up and downregulation (Bernstein et al., 2006). ChIP-SEQ data integrated 
to the Illumina microarray dataset allowed a prediction of bivalency to be made 
in hESC, and predicted FOXA2 to be bivalently marked in pluripotent H9 hESC 
(Ku et al., 2008). It was hypothesised that epigenetic modification was 
responsible for the transient expression of FOXA2 seen at hESC-EC day 2. To test 
this hypothesis, ChIP was performed using antibodies for H3K4me3 active 
chromatin state and H3K27me3 repressive chromatin state and qPCR primer 
pairs directed against the TSS of FOXA2. It can be seen for both H9 and SA461 
hESC maintained in our feeder-free pluripotent culture system, that FOXA2 is 
indeed bivalently marked at hESC-EC day 0, lending weight to the possibility of 
epigenetic changes illiciting its temporal gene expression. Due to time 
constraints, we were unable to test whether the loss of the repressive 
H3K27me3 at the FOXA2 TSS was found at hESC-EC day 2, but this will be 
investigated in the near future by performing ChIP on both hESC-EC day 0 and 
hESC-EC day 2 samples. 
Finding targets for the novel endothelial associated miRNAs miR-99b, miR-181a 
and miR-181b by integrating data from the LC Sciences miRNA microarray and 
data from the Illumina whole genome expression microarray proved to be 
challenging due to the large amount of data generated. Targets listed in Table 
4.2 and Table 4.3 were generated (Grimson et al., 2008) and those with 
significantly lower expression in hESC-EC day 10 compared with hESC-EC day 0 
displayed. Further confirmation of these targets by checking protein expression, 
overexpression and knockdown of miR-99b, miR-181a and miR-181b and 
generation of luciferase target constructs remain to be performed to fully 
elucidate the role of these miRs in EC differentiation. Previous publications have 
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suggested a role for miR-181a in regulating EC from a lymphatic to a blood 
vascular phenotype by targeting Prox1 (Kazenwadel et al., 2010). Overexpression 
of miR-181a during our directed differentiation protocol has been shown to 
reduce Prox1 levels and cause differential expression of EphrinB1, EphrinB2, 
Jagged2 and Hey2 (Kane et al., 2012) which are involved in arterial specification 
(dela Paz and D'Amore, 2009). Overexpression of miR-99b, and miR-181b in hESC-
EC transplanted into a mouse model of hindlimb ischaemia showed significant 
improvement of neoangiogenesis, whereas overexpression of miR-181a did not 
elicit the same effect (Kane et al., 2012). 
In order to refine approaches to creating a viable cell therapy product for the 
treatment of ischaemia, a thorough dissection of miRNA expression, gene 
expression and epigenetics is required in EC differentiation but remains highly 
challenging. 
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Chapter 5: General Discussion 
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This thesis contains studies concerned with the transcriptional control of lineage 
commitment in hESC differentiating to cardiovascular lineages. Cardiac 
regeneration, involving generation of new functional cardiomyoctes and 
therapeutic angiogenesis using “endothelial-like” cells remains a key goal in cell 
therapy for vascular and cardiovascular diseases. Limited improvements using 
progenitor cell types have been shown in diseases such as chronic angina, acute 
myocardial infarction and heart failure, however these therapies are by no 
means optimal at this juncture (Menasché et al., 2008, Britten et al., 2003, 
Wollert et al., Lunde et al., 2006, Janssens et al., 2006, Zimmet et al., 2011, 
Assmus et al., 2010, Strauer et al., 2010, Murry et al., 2004b). There remains an 
unmet clinical need for new therapies to alleviate the global burden caused by 
these diseases. In order for hESC therapies to progress to the clinic, more 
understanding of the transcriptional control of lineage commitment programs is 
therefore warranted. 
Although improvements in the scalability of cardiac differentiation have recently 
been reported (Lecina et al., 2010), an interest in improving yield still remains. 
Alternative methods to refine cardiomyocte differentiation from hESC could 
provide some solution to the issue of scalability in producing large enough 
numbers of cells for clinical benefit in humans. MiRNA modulation by lentivirus 
has previously been shown to potentiate cardiomyocyte differentiation using an 
embryoid body protocol (Ivey et al., 2008a). The body of work contained in 
chapter 3 attempted to dissect the role miR-1 and miR-133 had, if any, on 
monolayer cardiac differentiation using feeder-free hESC, therefore offering an 
opportunity to enhance production of these cells more directly. We began by 
optimising lentiviral infection of hESC and showing that transduction did not 
have an effect on the expression of Oct 4 or the ability of the cells to undergo 
embryoid body formation. Next, it was observed that the CMV promoter was 
silenced in SA461 hESC, consistent with previous findings (Xia et al., 2007, Liew 
et al., 2007). The SFFV promoter was found to be highly active in pluripotency, 
passive differentiation, cardiac and endothelial conditions. Previous studies had 
shown SFFV to be a strong promoter for transducing haematopoetic stem cells 
(Demaison et al., 2002b, Yam et al., 2002). As the miRNA overexpression 
constructs gifted from Reuvin Agami were pri-miR inserts encoding not only the 
miRNA of interest but other miRNAs as well, we redesigned the miRNA 
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overexpression strategy to a pre-miR format maintaining the native stem loop 
structure of the pre-miR in an effort to ensure the correct endogenous 
processing. It was noted at this point that miR-1 expression was substantially 
lower than miR-133 expression, although the experimental conditions were 
controlled. Following this, optimisation of cardiac differentiation was performed 
in SA461 hESC and H1 hESC, and it was observed that SA461 were incapable of 
generating beating cells regardless of time in cardiac differentiation culture 
conditions. The decision was taken to find an alternative hESC line to work with 
for cardiac differentiation, and it had previously been reported that H1 hESC 
could successfully differentiate to form beating cells with a cardiomyocyte 
phenotype (Laflamme et al., 2007). H1 hESC were subjected to a modified 
Laflamme protocol in monolayer which resulted in beating clusters by day 9 and 
by day 14 ICC staining for troponin T, tropomyosin, NKX2.5 and α-actinin. This 
result reinforced the reported existence of lineage bias in hESC lines, and could 
lend weight to the idea of different lines banked for different tissues in a cell 
therapy settinng (Hong et al., 2011, Alva et al., 2011). With the cardiac 
differentiation protocol optimised, an investigation of the role of miR-1 and miR-
133 in cardiac specification using overexpression lentiviruses was initiated. On 
day 9 of cardiac differentiation culture, spontaneous beating clusters could be 
observed, with the control LNT-SFFV-GFP transduced samples showing the 
highest prevalence of beating cells. When analysed by qRT-PCR for cardiac 
marker genes, it was found that those samples transduced with LNT-SFFV-GFP 
virus displayed significantly higher levels of ACTN2 and NKX2.5 than no virus 
control samples subjected to cardiac conditions. There have been no previously 
reported incidences where transduction of cells with control virus alone resulted 
in a potentiation of differentiation to any lineage. However, our group 
previously reported the induction of induced pluripotent stem cells (iPSC) upon 
transduction with control LNT-SFFV-GFP virus (Kane et al., 2010b). Contrary to 
what was previously reported (Ivey et al., 2008a), samples transduced with LNT-
SFFV-miR-1 had no statistically significant changes in cardiac gene expression 
compared with either of the control samples. In samples transduced with LNT-
SFFV-miR-133 there were no significant differences in cardiac gene expression 
when compared to the untreated cardiac differentiation, however, when 
compared with LNT-SFFV-GFP a significant reduction in ACTN2, NKX2.5, and 
TNNT2 was observed. This is consistent with previous findings published by Ivey 
177 
et al. 2008 however, the difference between the no virus control and the control 
LNT-SFFV-GFP transduced samples does raise some questions about the safety 
and off target effects of using integrating lentiviral vectors in cells destined for 
cell therapy in patients. It cannot be ruled out that lentiviruses can potentiate 
cardiac differentiation simply by integrating randomly into the host cell DNA. It 
has been shown previously that lentiviruses preferably integrate into active 
genes (Schröder et al., 2002). To understand this effect in the future, 
integration site analysis of cells could be performed. To exclude the 
unpredictability of using an integrating lentiviral vector, these studies could be 
repeated using a non-integrating lentiviral vector system, although at the deficit 
of long lasting transgene expression (Apolonia et al., 2007).  
The investigation of approaches for refinement of cardiac differentiation from 
hESC remains a clinically relevant pursuit. Recent publications which have 
attempted to address this goal include Dixon et al. who reported the 
overexpression of GATA4, TBX5, NKX2.5 and GTNB to generate beating cells 
which were cTnI/α-actinin double positive cells while under pluripotent culture 
conditions (Dixon et al., 2011). In addition, it was observed that overexpression 
of miR-499 in hESC differentiation to ventricular cardiomyocyte phenotype 
improved efficiency from 48% to 72% (Fu et al., 2011). It was also observed in 
this study that lentiviral overexpression of miR-1 did not increase the yield of 
cardiomyocytes from differentiation, but rather changed the gene expression 
profile of the cells derived to a more adult phenotype (Fu et al., 2011). 
Furthermore, it has been reported that miR-1 transfected mESC were 
transplanted into an MI model in mice which resulted in enhanced differentiation 
and engraftment compared to mESC alone (Glass and Singla, 2011). However this 
study is limited in that no hESC were used, and the group did not differentiate 
cells before transplantation but injected pluripotent mESC. Realistically, this 
would be unlikely to be translational due to the risk of teratoma formation from 
injecting pluripotent cells. Recently, a study performed to assess the safety of 
using lentivirus-transduced cells for transplant in Wiscott Aldrich Syndrome 
showed an improved safety profile and is currently undergoing phase I/II clinical 
testing (Scaramuzza et al., 2012) suggesting that lentiviral transduced cell 
products may be suitable for clinical use in certain circumstances. 
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The work contained within chapter 4 focused on differentiation to the 
vascular endothelial cell lineage, and the main aims were to profile miRNA 
expression, gene expression and epigenetic status of master regulating genes in 
hESC-EC. Generation of endothelial cells suitable for transplantation in 
ischaemic diseases would play a major role in reduction of cardiomyocyte death 
after MI, and could offer a preferred solution to PAD in critical limb ischaemia, 
circumventing the need for long term blood thinning drugs and much improving 
quality of life for the patient.  
It had previously been shown that injection of hESC-EC day 10 cells in a mouse 
model of hindlimb ischaemia could stimulate neoangiogenesis and restore 
perfusion to the limb (Kane et al., 2010a). Studies began with the miRNA 
microarray profiling of SA461 hESC subjected to a feeder-free monolayer 
endothelial differentiation protocol as previously published (Kane et al., 2010a). 
After statistical analyses, miR-99b, miR-181a and miR-181b were discovered to 
be significantly upregulated over time in hESC-EC differentiation. In addition, 
this induction of significant miRNA expression had also been observed in H1 and 
H9 hESC lines during endothelial differentiation (Kane et al., 2012). Investigation 
into the expression of these miRNAs was then carried out in alternative 
mesodermal lineage cells; HSVEC, HSVSMC, HPAEC and hESC subjected to a 
haematopoetic differentiation method as previously reported (Yung et al., 
2011). Expression of miR-99b, miR-181a and miR-181b could be found in all of 
the cells tested, with the most substantial levels being in HSVEC. There was a 
small but statistically significant difference in miR-181b expression between 
control HSVEC and CABG HSVEC, which suggested endothelial disease perhaps 
had an impact on miRNA expression. Expression of all 3 miRNAs was statistically 
significant in hESC-haem day 10 compared to both hESC-EC day 0 and hESC-haem 
day 0. This is consistent with a previous report that showed that miR-181b was 
significantly expressed in hESC derived haematopoetic cells (Huang et al., 2011).  
Next, expression in non-mesodermal cells of miR-99b, miR-181a and miR-181b 
was assessed. H1 hESC were subjected to a published and well validated 
neuronal differentiation protocol (Gerrard et al., 2005) as human neuronal tissue 
was not available to this study to represent ectoderm. In addition, HepG2 liver 
hepatocarcinoma cells were used to represent endoderm, despite the obvious 
limitations of using a cancer cell line. Time constraints meant that no hESC 
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differentiation protocol for generation of endodermal cell types was attempted, 
although this would have been a more appropriate approach. No samples tested 
reached statistical significance, which suggested that miR-99b, miR-181a and 
miR-181b were mesodermal associated miRNAs. It seems likely that these 
miRNAs are expressed as cells differentiate through a common mesodermal 
progenitor (de Bruijn et al., 2002) which would also account for miR-181b 
expression being present in haematopetic differentiated hESC (Huang et al., 
2011) and in HSVSMC. However, it has recently been reported that miR-99b is 
expressed in ectodermal mammary duct carcinoma cell line HCC1937 (Tanic et 
al., 2011), which would highlight the benefit of further miRNA expression 
profiling in a much wider variety of cell types than investigated here.   
To investigate the significant difference observed in miR-181b expression 
between control and CABG patients HSVEC, HSVEC were exposed to a range of 
physiological agents designed to cause endothelial stress and mimic vascular 
disease, and expression of miR-99b, miR-181a and miR-181b ascertained by qRT-
PCR on samples from 24, 48 and 72 hours. Surprisingly, none of the treatments 
elicited any significant change in miRNA expression in experiments performed on 
three independant occasions. This could have been due to an inability to mimic 
endothelial disease in this way, or a confounding factor in the patients tested for 
miRNA expression which caused the significant difference. Little is known on the 
differences in miRNA expression profile in healthy patients, with most studies 
concentrating on using miRNA expression as a biomarker to differentiate 
between disease modalities (Karaayvaz et al., 2012, Slaby et al., 2012, 
Hennessey et al., 2012, Liu et al., 2012). It has been recently reported that miR-
181b regulates NF-κB mediated EC activation and vascular inflammation (Sun et 
al., 2012), however the samples were taken at 1, 4, 8 and 24 hour timepoints 
whereas the earliest sample taken in this study was 24 hours. This could 
represent a limitation and warrants further investigation into the regulation of 
miR-99b, miR-181a and miR-181b at earlier timepoints.  
Next, we created a gene expression profile of hESC-EC differentiation in order to 
understand more about early lineage commitment and allow integration of the 
miRNA data with gene expression data to refine target gene selection. Previous 
studies have attempted to map key gene expression changes during 
differentiation of hESC to mesodermal lineages (Evseenko et al., 2010), however 
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no studies specific to the endothelial cell lineage were published at the time of 
writing. Samples were taken at hESC-EC day 0, day 2, day 4 and day 10 with 
pluripotent time matched controls and primary HSVEC ran in parallel as a 
positive control. Priniciple component analysis was used to see clustering of the 
sample groups. HSVEC were distinct from everything else analysed, which can be 
accounted for by 6133 significantly differentially expressed genes between hESC-
EC day 10 and HSVEC. When the hESC groups were further investigated, it was 
observed that hESC-EC day 4 and hESC-EC day 10 appeared distinct from 
everything else hESC derived. When samples were grouped into pairwise 
comparisons and statistically analysed, it could be observed that there were 
1040 statistically significant differential gene expression changes between hESC-
EC day 2 and hESC-EC day 0, 2400 statistically significant differential gene 
expression changes between hESC-EC day 4 and hESC-EC day 0 and 2157 
statistically significant differential gene expression changes between hESC-EC 
day 10 and hESC-EC day 0. Further analyses of hESC-EC day 2 were carried out, 
and it was observed that there were 221 statistically significant gene changes 
unique to hESC-EC day 2. Previous studies have analysed day 3.5 of mesoderm 
differentiation by embryoid body, however there were no similarities in the gene 
expression profile reported when compared to samples from the endothelial 
differentiation protocol used (Evseenko et al., 2010). When day 2 changes were 
analysed further, it was noted that 13% of the genes were transcription factors 
suggesting high transcriptional activity within the cells at this early commitment 
stage. To validate these changes qRT-PCR was employed, and CXXC1, EHMT2, 
FOXA2, L3MBTL2, MLL3, RBM14, TAF6L, TFAP4, TSC22D3, UBTF, USF2 and ZNF35 
were found to be significant by this method also, without being significantly 
expressed in HSVEC, suggesting that these TF’s to have no role in an adult EC or 
the venous lineage. Of these transcription factors the most dramatic fold change 
by qRT-PCR was FOXA2. FOXA2 is a hepatocyte nuclear factor and is a member 
of the forkhead class of DNA binding proteins, and has been reported to activate 
expression of liver-specific genes including albumin. We further validated in 
SA461, H1 and RC10 hESC the most highly upregulated TF’s by ICC in hESC-EC 
day 0 and hESC-EC day 2 in addition to Oct 4 expression. Oct 4 expression was 
clearly detected at hESC-EC day 0 with a marked reduction in staining by hESC-
EC day 2. It was also noted that Oct 4 expression was markedly reduced in 
pluripotent day 0 SA461 hESC when compared to H1 or RC10 hESC. Further 
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studies in our laboratory have continued without using the SA461 hESC line for 
this reason. There was markedly more expression of FOXA2 in hESC-EC day 2 
compared to hESC-EC day 0. Interestingly, even at hESC-EC day 0, there 
appeared to be no co-localisation of Oct 4 and FOXA2, and this became more 
apparent at hESC—(Lickert et al., 2002)EC day 2. A recent publication described 
FOXA2 overexpression to refine differentiation of hepatocyte-like cells from 
hESC (Takayama et al., 2012), it was therefore surprising to see FOXA2 in the 
context of early endothelial differentiation. Following these results, we were 
interested to understand more about FOXA2 and its regulation following such a 
marked but transient induction at hESC-EC day 2. In addition to having gene 
expression data from the Illumina microarray, we also integrated ChIP-SEQ data 
from Ku et al. which was performed on pluripotent H9 hESC and gave a 
numerical indication of whether a gene was bivalently marked and therefore 
transcriptionally “poised” (Ku et al., 2008). We sought to confirm this in our 
feeder-free monolayer pluripotency culture systems for H9 and SA461 hESC. ChIP 
qPCR primers were designed for the FOXA2 TSS area, and chromatin subjected to 
IP using antibodies for both histone modifications; H3K4me3 activation mark and 
H3K27me3 repressive mark in addition to appropriate positive and negative 
controls. It was found in our culture system that both H9 and SA461 hESC the 
FOXA2 TSS was bivalently marked with both modifications. We hypothesised that 
histone modification might be responsible for the hESC-EC day 2 specific 
expression of FOXA2, perhaps by loss of the repressive H3K27me3 from the TSS, 
however time constraints meant that at the time of submission of this thesis, we 
had not tested this hypothesis. In the near future, ChIP will be performed on 
hESC-EC day 2 samples compared to hESC-EC day 0 in order to address this 
question. Previous literature reporting a common progenitor cell type giving rise 
to both mesoderm and endoderm during embryonic development and stem cell 
differentiation may explain why an endodermal transcription factor was 
expressed in early endothelial commitment (Lickert et al., 2002, Kubo et al., 
2004).  
In order to interrogate key gene changes in the Illumina dataset, genes of 
interest were uploaded to IPA to allow visualisation of expression levels. A list of 
endothelial cell associated genes was uploaded in this fashion, and when hESC-
EC day 10 samples were compared to hESC-EC day 0 samples it was observed 
182 
that the only significantlly upregulated genes were TEK, KLF6 and FGF9. TEK is 
reported to be one of the earliest markers of endothelial cells, which would 
explain its presence in the hESC-EC samples examined from early endothelial 
differentiation (Yamaguchi et al., 1993). The lack of endothelial specific genes 
can perhaps be explained due to the early stage of differentiation at which the 
samples were harvested. When pluripotency genes were examined, it was 
observed that Oct 4, Nanog, and Sox 2 were significantly downregulated 
compared to hESC-EC day 0. This indicated a loss of pluripotency was taking 
place, however to confirm this hypothesis would require to inject cells into an 
immunodeficient mouse to check for teratoma formation. When HSVEC were 
compared with hESC-EC day 10 it was found that many of the endothelial list 
were significantly expressed, and pluripotency genes were significantly 
downregulated compared to hESC-EC day 10. This could have been due to hESC-
EC day 10 still expressing a higher level of pluripotency markers when compared 
to an adult cell type, or due to a residual population of pluripotent cells within 
the sample, skewing the result. This question could have been eliminated by the 
inclusion of a negative selection for pluripotency markers in a cell sorting stage 
prior to microarray analysis, utilising MACS or FACS technology to remove those 
pluripotent cells as has been previously described (Hewitt et al., 2006). Finally, 
computational prediction of mRNA targets of miR-99b, miR-181a and miR-181b 
produced large gene lists, some of which may never be expressed in pluripotent 
or endothelial cells, therefore we sought a way to refine targets of interest 
which were regulated between hESC-EC day 0 and hESC-EC day 10. Lists of 
predicted targets were uploaded to IPA, and overlayed with gene expression 
data from hESC-EC day 10 versus hESC-EC day 0. Further analysis past this stage 
was again limited by time when this thesis was submitted, and ideally these 
relavent targets require to be validated in independant replicates, as well as 
luciferase target constructs generated to prove miRNA targeting of these genes 
directly. Target genes found to be statistically significantly downregulated were 
subjected to analyses to find any common pathways or function relating to 
differentiation or suppression of alternate lineages linking them together, but no 
obvious link was clearly identifiable. 
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5.1 Conclusion 
This thesis shows that the effect of miR-1 and miR-133 overexpression in cardiac 
differentiation differs between protocols used. It also describes the expression 
profile of miRNAs only recently linked to endothelial differentiation and 
mesodermal cell types, as well as their absence from cell types of the other 
germ layers. Their stability of expression regardless of several pharmacological 
stimuli added to EC was also shown. Gene expression microarray profiling of a 
novel feeder and serum free endothelial differentiation protocol at early 
timepoints revealed previously unreported transcriptional changes and a 
potential novel role of the endodermal transcription factor FOXA2 in 
commitment to endothelial cells. It has also been shown that FOXA2 is bivalently 
marked in a feeder-free pluripotency maintenance system in H9 and SA461 hESC, 
indicating it as a master regulator for hESC differentiation. Taken together, 
these studies have added to existing knowledge on the master control of hESC 
differentiation to cardiovascular lineages, and provide further rational for the 
refinement of differentiation approaches toward clinically viable cell products.
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